30. Literaturverzeichnis – Zervixkarzinom
1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Staendige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:, https://www.awmf.org/regelwerk/
2. Wu, J, Jin, Q, Zhang, Y, Ji, Y, Li, J, Liu, X, et.al. Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022., J Natl Cancer Cent, 2025. 5 (3)(3): p. 322-329., https://pubmed.ncbi.nlm.nih.gov/40693230/
3. Arbyn, M, Weiderpass, E, Bruni, L, de Sanjosé, S, Saraiya, M, Ferlay, J, et.al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis., Lancet Glob Health, 2020. 8 (2)(2): p. e191-e203., https://pubmed.ncbi.nlm.nih.gov/31812369/
4. Seifert, U., Klug, S. J., Early detection of cervical cancer in Germany : Evidence and implementation, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2014. 57: p. 294-301., https://www.ncbi.nlm.nih.gov/pubmed/24562703
5. Stuebs, FA, Beckmann, MW, Pöschke, P, Heindl, F, Emons, J, Gaß, P, et.al. The Epidemiology of Cervical Cancer in Germany: A Registry-Based Analysis of Incidence, Survival, and Tumor Characteristics (2003–2021)., Dtsch Arztebl Int, 2025. 122 (18)(18): p. 483-488., https://pubmed.ncbi.nlm.nih.gov/40554656/
6. Wenzel, HHB, Bekkers, RLM, Lemmens, VEPP, Van der Aa, MA, Nijman, HW, No improvement in survival of older women with cervical cancer-A nationwide study., Eur J Cancer, 2021. 151 (): p. 159-167., https://pubmed.ncbi.nlm.nih.gov/33993062/
7. Monk, BJ, Tan, DSP, Hernández Chagüi, JD, Takyar, J, Paskow, MJ, Nunes, AT, et.al. Proportions and incidence of locally advanced cervical cancer: a global systematic literature review., Int J Gynecol Cancer, 2022. 32 (12)(12): p. 1531-1539., https://pubmed.ncbi.nlm.nih.gov/36241221/
8. Tekalign, T, Teshome, M, Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis., PLoS One, 2022. 17 (4)(4): p. e0267571., https://pubmed.ncbi.nlm.nih.gov/35476851/
9. Wang, M, Huang, K, Wong, MCS, Huang, J, Jin, Y, Zheng, ZJ, Global Cervical Cancer Incidence by Histological Subtype and Implications for Screening Methods., J Epidemiol Glob Health, 2024. 14 (1)(1): p. 94-101., https://pubmed.ncbi.nlm.nih.gov/38170398/
10. Chen, M, Han, L, Wang, Y, Chen, Y, Zheng, A, Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis., Int J Gynecol Cancer, 2024. 34 (11)(11): p. 1704-1710., https://pubmed.ncbi.nlm.nih.gov/39277184/
11. Hodgson, A, Park, KJ, Cervical Adenocarcinomas: A Heterogeneous Group of Tumors With Variable Etiologies and Clinical Outcomes., Arch Pathol Lab Med, 2019. 143 (1)(1): p. 34-46., https://pubmed.ncbi.nlm.nih.gov/30785336/
12. Vaccarella, S, Laversanne, M, Ferlay, J, Bray, F, Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends., Int J Cancer, 2017. 141 (10)(10): p. 1997-2001., https://pubmed.ncbi.nlm.nih.gov/28734013/
13. Baldur-Felskov, B, Munk, C, Nielsen, TS, Dehlendorff, C, Kirschner, B, Junge, J, et.al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012., Cancer Causes Control, 2015. 26 (8)(8): p. 1105-16., https://pubmed.ncbi.nlm.nih.gov/26033777/
14. Wang, SS, Sherman, ME, Hildesheim, A, Lacey, JV, Devesa, S, Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000., Cancer, 2004. 100 (5)(5): p. 1035-44., https://pubmed.ncbi.nlm.nih.gov/14983500/
15. Ring, LL, Munk, C, Galanakis, M, Tota, JE, Thomsen, LT, Kjaer, SK, Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection., Int J Cancer, 2023. 152 (7)(7): p. 1320-1327., https://pubmed.ncbi.nlm.nih.gov/36250312/
16. Jemal, A, Simard, EP, Dorell, C, Noone, AM, Markowitz, LE, Kohler, B, et.al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels., J Natl Cancer Inst, 2013. 105 (3)(3): p. 175-201., https://pubmed.ncbi.nlm.nih.gov/23297039/
17. Smith, H. O., Tiffany, M. F., Qualls, C. R., Key, C. R., The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study, Gynecol Oncol, 2000. 78: p. 97-105., https://www.ncbi.nlm.nih.gov/pubmed/10926787
18. Clarke, MA, Cheung, LC, Castle, PE, Schiffman, M, Tokugawa, D, Poitras, N, et.al. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women., JAMA Oncol, 2019. 5 (2)(2): p. 181-186., https://pubmed.ncbi.nlm.nih.gov/30325982/
19. Ronco, G, Dillner, J, Elfström, KM, Tunesi, S, Snijders, PJ, Arbyn, M, et.al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials., Lancet, 2014. 383 (9916)(9916): p. 524-32., https://pubmed.ncbi.nlm.nih.gov/24192252/
20. Schenck, U, Hantschke-Zerbich, H, Woellner, F, Michel, F, Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement: 2019 Annual Statistics for Cervical Cytology from 15608413 Women., Geburtshilfe Frauenheilkd, 2023. 83 (10)(10): p. 1235-1249., https://pubmed.ncbi.nlm.nih.gov/37808258/
21. Hellfritsch, J, Panzer, M, Wagner, S, Nieschke, K, Grohmann, M, First Results for the Evaluation of the Cervical Cancer Screening Carried Out in 2021 and 2022 in the Context of the Organized Cancer Screening Program (oKFE): Part 1 - Primary Screening., Geburtshilfe Frauenheilkd, 2025. 85 (4)(4): p. 417-433., https://pubmed.ncbi.nlm.nih.gov/40191552/
22. McCredie, MR, Sharples, KJ, Paul, C, Baranyai, J, Medley, G, Jones, RW, et.al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study., Lancet Oncol, 2008. 9 (5)(5): p. 425-34., https://pubmed.ncbi.nlm.nih.gov/18407790/
23. Wei, F, Georges, D, Man, I, Baussano, I, Clifford, GM, Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature., Lancet, 2024. 404 (10451)(10451): p. 435-444., https://pubmed.ncbi.nlm.nih.gov/39097395/
24. Chen, HC, Schiffman, M, Lin, CY, Pan, MH, You, SL, Chuang, LC, et.al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer., J Natl Cancer Inst, 2011. 103 (18)(18): p. 1387-96., https://pubmed.ncbi.nlm.nih.gov/21900119/
25. Choi, S, Ismail, A, Pappas-Gogos, G, Boussios, S, HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK., Pathogens, 2023. 12 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/36839570/
26. Bowden, SJ, Doulgeraki, T, Bouras, E, Markozannes, G, Athanasiou, A, Grout-Smith, H, et.al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies., BMC Med, 2023. 21 (1)(1): p. 274., https://pubmed.ncbi.nlm.nih.gov/37501128/
27. Stelzle, D, Tanaka, LF, Lee, KK, Ibrahim Khalil, A, Baussano, I, Shah, ASV, et.al. Estimates of the global burden of cervical cancer associated with HIV., Lancet Glob Health, 2021. 9 (2)(2): p. e161-e169., https://pubmed.ncbi.nlm.nih.gov/33212031/
28. Su, B., Qin, W., Xue, F., Wei, X., Guan, Q., Jiang, W., et.al. The relation of passive smoking with cervical cancer: A systematic review and meta-analysis, Medicine (Baltimore), 2018. 97(46): p. e13061., https://www.ncbi.nlm.nih.gov/pubmed/30431576
29. Castellsagué, X, Muñoz, N, Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking., J Natl Cancer Inst Monogr, 2003. (31)(31): p. 20-8., https://pubmed.ncbi.nlm.nih.gov/12807941/
30. Smith, JS, Green, J, Berrington de Gonzalez, A, Appleby, P, Peto, J, Plummer, M, et.al. Cervical cancer and use of hormonal contraceptives: a systematic review., Lancet, 2003. 361 (9364)(9364): p. 1159-67., https://pubmed.ncbi.nlm.nih.gov/12686037/
31. Brusselaers, N, Shrestha, S, van de Wijgert, J, Verstraelen, H, Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis., Am J Obstet Gynecol, 2019. 221 (1)(1): p. 9-18.e8., https://pubmed.ncbi.nlm.nih.gov/30550767/
32. So, KA, Yang, EJ, Kim, NR, Hong, SR, Lee, JH, Hwang, CS, et.al. Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection., PLoS One, 2020. 15 (9)(9): p. e0238705., https://pubmed.ncbi.nlm.nih.gov/32941440/
33. Javadi, K, Ferdosi-Shahandashti, E, Rajabnia, M, Khaledi, M, Vaginal microbiota and gynecological cancers: a complex and evolving relationship., Infect Agent Cancer, 2024. 19 (1)(1): p. 27., https://pubmed.ncbi.nlm.nih.gov/38877504/
34. Wang, S. S., Bratti, M. C., Rodriguez, A. C., Herrero, R., Burk, R. D., Porras, C., et.al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer, J Infect Dis, 2009. 199: p. 20-30., https://www.ncbi.nlm.nih.gov/pubmed/19012493
35. Wang, S. S., Gonzalez, P., Yu, K., Porras, C., Li, Q., Safaeian, M., et.al. Common genetic variants and risk for HPV persistence and progression to cervical cancer, PLoS One, 2010. 5: p. e8667., https://www.ncbi.nlm.nih.gov/pubmed/20084279
36. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et.al. Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 2003. 348: p. 518-27., https://www.ncbi.nlm.nih.gov/pubmed/12571259
37. Bowden, SJ, Bodinier, B, Kalliala, I, Zuber, V, Vuckovic, D, Doulgeraki, T, et.al. Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study., Lancet Oncol, 2021. 22 (4)(4): p. 548-557., https://pubmed.ncbi.nlm.nih.gov/33794208/
38. Ramachandran, D, Wang, Y, Schürmann, P, Hülse, F, Mao, Q, Jentschke, M, et.al. Association of genomic variants at PAX8 and PBX2 with cervical cancer risk., Int J Cancer, 2021. ():, https://pubmed.ncbi.nlm.nih.gov/33905146/
39. Juko-Pecirep, I, Ivansson, EL, Gyllensten, UB, Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility., Gynecol Oncol, 2011. 122 (2)(2): p. 377-81., https://pubmed.ncbi.nlm.nih.gov/21543111/
40. Hu, S, Pu, D, Xia, X, Guo, B, Zhang, C, CTLA-4 rs5742909 polymorphism and cervical cancer risk: A meta-analysis., Medicine (Baltimore), 2020. 99 (11)(11): p. e19433., https://pubmed.ncbi.nlm.nih.gov/32176070/
41. Gao, Y, Zi, D, Liang, W, Qiu, F, Zheng, J, Xiao, X, et.al. PAX1 and SOX1 Gene Methylation as a Detection and Triage Method for Cervical Intraepithelial Neoplasia Diagnosis., Acta Cytol, 2024. 68 (2)(2): p. 137-144., https://pubmed.ncbi.nlm.nih.gov/38527422/
42. Dovnik, A, Poljak, M, The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions., Int J Mol Sci, 2023. 24 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/37047452/
43. Hsu, YW, Huang, RL, Su, PH, Chen, YC, Wang, HC, Liao, CC, et.al. Genotype-specific methylation of HPV in cervical intraepithelial neoplasia., J Gynecol Oncol, 2017. 28 (4)(4): p. e56., https://pubmed.ncbi.nlm.nih.gov/28541643/
44. Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., et.al. Condom use and the risk of genital human papillomavirus infection in young women, N Engl J Med, 2006. 354: p. 2645-54., https://www.ncbi.nlm.nih.gov/pubmed/16790697
45. Frazer, I. H., Leggatt, G. R., Mattarollo, S. R., Prevention and treatment of papillomavirus-related cancers through immunization, Annu Rev Immunol, 2011. 29: p. 111-38., https://www.ncbi.nlm.nih.gov/pubmed/21166538
46. Bray, F., Carstensen, B., Moller, H., Zappa, M., Zakelj, M. P., Lawrence, G., et.al. Incidence trends of adenocarcinoma of the cervix in 13 European countries, Cancer Epidemiol Biomarkers Prev, 2005. 14: p. 2191-9., https://www.ncbi.nlm.nih.gov/pubmed/16172231
47. Hillemanns, Peter, HPV-Impfstoff der Zweiten Generation: Gegen neun Virustypen gerichtet, Dtsch Arztebl International, 2013. 110(51-52): p. 2479-80., https://www.aerzteblatt.de/archiv/hpv-impfstoff-der-zweiten-generation-gegen-neun-virustypen-gerichtet-1597750b-11d3-4372-83bd-c0495a6e17ac
48. Joura, E. A., Giuliano, A. R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., et.al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women, N Engl J Med, 2015. 372(8): p. 711-23., https://www.ncbi.nlm.nih.gov/pubmed/25693011
49. Ständige Impfkommission (STIKO) am RKI, Epidemiologisches Bulletin Nr. 35/2014Robert Koch-Institut, 2014., https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2014/35_14.html
50. Ständige Impfkommission (STIKO) am RKI, Epidemiologisches Bulletin Nr. 26/2018Robert Koch Institut, 2018., https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2018/26_18.html
51. Gemeinsamer Bundesausschuss, Beschluss über eine Änderung der Beauftragung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen: zur Erstellung von Einladungsschreiben und Versicherteninformation zum ZervixkarzinomscreeningGemeinsamer Bundesausschuss,, 2016., https://www.g-ba.de/downloads/39-261-2713/2016-09-15_Aenderung_Beauftragung-IQWiG_Einladung_Zervixkarzinom-Screening_vom-2015-03-19.pdf
52. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen, 2018., https://www.g-ba.de/downloads/39-261-3597/2018-11-22_oKFE-RL_Zervixkarzinom.pdf
53. S3-LL_Prävention_des_Zervixkarzinoms_Langversion 1.1 - März 2020 AWMF-Registernummer 015/025OL, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Zervixkarzinom_Praevention/LL_Prävention_des_Zervixkarzinoms_Langversion_1.1.pdf
54. Urologie, DGU- Deutsche Gesellschaft für, S3-LL-Prostata-Ca.pdf, 2011., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatatkarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.0.pdf
55. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15: p. 7-20., https://www.ncbi.nlm.nih.gov/books/NBK73771/
56. Nilsen, E. S., Myrhaug, H. T., Johansen, M., Oliver, S., Oxman, A. D., Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material, Cochrane Database Syst Rev, 2006. p. CD004563., https://pubmed.ncbi.nlm.nih.gov/16856050/
57. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59: p. 148-57., https://pubmed.ncbi.nlm.nih.gov/16257619/
58. Horton, John, Principles of biomedical ethics: Fifth edition. T. L. Beauchamp and J. F. Childress. New York: Oxford University Press, 2001. xiv454pp. ISBN 0-19-514332-9, Trans R Soc Trop Med Hyg, 2002. 96: p. 107., https://www.researchgate.net/publication/256852850_Principles_of_biomedical_ethics_Fifth_edition_T_L_Beauchamp_J_F_Childress_New_York_Oxford_University_Press_2001_xiv454pp_Price_1995_ISBN_0-19-514332-9
59. DKG - German Cancer Society, Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau (Leitlinienprogramm Onkologie von AWMF, DKG und DKH), 2012., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
60. Sieber, W. J., Kaplan, R. M., Informed adherence: the need for shared medical decision making, Control Clin Trials, 2000. 21(5 Suppl): p. 233s-40s., https://pubmed.ncbi.nlm.nih.gov/11018581/
61. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328: p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
62. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23: p. 6623-30., https://www.ncbi.nlm.nih.gov/pubmed/16170169
63. Wagner, K., Koller, M., Keil, A., Trott, D., Engenhart-Cabillic, R., Pfab, R., et.al. Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment, Chirurg, 1998. 69: p. 252-8., https://www.ncbi.nlm.nih.gov/pubmed/9576035
64. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394
65. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602., https://pubmed.ncbi.nlm.nih.gov/15520059/
66. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53., https://pubmed.ncbi.nlm.nih.gov/15939716/
67. Steinbach K., van Oorschot B., Anselm R., Leppert K, Schweitzer S, Hausmann C, et.al. Wer soll entscheiden?, Deutsches Ärzteblatt, 2004. 41: p. A2741., https://www.aerzteblatt.de/archiv/patienten-als-partner-wer-soll-entscheiden-c28332e5-6447-41dc-b7ea-8168fb23b4f8
68. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms - Langversion 4.2 – August 2019 AWMF-Registernummer: 032-045OL, 2019., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
69. Leroy, T., Gabelle Flandin, I., Habold, D., Hannoun-Levi, J. M., The impact of radiation therapy on sexual function, Cancer Radiother, 2012. 16: p. 377-85., https://www.ncbi.nlm.nih.gov/pubmed/22921960
70. Berger-Hoger, B., Liethmann, K., Muhlhauser, I., Haastert, B., Steckelberg, A., Informed shared decision-making supported by decision coaches for women with ductal carcinoma in situ: study protocol for a cluster randomized controlled trial, Trials, 2015. 16: p. 452., https://www.ncbi.nlm.nih.gov/pubmed/26458964
71. Rahn, A. C., Kopke, S., Kasper, J., Vettorazzi, E., Muhlhauser, I., Heesen, C., Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial, Trials, 2015. 16: p. 106., https://www.ncbi.nlm.nih.gov/pubmed/25872529
72. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. A guideline for guidelines-methodological report and use of the guideline women's information, Zentralbl Gynakol, 2003. 125: p. 484-93., https://www.ncbi.nlm.nih.gov/pubmed/14755359
73. O'Connor, A. M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, BMJ, 1999. 319: p. 731-4., https://www.ncbi.nlm.nih.gov/pubmed/10487995
74. Bürgerliches Gesetzbuch §630d Einwilligung, 2020., https://www.buergerliches-gesetzbuch.info/bgb/630d.html
75. Gilligan, T, Coyle, N, Frankel, RM, Berry, DL, Bohlke, K, Epstein, RM, et.al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline., J Clin Oncol, 2017. 35 (31)(31): p. 3618-3632., https://pubmed.ncbi.nlm.nih.gov/28892432/
76. NHS, Effective Health Care: Informing, communicating and sharing decision with people who have cancer, NHS Centre for Reviews and Dissemination. Plymouth: Latimer Trend & Company Ltd, 2000., https://pmc.ncbi.nlm.nih.gov/articles/PMC1743426/
77. Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., et.al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline, CA Cancer J Clin, 2016. 66(1): p. 43-73., https://www.ncbi.nlm.nih.gov/pubmed/26641959
78. Du, S., Hu, L., Dong, J., Xu, G., Jin, S., Zhang, H., et.al. Patient education programs for cancer-related fatigue: A systematic review, Patient Educ Couns, 2015. 98(11): p. 1308-19., https://www.ncbi.nlm.nih.gov/pubmed/26072422
79. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603., https://www.ncbi.nlm.nih.gov/pubmed/25071125
80. Konsultationsfassung S3 Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen - Langerversion 1.01 - November 2020 AWMF-Registernummer: 032/055OL, 2020., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Komplement%C3%A4r/Version_1/LL_Komplement%C3%A4r_Langversion_1.01.pdf
81. DKG - German Cancer Society, Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau (Leitlinienprogramm Onkologie von AWMF, DKG und DKH), 2012., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
82. Crockett, R. A., Sutton, S., Walter, F. M., Clinch, M., Marteau, T. M., Benson, J., Impact on decisions to start or continue medicines of providing information to patients about possible benefits and/or harms: a systematic review and meta-analysis, Med Decis Making, 2011. 31: p. 767-77., https://pubmed.ncbi.nlm.nih.gov/21447731/
83. Butow, P. N., Maclean, M., Dunn, S. M., Tattersall, M. H., Boyer, M. J., The dynamics of change: cancer patients preferences for information, involvement and support, Ann Oncol, 1997. 8: p. 857-63., https://www.ncbi.nlm.nih.gov/pubmed/9358935
84. Degner, L. F., Kristjanson, L. J., Bowman, D., Sloan, J. A., Carriere, K. C., O'Neil, J., et.al. Information needs and decisional preferences in women with breast cancer, JAMA, 1997. 277: p. 1485-92., https://www.ncbi.nlm.nih.gov/pubmed/9145723
85. Leinster SJ, Ashcroft JJ, Slade PD, et al., Mastectomy versus conservative surgery: psychosocial effects of the patients choice of treatment, J Psychosoc Oncol, 1989. 7: p. 179-192., https://www.tandfonline.com/doi/abs/10.1300/J077v07n01_12
86. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., WHO Classification of Tumours of the Female Genital TractIARC Press, 2014. p. 169-206., https://www.ncbi.nlm.nih.gov/nlmcatalog/101656343
87. Horn, L. C., Brambs, C. E., Opitz, S., Ulrich, U. A., Hohn, A. K., [The 2019 FIGO classification for cervical carcinoma-what's new?], Pathologe, 2019. 40(6): p. 629-635., https://www.ncbi.nlm.nih.gov/pubmed/31612260
88. Dappa, E., Elger, T., Hasenburg, A., Duber, C., Battista, M. J., Hotker, A. M., The value of advanced MRI techniques in the assessment of cervical cancer: a review, Insights Imaging, 2017. 8(5): p. 471-481., https://www.ncbi.nlm.nih.gov/pubmed/28828723
89. Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., Kim, S. H., Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: An updated systematic review and meta-analysis of the literature between 2012 and 2016, Eur Radiol, 2018. 28(2): p. 530-541., https://www.ncbi.nlm.nih.gov/pubmed/28726120
90. Cibula, D, Raspollini, MR, Planchamp, F, Centeno, C, Chargari, C, Felix, A, et.al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023., Int J Gynecol Cancer, 2023. 33 (5)(5): p. 649-666., https://pubmed.ncbi.nlm.nih.gov/37127326/
91. Shinagare, AB, Burk, KS, Kilcoyne, A, Akin, EA, Chuang, L, Hindman, NM, et.al. ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update., J Am Coll Radiol, 2024. 21 (6S)(6S): p. S249-S267., https://pubmed.ncbi.nlm.nih.gov/38823948/
92. Woo, S, Atun, R, Ward, ZJ, Scott, AM, Hricak, H, Vargas, HA, Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis., Eur Radiol, 2020. 30 (10)(10): p. 5560-5577., https://pubmed.ncbi.nlm.nih.gov/32415584/
93. Lee, SI, Atri, M, 2018 FIGO Staging System for Uterine Cervical Cancer: Enter Cross-sectional Imaging., Radiology, 2019. 292 (1)(1): p. 15-24., https://pubmed.ncbi.nlm.nih.gov/31135294/
94. Thomeer, M. G., Gerestein, C., Spronk, S., van Doorn, H. C., van der Ham, E., Hunink, M. G., Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis, Eur Radiol, 2013. 23(7): p. 2005-18., https://www.ncbi.nlm.nih.gov/pubmed/23455762
95. SIGN, SIGN: Management of Cervical Cancer, 2008., https://pmc.ncbi.nlm.nih.gov/articles/PMC2174776/
96. Bipat, S., Glas, A. S., van der Velden, J., Zwinderman, A. H., Bossuyt, P. M., Stoker, J., Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review, Gynecol Oncol, 2003. 91: p. 59-66., https://www.ncbi.nlm.nih.gov/pubmed/14529663
97. Choi, H. J., Ju, W., Myung, S. K., Kim, Y., Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis (Structured abstract), Cancer Science, 2010. 101: p. 1471-1479., https://www.ncbi.nlm.nih.gov/pubmed/20298252
98. Epstein, E., Testa, A., Gaurilcikas, A., Di Legge, A., Ameye, L., Atstupenaite, V., et.al. Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial, Gynecol Oncol, 2013. 128(3): p. 449-53., https://www.ncbi.nlm.nih.gov/pubmed/23022593
99. Delgado, G., Bundy, B., Zaino, R., Sevin, B. U., Creasman, W. T., Major, F., Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, Gynecol Oncol, 1990. 38: p. 352-7., https://www.ncbi.nlm.nih.gov/pubmed/2227547
100. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31(24): p. 3026-33., https://www.ncbi.nlm.nih.gov/pubmed/23857967
101. Tsai, C. S., Lai, C. H., Chang, T. C., Yen, T. C., Ng, K. K., Hsueh, S., et.al. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy, Int J Radiat Oncol Biol Phys, 2010. 76: p. 477-84., https://www.ncbi.nlm.nih.gov/pubmed/19464824
102. Kang, S., Kim, S. K., Chung, D. C., Seo, S. S., Kim, J. Y., Nam, B. H., et.al. Diagnostic value of 18F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a meta-analysis (Structured abstract), Journal of Nuclear Medicine, 2010. 51: p. 360-367., https://www.ncbi.nlm.nih.gov/pubmed/20150275
103. De Cuypere, M., Lovinfosse, P., Goffin, F., Gennigens, C., Rovira, R., Duch, J., et.al. Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study, Eur J Surg Oncol, 2020. 46(5): p. 883-887., https://www.ncbi.nlm.nih.gov/pubmed/31784203
104. Martinez, A., Voglimacci, M., Lusque, A., Ducassou, A., Gladieff, L., Dupuis, N., et.al. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer, Eur J Nucl Med Mol Imaging, 2020. 47(5): p. 1252-1260., https://www.ncbi.nlm.nih.gov/pubmed/31915897
105. Liu, B., Gao, S., Li, S., A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67 Studies, Gynecol Obstet Invest, 2017. 82(3): p. 209-222., https://www.ncbi.nlm.nih.gov/pubmed/28183074
106. Choi, H. J., Ju, W., Myung, S. K., Kim, Y., Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis (Structured abstract), Cancer Science, 2010. 101: p. 1471-1479., https://pubmed.ncbi.nlm.nih.gov/20298252/
107. Kang, S., Kim, S. K., Chung, D. C., Seo, S. S., Kim, J. Y., Nam, B. H., et.al. Diagnostic value of 18F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a meta-analysis (Structured abstract), Journal of Nuclear Medicine, 2010. 51: p. 360-367., https://pubmed.ncbi.nlm.nih.gov/20150275/
108. Meads, C., Auguste, P., Davenport, C., Malysiak, S., Sundar, S., Kowalska, M., et.al. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling, Health Technol Assess, 2013. 17: p. 1-323., https://www.ncbi.nlm.nih.gov/books/NBK260428/
109. Ding, X. P., Feng, L., Ma, L., Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis, Arch Gynecol Obstet, 2014. 290(4): p. 741-7., https://www.ncbi.nlm.nih.gov/pubmed/24798933
110. Xiao, Y., Wei, J., Zhang, Y., Xiong, W., Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis, Arch Med Sci, 2014. 10(2): p. 222-31., https://www.ncbi.nlm.nih.gov/pubmed/24904653
111. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31: p. 3026-33., https://ascopubs.org/doi/pdf/10.1200/JCO.2012.47.3520
112. Elit, L. M., Fyles, A. W., Gu, C. S., Pond, G. R., D'Souza, D., Samant, R., et.al. Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial, JAMA Netw Open, 2018. 1(5): p. e182081., https://www.ncbi.nlm.nih.gov/pubmed/30646153
113. Lin, S. Y., Tsai, C. S., Chang, Y. C., Ng, K. K., Chang, T. C., Kao, W. H., et.al. The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up, International journal of radiation oncology, biology, physics, 2015. 92(3): p. 577-85., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/013/CN-01084013/frame.html
114. Small, W., Jr., Winter, K., Levenback, C., Iyer, R., Gaffney, D., Asbell, S., et.al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116, Int J Radiat Oncol Biol Phys, 2007. 68(4): p. 1081-7., https://pubmed.ncbi.nlm.nih.gov/17398031/
115. Atri, M., Zhang, Z., Dehdashti, F., Lee, S. I., Ali, S., Marques, H., et.al. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial, Gynecol Oncol, 2016. 142(3): p. 413-9., https://www.ncbi.nlm.nih.gov/pubmed/27178725
116. Han, S., Kim, H., Kim, Y. J., Suh, C. H., Woo, S., Prognostic Value of Volume-Based Metabolic Parameters of (18)F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis, AJR Am J Roentgenol, 2018. 211(5): p. 1112-1121., https://www.ncbi.nlm.nih.gov/pubmed/30207790
117. Liu, F. Y., Lai, C. H., Yang, L. Y., Wang, C. C., Lin, G., Chang, C. J., et.al. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial, Eur J Nucl Med Mol Imaging, 2016. 43(10): p. 1812-23., https://www.ncbi.nlm.nih.gov/pubmed/27160224
118. Adam, JA, Loft, A, Chargari, C, Delgado Bolton, RC, Kidd, E, Schöder, H, et.al. EANM/SNMMI practice guideline for [, Eur J Nucl Med Mol Imaging, 2021. 48 (4)(4): p. 1188-1199., https://pubmed.ncbi.nlm.nih.gov/33275178/
119. Fischerova, D, Smet, C, Scovazzi, U, Sousa, DN, Hundarova, K, Haldorsen, IS, Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statements., Int J Gynecol Cancer, 2024. 34 (3)(3): p. 363-378., https://pubmed.ncbi.nlm.nih.gov/38438175/
120. Alcazar, JL, García, E, Machuca, M, Quintana, R, Escrig, J, Chacón, E, et.al. Magnetic resonance imaging and ultrasound for assessing parametrial infiltration in cervical cancer. A systematic review and meta-analysis., Med Ultrason, 2020. 22 (1)(1): p. 85-91., https://pubmed.ncbi.nlm.nih.gov/32096793/
121. Tian, Y, Luo, H, Diagnostic accuracy of transvaginal ultrasound examination for local staging of cervical cancer: a systematic review and meta-analysis., Med Ultrason, 2022. 24 (3)(3): p. 348-355., https://pubmed.ncbi.nlm.nih.gov/34762728/
122. Palsdottir, K., Fischerova, D., Franchi, D., Testa, A., Di Legge, A., Epstein, E., Preoperative prediction of lymph node metastasis and deep stromal invasion in women with invasive cervical cancer: prospective multicenter study using 2D and 3D ultrasound, Ultrasound Obstet Gynecol, 2015. 45(4): p. 470-5., https://www.ncbi.nlm.nih.gov/pubmed/25092154
123. Zhu, Y, Leng, XF, Zhang, GN, Huang, ZY, Qiu, L, Huang, W, Accuracy of transvaginal sonoelastography for differential diagnosis between malignant and benign cervical lesions: A systematic review and meta-analysis., Cancer Med, 2020. 9 (21)(21): p. 7943-7953., https://pubmed.ncbi.nlm.nih.gov/32869506/
124. WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4), 2020. 2020:, https://publications.iarc.fr/592
125. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, et.al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries., CA Cancer J Clin, 2021. 71 (3)(3): p. 209-249., https://pubmed.ncbi.nlm.nih.gov/33538338/
126. Salvo, G, Flores Legarreta, A, Ramalingam, P, Jhingran, A, Bhosale, P, Saab, R, et.al. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study., Int J Gynecol Cancer, 2023. 33 (9)(9): p. 1359-1369., https://pubmed.ncbi.nlm.nih.gov/37567596/
127. Ren, Y, Li, S, Xiang, S, Xu, J, A Retrospective Study on the Clinicopathological Characteristics and Prognostic Analysis of Gynecologic Neuroendocrine Carcinoma., Cancer Med, 2026. 15 (1)(1): p. e71488., https://pubmed.ncbi.nlm.nih.gov/41474616/
128. Horn, L. C., Hentschel, B., Bilek, K., Richter, C. E., Einenkel, J., Leo, C., Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index, Ann Diagn Pathol, 2006. 10: p. 140-3., https://www.ncbi.nlm.nih.gov/pubmed/16730307
129. Rekhi, B, Patil, B, Deodhar, KK, Maheshwari, A, A Kerkar, R, Gupta, S, et.al. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India., Ann Diagn Pathol, 2013. 17 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/22534245/
130. Talia, KL, Oliva, E, Rabban, JT, Singh, N, Stolnicu, S, McCluggage, WG, Grading of Endocervical Adenocarcinomas: Review of the Literature and Recommendations From the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2021. 40 (Suppl 1)(Suppl 1): p. S66-S74., https://pubmed.ncbi.nlm.nih.gov/33570864/
131. Park, KJ, Selinger, CI, Alvarado-Cabrero, I, Duggan, MA, Kiyokawa, T, Mills, AM, et.al. Dataset for the Reporting of Carcinoma of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR)., Int J Gynecol Pathol, 2022. 41 (Suppl 1)(Suppl 1): p. S64-S89., https://pubmed.ncbi.nlm.nih.gov/36305535/
132. Horn, L. C., Handzel, R., Borte, G., Siebolts, U., Haak, A., Brambs, C. E., Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma, J Cancer Res Clin Oncol, 2019. 145(10): p. 2573-2582., https://www.ncbi.nlm.nih.gov/pubmed/31385027
133. Stolnicu, S., Hoang, L., Chiu, D., Hanko-Bauer, O., Terinte, C., Pesci, A., et.al. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC), Am J Surg Pathol, 2019. 43(4): p. 466-474., https://www.ncbi.nlm.nih.gov/pubmed/30720532
134. Stolnicu, S, Role of human papillomavirus status in the classification, diagnosis, and prognosis of malignant cervical epithelial tumors and precursor lesions., Pathologie (Heidelb), 2026. 47 (Suppl 1)(Suppl 1): p. 97-103., https://pubmed.ncbi.nlm.nih.gov/41335338/
135. Hodgson, A, Olkhov-Mitsel, E, Howitt, BE, Nucci, MR, Parra-Herran, C, International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome., J Clin Pathol, 2019. 72 (5)(5): p. 347-353., https://pubmed.ncbi.nlm.nih.gov/30679193/
136. Darragh, T. M., Colgan, T. J., Thomas Cox, J., Heller, D. S., Henry, M. R., Luff, R. D., et.al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, Int J Gynecol Pathol, 2013. 32(1): p. 76-115., https://www.ncbi.nlm.nih.gov/pubmed/23202792
137. Park, KJ, Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification., Histopathology, 2020. 76 (1)(1): p. 112-127., https://pubmed.ncbi.nlm.nih.gov/31846527/
138. Duggan, MA, Duan, Q, Pfeiffer, RM, Brett, MA, Lee, S, Abubakar, M, et.al. Testing Algorithms for the Diagnosis of Malignant Glandular Tumors of the Uterine Cervix Histotyped per the International Endocervical Adenocarcinoma Criteria and Classification (IECC) System., Appl Immunohistochem Mol Morphol, 2022. 30 (2)(2): p. 91-98., https://pubmed.ncbi.nlm.nih.gov/34799503/
139. Ren, H, Pors, J, Chow, C, Ta, M, Stolnicu, S, Soslow, R, et.al. Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization., J Pathol Transl Med, 2020. 54 (6)(6): p. 480-488., https://pubmed.ncbi.nlm.nih.gov/32854489/
140. Jung, H, Bae, GE, Kim, HM, Kim, HS, Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix., Cancer Genomics Proteomics, 2020. 17 (5)(5): p. 627-641., https://pubmed.ncbi.nlm.nih.gov/32859641/
141. Stolnicu, S, Allison, D, Patrichi, A, Flynn, J, Iasonos, A, Soslow, RA, Invasive Squamous Cell Carcinoma of the Cervix: A Review of Morphological Appearances Encountered in Human Papillomavirus-associated and Papillomavirus-independent Tumors and Precursor Lesions., Adv Anat Pathol, 2024. 31 (1)(1): p. 1-14., https://pubmed.ncbi.nlm.nih.gov/37638549/
142. Stolnicu, S, Allison, D, Tessier-Cloutier, B, Momeni-Boroujeni, A, Hoang, L, Ieni, A, et.al. Presence and extent of lymphovascular invasion in surgical stage I squamous cell carcinoma of the cervix: a comprehensive, international, multicentre, retrospective clinicopathological study., Pathology, 2025. 57 (1)(1): p. 17-26., https://pubmed.ncbi.nlm.nih.gov/39477763/
143. Kır, G, Erbağcı, A, Özen, F, Sayit, D, Karateke, A, HPV-independent squamous sell carcinoma of cervix: a clinicopathological, immunohistochemical, and molecular analysis of six cases., Virchows Arch, 2025. 487 (4)(4): p. 775-786., https://pubmed.ncbi.nlm.nih.gov/40347270/
144. Horn, LC, Brambs, CE, Aktas, B, Dannenmann, A, Einenkel, J, Höckel, M, et.al. Human Papilloma Virus-Independent/p53abnormal Keratinizing Squamous Cell Carcinoma of the Uterine Cervix Associated With Uterine Prolapse., Int J Gynecol Pathol, 2025. 44 (1)(1): p. 2-14., https://pubmed.ncbi.nlm.nih.gov/38959413/
145. McCluggage, WG, New histopathological and molecular findings in gynecological cancers., Int J Gynaecol Obstet, 2025. 171 Suppl 1 (Suppl 1)(Suppl 1): p. 109-119., https://pubmed.ncbi.nlm.nih.gov/40739655/
146. Jain, D, Wahidi, M, Effendi, J, Hoang, L, Terinte, C, Pesci, A, et.al. Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status., Gynecol Oncol, 2026. 205 (): p. 89-98., https://pubmed.ncbi.nlm.nih.gov/41576549/
147. Darragh, T. M., Colgan, T. J., Thomas Cox, J., Heller, D. S., Henry, M. R., Luff, R. D., et.al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, Int J Gynecol Pathol, 2013. 32: p. 76-115., https://www.ncbi.nlm.nih.gov/pubmed/22742517
148. Turashvili, G, Karnezis, AN, Hulkower, KI, Hebert, C, Harik, L, Crothers, B, et.al. Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol., Arch Pathol Lab Med, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40956279/
149. Williams, GA, Wu, AA, Eugene, HC, Tsai, YC, Wong, M, Nonogaki, H, et.al. Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva., Am J Surg Pathol, 2025. 49 (5)(5): p. 458-470., https://pubmed.ncbi.nlm.nih.gov/39886739/
150. Sun, Y, Smith, C, Murray, J, Zhu, J, Pallavajjala, A, Liang, S, et.al. Comparative Analysis Reveals Recurrent Molecular Alterations in Low-Risk Human Papillomavirus 6 and Human Papillomavirus 11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva., Mod Pathol, 2025. 38 (12)(12): p. 100909., https://pubmed.ncbi.nlm.nih.gov/41077352/
151. Parra-Herran, C, Nucci, MR, Singh, N, Rakislova, N, Howitt, BE, Hoang, L, et.al. HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva., Mod Pathol, 2022. 35 (10)(10): p. 1317-1326., https://pubmed.ncbi.nlm.nih.gov/35437330/
152. Ko, K, Fukuda, M, Yamanoi, K, Hayashi, N, Yasui, H, Hayashi, T, et.al. Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes., Int J Clin Oncol, 2026. 31 (1)(1): p. 203-213., https://pubmed.ncbi.nlm.nih.gov/41296221/
153. Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D. Y., Banerjee, S., González-Martín, A., et.al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial, J Clin Oncol, 2024. 42(1): p. 47-58., https://pubmed.ncbi.nlm.nih.gov/37870536/
154. Bartley, AN, Washington, MK, Colasacco, C, Ventura, CB, Ismaila, N, Benson, AB, et.al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology., J Clin Oncol, 2017. 35 (4)(4): p. 446-464., https://pubmed.ncbi.nlm.nih.gov/28129524/
155. Mendoza, RP, Ramineni, M, Doytcheva, K, Gabutan, EC, Gupta, R, Miller, C, et.al. Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix., Int J Gynecol Pathol, 2025. 44 (4)(4): p. 323-330., https://pubmed.ncbi.nlm.nih.gov/39480104/
156. Meric-Bernstam, F, Makker, V, Oaknin, A, Oh, DY, Banerjee, S, González-Martín, A, et.al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial., J Clin Oncol, 2024. 42 (1)(1): p. 47-58., https://pubmed.ncbi.nlm.nih.gov/37870536/
157. Muzzarelli, A, Paderno, M, Lorusso, D, New developments in the treatment of cervical cancer in 2026., Curr Opin Obstet Gynecol, 2026. 38 (1)(1): p. 14-21., https://pubmed.ncbi.nlm.nih.gov/41247725/
158. Jöhrens, K, Lazzerini, L, Barinoff, J, Sehouli, J, Cichon, G, Mesothelin as a target for cervical cancer therapy., Arch Gynecol Obstet, 2019. 299 (1)(1): p. 211-216., https://pubmed.ncbi.nlm.nih.gov/30324544/
159. Yasutake, N, Yokawa, Y, Tanaka, T, Mishima, R, Komamizu, M, Kuga, R, et.al. Claudin-18 expression in gastric type adenocarcinoma and HPV-associated adenocarcinoma of the uterine cervix., Histopathology, 2026. 88 (5)(5): p. 1003-1015., https://pubmed.ncbi.nlm.nih.gov/41424299/
160. Hiller, GGR, Wolf, B, Forberger, M, Freude, A, Brambs, CE, Droste, S, et.al. Trop2 expression, p16 expression status, and histologic subtype in carcinoma of the uterine cervix., Pathol Oncol Res, 2025. 31 (): p. 1612252., https://pubmed.ncbi.nlm.nih.gov/41280245/
161. Bhatla, N., Berek, J. S., Cuello Fredes, M., Denny, L. A., Grenman, S., Karunaratne, K., et.al. Revised FIGO staging for carcinoma of the cervix uteri, Int J Gynaecol Obstet, 2019. 145(1): p. 129-135., https://www.ncbi.nlm.nih.gov/pubmed/30656645
162. Wright, J. D., Matsuo, K., Huang, Y., Tergas, A. I., Hou, J. Y., Khoury-Collado, F., et.al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines, Obstet Gynecol, 2019. 134(1): p. 49-57., https://www.ncbi.nlm.nih.gov/pubmed/31188324
163. Raut, A, Chopra, S, Mittal, P, Patil, G, Mahantshetty, U, Gurram, L, et.al. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation., Int J Radiat Oncol Biol Phys, 2020. 108 (5)(5): p. 1248-1256., https://pubmed.ncbi.nlm.nih.gov/32681859/
164. Nicolai, L, Yigit, R, Bleeker, MCG, Bart, J, van der Velden, J, Mom, CH, The risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter., J Gynecol Oncol, 2023. 34 (6)(6): p. e75., https://pubmed.ncbi.nlm.nih.gov/37477098/
165. Ten Eikelder, MLG, Hinten, F, Smits, A, Van der Aa, MA, Bekkers, RLM, IntHout, J, et.al. Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study., Cancers (Basel), 2022. 14 (13)(13):, https://pubmed.ncbi.nlm.nih.gov/35804912/
166. Sponholtz, SE, Mogensen, O, Hildebrandt, MG, Schledermann, D, Parner, E, Markauskas, A, et.al. From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?, Gynecol Oncol, 2021. 163 (2)(2): p. 281-288., https://pubmed.ncbi.nlm.nih.gov/34503847/
167. Dunn, M., Morgan, M. B., Beer, T. W., Perineural invasion: identification, significance, and a standardized definition, Dermatol Surg, 2009. 35: p. 214-21., https://www.ncbi.nlm.nih.gov/pubmed/19215258
168. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., Albo, D., Perineural invasion in cancer: a review of the literature, Cancer, 2009. 115: p. 3379-91., https://pubmed.ncbi.nlm.nih.gov/19484787/
169. Praiss, AM, Allison, D, Tessier-Cloutier, B, Flynn, J, Iasonos, A, Hoang, L, et.al. Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study., Gynecol Oncol, 2023. 176 (): p. 147-154., https://pubmed.ncbi.nlm.nih.gov/37541128/
170. Stolnicu, S, Rakislova, N, Morató, A, Allison, D, Dieguez, NC, Hoang, L, et.al. Cervical Human Papillomavirus-Independent Squamous Cell Carcinoma: A Clinicopathological Review and Outcomes Analysis Compared With Human Papillomavirus-Associated Squamous Cell Carcinoma., Mod Pathol, 2025. 38 (6)(6): p. 100742., https://pubmed.ncbi.nlm.nih.gov/40010435/
171. Ronsini, C, Anchora, LP, Restaino, S, Fedele, C, Arciuolo, D, Teodorico, E, et.al. The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients., Gynecol Oncol, 2021. 162 (2)(2): p. 299-307., https://pubmed.ncbi.nlm.nih.gov/34116834/
172. Horn, L. C., Hohn, A. K., Hentschel, B., Fischer, U., Bilek, K., Brambs, C. E., Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas, J Cancer Res Clin Oncol, 2019. 145(2): p. 457-462., https://www.ncbi.nlm.nih.gov/pubmed/30603900
173. Stolnicu, S, Praiss, AM, Allison, D, Tessier-Cloutier, B, Flynn, J, Iasonos, A, et.al. Proposal of Novel Binary Grading Systems for Cervical Squamous Cell Carcinoma., Int J Gynecol Pathol, 2024. 43 (3)(3): p. 203-214., https://pubmed.ncbi.nlm.nih.gov/38085957/
174. Roma, A. A., Diaz De Vivar, A., Park, K. J., Alvarado-Cabrero, I., Rasty, G., Chanona-Vilchis, J. G., et.al. Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance, Am J Surg Pathol, 2015. 39(5): p. 667-72., https://www.ncbi.nlm.nih.gov/pubmed/25724003
175. Park, KJ, Roma, AA, Pattern based classification of endocervical adenocarcinoma: a review., Pathology, 2018. 50 (2)(2): p. 134-140., https://pubmed.ncbi.nlm.nih.gov/29241973/
176. Byun, JM, Cho, HJ, Park, HY, Kim, YN, Lee, KB, Sung, MS, et.al. Clinical significance of the pattern-based classification in endocervical adenocarcinoma, usual and variants., Int J Clin Oncol, 2019. 24 (10)(10): p. 1264-1272., https://pubmed.ncbi.nlm.nih.gov/31140099/
177. Sinha, N, Lara, OD, Dessources, K, Jones, EP, Clark, LH, Broaddus, R, et.al. Identification of low-risk cases of invasive endocervical adenocarcinoma with Silva pattern-based classification: a systematic review and , Gynecol Oncol Rep, 2025. 59 (): p. 101764., https://pubmed.ncbi.nlm.nih.gov/40491861/
178. Alvarado-Cabrero, I, Parra-Herran, C, Stolnicu, S, Roma, A, Oliva, E, Malpica, A, The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2021. 40 (Suppl 1)(Suppl 1): p. S48-S65., https://pubmed.ncbi.nlm.nih.gov/33570863/
179. Hagen, KK, Lie, AK, Dahl, GF, Eyjolfsdottir, B, Wang, Y, Ranum, P, et.al. The Silva pattern-based classification and oncological outcomes in women undergoing fertility-sparing surgery for early-stage cervical cancer., Int J Gynecol Cancer, 2025. 35 (9)(9): p. 102012., https://pubmed.ncbi.nlm.nih.gov/40737722/
180. Zyla, RE, Dodington, DW, Pakbaz, S, Terzic, T, Robinson, C, Clarke, B, et.al. Assessment of Interobserver Agreement Among Gynecologic Pathologists Between Three-Tier Versus Binary Pattern-based Classification Systems for HPV-associated Endocervical Adenocarcinoma., Am J Surg Pathol, 2024. 48 (12)(12): p. 1522-1529., https://pubmed.ncbi.nlm.nih.gov/39014547/
181. Ben-Mussa, A, Shah, R, Rajendran, S, McCluggage, WG, A Population-based Study Investigating the Incidence of Human Papillomavirus-Associated and Human Papillomavirus-Independent Cervical Adenocarcinomas., Int J Gynecol Pathol, 2025. 44 (3)(3): p. 249-254., https://pubmed.ncbi.nlm.nih.gov/39052435/
182. Sharma, AE, Hodgson, AJ, Howitt, BE, Olkhov-Mitsel, E, Djordevic, B, Park, KJ, et.al. Molecular correlates of invasion pattern in HPV-associated endocervical adenocarcinoma: emergence of two distinct risk-stratified tiers., Histopathology, 2023. 82 (7)(7): p. 1067-1078., https://pubmed.ncbi.nlm.nih.gov/36849702/
183. Giannella, L, Grelloni, C, Natalini, L, Sartini, G, Bordini, M, Delli Carpini, G, et.al. Molecular Features of HPV-Independent Cervical Cancers., Pathogens, 2025. 14 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/40732715/
184. Darragh, T. M., Colgan, T. J., Thomas Cox, J., Heller, D. S., Henry, M. R., Luff, R. D., et.al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, Int J Gynecol Pathol, 2013. 32: p. 76-115., https://pubmed.ncbi.nlm.nih.gov/23202792/
185. Luo, Y. V., Prihoda, T. J., Sharkey, F. E., Number of levels needed for diagnosis of cervical biopsies, Arch Pathol Lab Med, 2002. 126: p. 1205-8., https://www.ncbi.nlm.nih.gov/pubmed/12296760
186. Fadare, O., Rodriguez, R., Squamous dysplasia of the uterine cervix: tissue sampling-related diagnostic considerations in 600 consecutive biopsies, Int J Gynecol Pathol, 2007. 26: p. 469-74., https://www.ncbi.nlm.nih.gov/pubmed/17885500
187. Girardi, F., Frey Tirri, B., Küppers, V., Menton, M., Quaas, J, Reich, O., Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011) - Approbierte Darstellung und Erläuterung für Deutschland, Österreich und die deutschsprachige Schweiz, FRAUENARZT, 2012. 53: p. 1064-1066., https://frauenarzt-archiv.de/mgof-xaveropp/frauenarzt/start.xav
188. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration, Pathologe, 2007. 28: p. 249-60., https://www.ncbi.nlm.nih.gov/pubmed/16838175
189. Kurman, R. J., Amin, M. B., Protocol for the examination of specimens from patients with carcinomas of the cervix: a basis for checklists. Cancer Committee, College of American Pathologists, Arch Pathol Lab Med, 1999. 123: p. 55-61., https://www.ncbi.nlm.nih.gov/pubmed/9923838
190. CAP, College of American Pathologists, 2013., https://www.cap.org/search/?q=cervical%20cancer&size=n_20_n
191. Horn, L. C., Klostermann, K., Precancerous lesions of the uterine cervix: morphology and molecular pathology, Pathologe, 2011. 32 Suppl 2: p. 242-54., https://www.ncbi.nlm.nih.gov/pubmed/21909794
192. Miroshnichenko, G. G., Parva, M., Holtz, D. O., Klemens, J. A., Dunton, C. J., Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision, J Low Genit Tract Dis, 2009. 13: p. 10-2., https://www.ncbi.nlm.nih.gov/pubmed/19098600
193. Shin, J. W., Rho, H. S., Park, C. Y., Factors influencing the choice between cold knife conization and loop electrosurgical excisional procedure for the treatment of cervical intraepithelial neoplasia, J Obstet Gynaecol Res, 2009. 35: p. 126-30., https://pubmed.ncbi.nlm.nih.gov/19215559/
194. McIlwaine, P., Nagar, H., McCluggage, W. G., Multifocal FIGO stage 1A1 cervical squamous carcinomas have an extremely good prognosis equivalent to unifocal lesions, Int J Gynecol Pathol, 2014. 33(3): p. 213-7., https://www.ncbi.nlm.nih.gov/pubmed/24681729
195. Hu, J, Rawish, KR, Leivo, M, Adams, D, Zare, SY, Fadare, O, Pathologic Determination of Multifocality in pT1a1 Squamous Cell Carcinoma of the Cervix: A Retrospective Analysis., Int J Surg Pathol, 2021. 29 (5)(5): p. 482-487., https://pubmed.ncbi.nlm.nih.gov/33616457/
196. Day, E., Duffy, S., Bryson, G., Syed, S., Shanbhag, S., Burton, K., et.al. Multifocal FIGO Stage IA1 Squamous Carcinoma of the Cervix: Criteria for Identification, Staging, and its Good Clinical Outcome, Int J Gynecol Pathol, 2016. 35(5): p. 467-74., https://www.ncbi.nlm.nih.gov/pubmed/26863478
197. Raspollini, MR, Lax, SF, McCluggage, WG, The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines., Virchows Arch, 2018. 473 (1)(1): p. 45-54., https://pubmed.ncbi.nlm.nih.gov/29799071/
198. Lee, S, Rose, MS, Sahasrabuddhe, VV, Zhao, R, Duggan, MA, Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis., Int J Gynecol Pathol, 2017. 36 (4)(4): p. 310-322., https://pubmed.ncbi.nlm.nih.gov/27801764/
199. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31: p. 3026-33., https://www.ncbi.nlm.nih.gov/pubmed/23857967
200. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration, Pathologe, 2007. 28: p. 249-60., https://www.ncbi.nlm.nih.gov/pubmed/16838175
201. Alvarado-Cabrero, I., McCluggage, W. G., Estevez-Castro, R., Perez-Montiel, D., Stolnicu, S., Ganesan, R., et.al. Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases, Am J Surg Pathol, 2019. 43(6): p. 802-809., https://www.ncbi.nlm.nih.gov/pubmed/30864975
202. Stolnicu, S, Segura, S, Parra-Herran, C, Horn, LC, Hoang, L, Terinte, C, et.al. Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Cervix: A Study on Morphologic Diversity., Am J Surg Pathol, 2020. 44 (7)(7): p. 873-880., https://pubmed.ncbi.nlm.nih.gov/32235154/
203. Cavalcanti, MS, Schultheis, AM, Ho, C, Wang, L, DeLair, DF, Weigelt, B, et.al. Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis., Int J Gynecol Pathol, 2017. 36 (1)(1): p. 76-89., https://pubmed.ncbi.nlm.nih.gov/27532149/
204. Ganesan, R., Hirschowitz, L., Dawson, P., Askew, S., Pearmain, P., Jones, P. W., et.al. Neuroendocrine Carcinoma of the Cervix: Review of a Series of Cases and Correlation With Outcome, Int J Surg Pathol, 2016. 24(6): p. 490-6., https://www.ncbi.nlm.nih.gov/pubmed/27098591
205. Wei, KN, Fu, XD, Wang, MY, Wang, LX, Two cases of mixed large cell neuroendocrine carcinoma and adenocarcinoma of the cervix: case report and review of the literature., Diagn Pathol, 2024. 19 (1)(1): p. 166., https://pubmed.ncbi.nlm.nih.gov/39726011/
206. Pan, TL, Pareja, R, Chiva, L, Rodriguez, J, Munsell, MF, Iniesta, MD, et.al. Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer., Int J Gynecol Cancer, 2024. 34 (12)(12): p. 1861-1866., https://pubmed.ncbi.nlm.nih.gov/39448083/
207. Ren, H, Almadani, N, Pors, J, Leung, S, Ho, J, Chow, C, et.al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings., Int J Gynecol Pathol, 2021. 40 (6)(6): p. 533-540., https://pubmed.ncbi.nlm.nih.gov/34612210/
208. Schmeler, KM, Pareja, R, Lopez Blanco, A, Humberto Fregnani, J, Lopes, A, Perrotta, M, et.al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer., Int J Gynecol Cancer, 2021. 31 (10)(10): p. 1317-1325., https://pubmed.ncbi.nlm.nih.gov/34493587/
209. Lucchini, SM, Ferreyra, HD, Landeros, J, Esteban, A, Donetch, G, Goldsman, MG, et.al. Conization and lymph node evaluation in low-risk cervical cancer. Is it time to avoid radical surgery? Retrospective series and literature review., Eur J Obstet Gynecol Reprod Biol, 2021. 266 (): p. 163-168., https://pubmed.ncbi.nlm.nih.gov/34673464/
210. Nica, A, Marchocki, Z, Gien, LT, Kupets, R, Vicus, D, Covens, A, Cervical conization and lymph node assessment for early stage low-risk cervical cancer., Int J Gynecol Cancer, 2021. 31 (3)(3): p. 447-451., https://pubmed.ncbi.nlm.nih.gov/33649012/
211. Kodama, J., Kusumoto, T., Nakamura, K., Seki, N., Hongo, A., Hiramatsu, Y., Factors associated with parametrial involvement in stage IB1 cervical cancer and identification of patients suitable for less radical surgery, Gynecol Oncol, 2011. 122: p. 491-4., https://www.ncbi.nlm.nih.gov/pubmed/21703671
212. Hruda, M, Robova, H, Rob, L, Halaska, MJ, Drozenova, J, Pichlik, T, et.al. Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes., Gynecol Oncol, 2021. 163 (1)(1): p. 100-104., https://pubmed.ncbi.nlm.nih.gov/34330536/
213. Stewart, CJR, Crum, CP, McCluggage, WG, Park, KJ, Rutgers, JK, Oliva, E, et.al. Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites., Int J Gynecol Pathol, 2019. 38 Suppl 1 (Iss 1 Suppl 1)(Iss 1 Suppl 1): p. S75-S92., https://pubmed.ncbi.nlm.nih.gov/30550485/
214. Malpica, A, Euscher, ED, Hecht, JL, Ali-Fehmi, R, Quick, CM, Singh, N, et.al. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (Iss 1 Suppl 1)(Iss 1 Suppl 1): p. S9-S24., https://pubmed.ncbi.nlm.nih.gov/30550481/
215. Medeiros, F, Muto, MG, Lee, Y, Elvin, JA, Callahan, MJ, Feltmate, C, et.al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome., Am J Surg Pathol, 2006. 30 (2)(2): p. 230-6., https://pubmed.ncbi.nlm.nih.gov/16434898/
216. Parkash, V, Matias-Guiu, X, Oliva, E, Malpica, A, McCluggage, WG, Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP)., Int J Gynecol Pathol, 2019. 38 Suppl 1 (Iss 1 Suppl 1)(Iss 1 Suppl 1): p. S3-S8., https://pubmed.ncbi.nlm.nih.gov/30550480/
217. Höhn, AK, Klagges, S, Gläser, A, Taubenheim, S, Dornhöfer, N, Einenkel, J, et.al. Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?, J Cancer Res Clin Oncol, 2021. 147 (3)(3): p. 911-925., https://pubmed.ncbi.nlm.nih.gov/32915262/
218. Balaya, V, Guani, B, Pache, B, Durand, YG, Bonsang-Kitzis, H, Ngô, C, et.al. Sentinel lymph node in cervical cancer: time to move forward., Chin Clin Oncol, 2021. 10 (2)(2): p. 18., https://pubmed.ncbi.nlm.nih.gov/33951917/
219. Guani, B., Dorez, M., Magaud, L., Buenerd, A., Lecuru, F., Mathevet, P., Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial, Int J Gynecol Cancer, 2019. 29(3): p. 447-452., https://www.ncbi.nlm.nih.gov/pubmed/30833435
220. Bianchi, T, Grassi, T, Di Martino, G, Negri, S, Trezzi, G, Fruscio, R, et.al. Low-Volume Metastases in Cervical Cancer: Does Size Matter?, Cancers (Basel), 2024. 16 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/38539442/
221. Euscher, E. D., Malpica, A., Atkinson, E. N., Levenback, C. F., Frumovitz, M., Deavers, M. T., Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma, Am J Surg Pathol, 2008. 32: p. 1336-43., https://www.ncbi.nlm.nih.gov/pubmed/18670356
222. Dundr, P., Cibula, D., Nemejcova, K., Ticha, I., Bartu, M., Jaksa, R., Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer, Arch Pathol Lab Med, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31869245
223. Nemejcova, K, Kocian, R, Kohler, C, Jarkovsky, J, Klat, J, Berjon, A, et.al. Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)., Cancers (Basel), 2020. 12 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/32365651/
224. Balan, L, Rusu, EL, Ciurescu, S, Larisa, TV, Secosa, C, Potre, C, et.al. Feasibility and Diagnostic Accuracy of Ultrastaging in the Detection of Micrometastases in Sentinel and Non-sentinel Lymph Nodes in Cervical Cancer: A Single-Center Retrospective Study With a Five-Year Follow-Up Period., Cureus, 2024. 16 (5)(5): p. e61336., https://pubmed.ncbi.nlm.nih.gov/38947581/
225. Houghton, O, Jamison, J, Wilson, R, Carson, J, McCluggage, WG, p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection., Histopathology, 2010. 57 (3)(3): p. 342-50., https://pubmed.ncbi.nlm.nih.gov/20727021/
226. Stolnicu, S, Barsan, I, Hoang, L, Patel, P, Chiriboga, L, Terinte, C, et.al. Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas., Am J Surg Pathol, 2018. 42 (8)(8): p. 989-1000., https://pubmed.ncbi.nlm.nih.gov/29851704/
227. Yasutake, N, Yamamoto, H, Kuga, R, Jiromaru, R, Hongo, T, Katayama, Y, et.al. Immunohistochemical p16 overexpression and Rb loss correlate with high-risk human papillomavirus infection in endocervical adenocarcinomas., Histopathology, 2024. 84 (7)(7): p. 1178-1191., https://pubmed.ncbi.nlm.nih.gov/38445509/
228. Rychlik, A, Angeles, MA, Migliorelli, F, Croce, S, Mery, E, Martinez, A, et.al. Frozen section examination of sentinel lymph nodes can be used as a decisional tool in the surgical management of early cervical cancer., Int J Gynecol Cancer, 2020. 30 (3)(3): p. 358-363., https://pubmed.ncbi.nlm.nih.gov/31911532/
229. Cibula, D, Kocian, R, Plaikner, A, Jarkovsky, J, Klat, J, Zapardiel, I, et.al. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial., Eur J Cancer, 2020. 137 (): p. 69-80., https://pubmed.ncbi.nlm.nih.gov/32750501/
230. Cohen, P. A., Jhingran, A., Oaknin, A., Denny, L., Cervical cancer, Lancet, 2019. 393(10167): p. 169-182., https://www.ncbi.nlm.nih.gov/pubmed/30638582
231. Horn, L. C., Bilek, K., Fischer, U., Einenkel, J., Hentschel, B., A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer, Gynecol Oncol, 2014. 134(1): p. 42-6., https://www.ncbi.nlm.nih.gov/pubmed/24768850
232. Hou, W, Ma, Y, Sun, S, Gao, Y, Ling, J, Shi, R, Predictive factors for postoperative recurrence in early cervical cancer patients: a meta-analysis., Front Surg, 2025. 12 (): p. 1588558., https://pubmed.ncbi.nlm.nih.gov/40611924/
233. Yoneda, JY, Braganca, JF, Sarian, LO, Borba, PP, Conceição, JC, Zeferino, LC, Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality., Int J Gynecol Cancer, 2015. 25 (4)(4): p. 694-8., https://pubmed.ncbi.nlm.nih.gov/25742569/
234. Chernofsky, MR, Felix, JC, Muderspach, LI, Morrow, CP, Ye, W, Groshen, SG, et.al. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix., Gynecol Oncol, 2006. 100 (2)(2): p. 288-93., https://pubmed.ncbi.nlm.nih.gov/16182347/
235. Obrzut, B., Semczuk, A., Narog, M., Obrzut, M., Krol, P., Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up, Oncology, 2017. 93(2): p. 106-114., https://www.ncbi.nlm.nih.gov/pubmed/28463843
236. Kong, TW, Son, JH, Paek, J, Chang, SJ, Ryu, HS, Prognostic factors influencing pelvic, extra-pelvic, and intraperitoneal recurrences in lymph node-negative early-stage cervical cancer patients following radical hysterectomy., Eur J Obstet Gynecol Reprod Biol, 2020. 252 (): p. 94-99., https://pubmed.ncbi.nlm.nih.gov/32590168/
237. Zhu, HT, Yan, WJ, Gao, YH, The Clinical Aspects and Prognostic Factors Concerning Survival in Patients With Recurrent Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiotherapy., Front Oncol, 2021. 11 (): p. 782403., https://pubmed.ncbi.nlm.nih.gov/35127489/
238. Arango-Bravo, EA, Galicia-Carmona, T, Cetina-Pérez, L, Flores-de la Torre, CB, Enríquez-Aceves, MI, García-Pacheco, JA, et.al. State of the art of cervical cancer treatment in rare histologies., Front Oncol, 2024. 14 (): p. 1386294., https://pubmed.ncbi.nlm.nih.gov/39007101/
239. Gibbs, J, Mei, S, Economos, K, Lee, YC, Kanis, MJ, Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis., Am J Obstet Gynecol, 2019. 221 (1)(1): p. 53.e1-53.e6., https://pubmed.ncbi.nlm.nih.gov/30849352/
240. Rose, P. G., Java, J. J., Whitney, C. W., Stehman, F. B., Lanciano, R., Thomas, G. M., Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation, Gynecol Oncol, 2014. 135(2): p. 208-12., https://www.ncbi.nlm.nih.gov/pubmed/25152438
241. Jesinghaus, M., Strehl, J., Boxberg, M., Bruhl, F., Wenzel, A., Konukiewitz, B., et.al. Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix, J Pathol Clin Res, 2018. 4(2): p. 93-102., https://www.ncbi.nlm.nih.gov/pubmed/29665323
242. Powell, A, Hodgson, A, Cohen, PA, Rabban, JT, Park, KJ, McCluggage, WG, et.al. Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP)., Int J Gynecol Pathol, 2024. 43 (5)(5): p. 436-446., https://pubmed.ncbi.nlm.nih.gov/39164939/
243. Shi, H, Ye, L, Lu, W, Lu, B, Grading of endocervical adenocarcinoma: a novel prognostic system based on tumor budding and cell cluster size., Mod Pathol, 2022. 35 (4)(4): p. 524-532., https://pubmed.ncbi.nlm.nih.gov/34593968/
244. Cairns, M., Tidy, J., Cruickshank, M. E., Management of Microinvasive Cervical Cancer: A British Society for Colposcopy and Cervical Pathology Audit, J Low Genit Tract Dis, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22659775
245. Margolis, B., Cagle-Colon, K., Chen, L., Tergas, A. I., Boyd, L., Wright, J. D., Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer, Int J Gynecol Cancer, 2020. 30(6): p. 735-743., https://www.ncbi.nlm.nih.gov/pubmed/32179697
246. Lim, C. S., Alexander-Sefre, F., Allam, M., Singh, N., Aleong, J. C., Al-Rawi, H., et.al. Clinical value of immunohistochemically detected lymphovascular space invasion in early stage cervical carcinoma, Ann Surg Oncol, 2008. 15: p. 2581-8., https://www.ncbi.nlm.nih.gov/pubmed/18622648
247. Stolnicu, S, Hoang, L, Almadani, N, De Brot, L, Baiocchi, G, Bovolim, G, et.al. Clinical correlation of lymphovascular invasion and Silva pattern of invasion in early-stage endocervical adenocarcinoma: proposed binary Silva classification system., Pathology, 2022. 54 (5)(5): p. 548-554., https://pubmed.ncbi.nlm.nih.gov/35501168/
248. Hockel, M., Horn, L. C., Tetsch, E., Einenkel, J., Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy, Gynecol Oncol, 2012. 125: p. 168-74., https://www.ncbi.nlm.nih.gov/pubmed/22155677
249. van Bommel, P. F., van Lindert, A. C., Kock, H. C., Leers, W. H., Neijt, J. P., A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy, Eur J Obstet Gynecol Reprod Biol, 1987. 26: p. 69-84., https://www.ncbi.nlm.nih.gov/pubmed/3311843
250. Horn, L. C., Meinel, A., Fischer, U., Bilek, K., Hentschel, B., Perineural invasion in carcinoma of the cervix uteri-prognostic impact, J Cancer Res Clin Oncol, 2010. 136: p. 1557-62., https://www.ncbi.nlm.nih.gov/pubmed/20169362
251. Tang, M, Liu, Q, Yang, X, Chen, L, Yu, J, Qi, X, et.al. Perineural invasion as a prognostic risk factor in patients with early cervical cancer., Oncol Lett, 2019. 17 (1)(1): p. 1101-1107., https://pubmed.ncbi.nlm.nih.gov/30655871/
252. Cai, G, Zhang, S, Gao, S, Deng, T, Huang, H, Feng, Y, et.al. What is the impact of perineural invasion on the prognosis of cervical cancer: a systematic review and meta-analysis., BMC Cancer, 2025. 25 (1)(1): p. 491., https://pubmed.ncbi.nlm.nih.gov/40098102/
253. Narayan, K, Fisher, R, Bernshaw, D, Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy., Int J Gynecol Cancer, 2006. 16 (2)(2): p. 623-30., https://pubmed.ncbi.nlm.nih.gov/16681737/
254. Kim, H, Kim, W, Lee, M, Song, E, Loh, JJ, Tumor volume and uterine body invasion assessed by MRI for prediction of outcome in cervical carcinoma treated with concurrent chemotherapy and radiotherapy., Jpn J Clin Oncol, 2007. 37 (11)(11): p. 858-66., https://pubmed.ncbi.nlm.nih.gov/18037686/
255. Juretzka, M. M., Jensen, K. C., Longacre, T. A., Teng, N. N., Husain, A., Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis, Gynecol Oncol, 2004. 93: p. 107-11., https://www.ncbi.nlm.nih.gov/pubmed/15047221
256. Marchiole, P., Buenerd, A., Benchaib, M., Nezhat, K., Dargent, D., Mathevet, P., Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study, Gynecol Oncol, 2005. 97: p. 727-32., https://www.ncbi.nlm.nih.gov/pubmed/15943983
257. Cibula, D., Abu-Rustum, N. R., Dusek, L., Zikan, M., Zaal, A., Sevcik, L., et.al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer, Gynecol Oncol, 2012. 124: p. 496-501., https://www.ncbi.nlm.nih.gov/pubmed/22120175
258. Martinez, A., Mery, E., Ferron, G., Querleu, D., Incidence of micrometastases in histologically negative para-aortic lymph nodes in advanced cervical cancer patients, Gynecol Oncol, 2010. 119: p. 76-80., https://www.ncbi.nlm.nih.gov/pubmed/20667586
259. Zand, B., Euscher, E. D., Soliman, P. T., Schmeler, K. M., Coleman, R. L., Frumovitz, M., et.al. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer, Gynecol Oncol, 2010. 119: p. 422-5., https://www.ncbi.nlm.nih.gov/pubmed/20837355
260. Lee, Y. J., Kim, D. Y., Lee, S. W., Park, J. Y., Suh, D. S., Kim, J. H., et.al. A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection, Gynecol Oncol, 2017. 144(3): p. 536-540., https://www.ncbi.nlm.nih.gov/pubmed/28108027
261. Jia, SZ, Yang, D, Yang, XJ, Wang, R, Yang, X, Huang, MN, et.al. Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study., Radiat Oncol, 2025. 20 (1)(1): p. 73., https://pubmed.ncbi.nlm.nih.gov/40361146/
262. Olthof, EP, Mom, CH, Snijders, MLH, Wenzel, HHB, van der Velden, J, van der Aa, MA, The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer., Acta Obstet Gynecol Scand, 2022. 101 (5)(5): p. 550-557., https://pubmed.ncbi.nlm.nih.gov/35218205/
263. Wang, Y, Liu, X, Liu, J, Liu, L, Ma, Y, Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study., Arch Gynecol Obstet, 2025. 311 (1)(1): p. 123-134., https://pubmed.ncbi.nlm.nih.gov/39751823/
264. Chen, M, Wang, Y, Chen, Y, Han, L, Zheng, A, The prognostic values of lymph node ratio for gynecological cancer: a systematic review and meta-analysis., Front Oncol, 2024. 14 (): p. 1475348., https://pubmed.ncbi.nlm.nih.gov/39411125/
265. Horn, LC, Hentschel, B, Galle, D, Bilek, K, Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri., Gynecol Oncol, 2008. 108 (1)(1): p. 63-7., https://pubmed.ncbi.nlm.nih.gov/17920109/
266. Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., et.al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix, Cancer, 2013. 119(21): p. 3776-83., https://www.ncbi.nlm.nih.gov/pubmed/24037752
267. Ojesina, A. I., Lichtenstein, L., Freeman, S. S., Pedamallu, C. S., Imaz-Rosshandler, I., Pugh, T. J., et.al. Landscape of genomic alterations in cervical carcinomas, Nature, 2014. 506(7488): p. 371-5., https://www.ncbi.nlm.nih.gov/pubmed/24390348
268. Cancer Genome Atlas Research, Network, Albert Einstein College of, Medicine, Analytical Biological, Services, Barretos Cancer, Hospital, Baylor College of, Medicine, Beckman Research Institute of City of, Hope, et.al. Integrated genomic and molecular characterization of cervical cancer, Nature, 2017. 543(7645): p. 378-384., https://www.ncbi.nlm.nih.gov/pubmed/28112728
269. Mirkovic, J., Sholl, L. M., Garcia, E., Lindeman, N., MacConaill, L., Hirsch, M., et.al. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract, Mod Pathol, 2015. 28(11): p. 1504-14., https://www.ncbi.nlm.nih.gov/pubmed/26336887
270. Brambs, CE, Horn, LC, Hiller, R, Krücken, I, Braun, C, Christmann, C, et.al. Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations., J Cancer Res Clin Oncol, 2023. 149 (17)(17): p. 15727-15736., https://pubmed.ncbi.nlm.nih.gov/37668797/
271. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Filipits, M., Bartsch, R., Molecularly targeted therapies in cervical cancer. A systematic review, Gynecol Oncol, 2012. 126: p. 291-303., https://www.ncbi.nlm.nih.gov/pubmed/22504292
272. Roszik, J., Ring, K. L., Wani, K. M., Lazar, A. J., Yemelyanova, A. V., Soliman, P. T., et.al. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy, Front Immunol, 2018. 9: p. 2102., https://www.ncbi.nlm.nih.gov/pubmed/30283446
273. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2018. 68(6): p. 394-424., https://www.ncbi.nlm.nih.gov/pubmed/30207593
274. Denschlag, D, Czogalla, B, Heitz, F, Kerkmann, M, Fangmann, LC, Klecker, PH, et.al. Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus., Geburtshilfe Frauenheilkd, 2025. 85 (5)(5): p. 520-532., https://pubmed.ncbi.nlm.nih.gov/40386500/
275. Wang, H, Ni, C, Xiao, W, Yang, T, Sun, W, Comparison of Radical Surgery and Radiotherapy for the Treatment of Early-Stage Cervical Carcinoma: A Meta-Analysis., Oncol Res Treat, 2021. 44 (4)(4): p. 176-183., https://pubmed.ncbi.nlm.nih.gov/33706315/
276. Vistad, I, Fosså, SD, Dahl, AA, A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer., Gynecol Oncol, 2006. 102 (3)(3): p. 563-72., https://pubmed.ncbi.nlm.nih.gov/16716379/
277. Mota, F., Microinvasive squamous carcinoma of the cervix: treatment modalities, Acta Obstet Gynecol Scand, 2003. 82: p. 505-9., https://pubmed.ncbi.nlm.nih.gov/12780420/
278. Kalliala, I., Nieminen, P., Dyba, T., Pukkala, E., Anttila, A., Cancer free survival after CIN treatment: comparisons of treatment methods and histology, Gynecol Oncol, 2007. 105: p. 228-33., https://pubmed.ncbi.nlm.nih.gov/17289128/
279. Martin-Hirsch, P. P., Paraskevaidis, E., Bryant, A., Dickinson, H. O., Keep, S. L., Surgery for cervical intraepithelial neoplasia, Cochrane Database Syst Rev, 2010. p. CD001318., https://pubmed.ncbi.nlm.nih.gov/20556751/
280. Mehlhorn, G., Lanowska, M., Thiel, F., Köhler, C., Beckmann, M.W., GebFra-Refresher: Organerhaltende operative Methoden im Bereich der Cervix uteri, Geburtsh Frauenheilk, 2008. 68: p. R121-R144., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2008-1039163?lang=en&device=desktop
281. Koch, M. C., Hautmann, S., Thiel, F., Beckmann, M. W., Mehlhorn, G., Ist die Messerkonisation mit anschließender Sturmdorfnaht Out? Gilt die Meinung: „Eine Messerkonisation macht heute kein Mensch mehr!?“ Wie ist der Stellenwert der Laserkonisation? Wie ist es mit der Bewertung der Schnittränder beim Lasern? Ist nicht beim Lasern der Aufwand viel zu hoch und teuer?, gynäkologische Praxis, 2014., https://www.med-search.info/mgof-xaveropp/praxis-zeitschriften/start.xav?start=%2F%2F*%5B@attr_id=%27gp-038-04-0645-0.pdf%27+and+@outline_id=%27gp-038-04-0645-0.pdf%27%5D&
282. AWMF, Diagnostik und Therapie des Zervixkarzinoms, 2008.
283. Covens, A., Rosen, B., Murphy, J., Laframboise, S., DePetrillo, A. D., Lickrish, G., et.al. How important is removal of the parametrium at surgery for carcinoma of the cervix?, Gynecol Oncol, 2002. 84: p. 145-9., https://pubmed.ncbi.nlm.nih.gov/11748991/
284. Jolley, J. A., Battista, L., Wing, D. A., Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature, Am J Perinatol, 2007. 24: p. 531-9., https://www.researchgate.net/publication/5946235_Management_of_Pregnancy_after_Radical_Trachelectomy_Case_Reports_and_Systematic_Review_of_the_Literature
285. Schneider, A., Erdemoglu, E., Chiantera, V., Reed, N., Morice, P., Rodolakis, A., et.al. Clinical recommendation radical trachelectomy for fertility preservation in patients with early-stage cervical cancer, Int J Gynecol Cancer, 2012. 22: p. 659-66., https://pubmed.ncbi.nlm.nih.gov/22398708/
286. Smith, A. L., Frumovitz, M., Schmeler, K. M., dos Reis, R., Nick, A. M., Coleman, R. L., et.al. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?, Gynecol Oncol, 2010. 119: p. 183-6., https://pubmed.ncbi.nlm.nih.gov/20708227/
287. Suri, A., Frumovitz, M., Milam, M. R., dos Reis, R., Ramirez, P. T., Preoperative pathologic findings associated with residual disease at radical hysterectomy in women with stage IA2 cervical cancer, Gynecol Oncol, 2009. 112: p. 110-3., https://pmc.ncbi.nlm.nih.gov/articles/PMC4361069/
288. Lee, S. W., Kim, Y. M., Son, W. S., You, H. J., Kim, D. Y., Kim, J. H., et.al. The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma, Acta Obstet Gynecol Scand, 2009. 88: p. 209-15., https://pubmed.ncbi.nlm.nih.gov/19093236/
289. Chen, H, Chen, Y, Zheng, A, Tan, X, Han, L, Clinical Outcomes Between Completion and Abandonment of Radical Hysterectomy in Early-Stage Cervical Cancer Patients with Lymph Nodal Involvement Identified During Surgery: A Systematic Review and Meta-Analysis., Ann Surg Oncol, 2024. 31 (13)(13): p. 8954-8960., https://pubmed.ncbi.nlm.nih.gov/39373932/
290. Ang, C., Bryant, A., Barton, D. P., Pomel, C., Naik, R., Exenterative surgery for recurrent gynaecological malignancies, Cochrane Database Syst Rev, 2014. 2: p. CD010449., https://pubmed.ncbi.nlm.nih.gov/24497188/
291. Abu-Rustum, NR, Yashar, CM, Arend, R, Barber, E, Bradley, K, Brooks, R, et.al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024., J Natl Compr Canc Netw, 2023. 21 (12)(12): p. 1224-1233., https://pubmed.ncbi.nlm.nih.gov/38081139/
292. Piver, M. S., Rutledge, F., Smith, J. P., Five classes of extended hysterectomy for women with cervical cancer, Obstet Gynecol, 1974. 44: p. 265-72., https://pubmed.ncbi.nlm.nih.gov/4417035/
293. Verleye, L, Vergote, I, Reed, N, Ottevanger, PB, Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG)., Ann Oncol, 2009. 20 (10)(10): p. 1631-8., https://pubmed.ncbi.nlm.nih.gov/19556323/
294. Querleu, D., Morrow, C. P., Classification of radical hysterectomy, Lancet Oncol, 2008. 9(3): p. 297-303., https://pubmed.ncbi.nlm.nih.gov/18308255/
295. Morelli, M., Venturella, R., Mocciaro, R., Di Cello, A., Rania, E., Lico, D., et.al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere, Gynecol Oncol, 2013. 129(3): p. 448-51., https://www.ncbi.nlm.nih.gov/pubmed/23558052
296. Van Lieshout, L. A. M., Pijlman, B., Vos, M. C., de Groot, M. J. M., Houterman, S., Coppus, Sfpj, et.al. Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial, Maturitas, 2018. 107: p. 1-6., https://www.ncbi.nlm.nih.gov/pubmed/29169572
297. Dietl, J., Wischhusen, J., Hausler, S. F., The post-reproductive Fallopian tube: better removed?, Hum Reprod, 2011. 26: p. 2918-24., https://www.ncbi.nlm.nih.gov/pubmed/21849300
298. Falconer, H., Yin, L., Gronberg, H., Altman, D., Ovarian cancer risk after salpingectomy: a nationwide population-based study, J Natl Cancer Inst, 2015. 107(2):, https://www.ncbi.nlm.nih.gov/pubmed/25628372
299. Kho, R. M., Wechter, M. E., Operative Outcomes of Opportunistic Bilateral Salpingectomy at the Time of Benign Hysterectomy in Low-Risk Premenopausal Women: A Systematic Review, J Minim Invasive Gynecol, 2017. 24(2): p. 218-229., https://www.ncbi.nlm.nih.gov/pubmed/27988392
300. Fan, Y, Wang, MY, Mu, Y, Mo, SP, Zheng, A, Li, JK, Ovarian metastasis in women with cervical carcinoma in stages IA to IIB: A systematic review and meta-analysis., Medicine (Baltimore), 2020. 99 (31)(31): p. e21146., https://pubmed.ncbi.nlm.nih.gov/32756092/
301. Shimada, M., Kigawa, J., Nishimura, R., Yamaguchi, S., Kuzuya, K., Nakanishi, T., et.al. Ovarian metastasis in carcinoma of the uterine cervix, Gynecol Oncol, 2006. 101: p. 234-7., https://www.ncbi.nlm.nih.gov/pubmed/16300819
302. Ramirez, PT, Robledo, KP, Frumovitz, M, Pareja, R, Ribeiro, R, Lopez, A, et.al. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer., J Clin Oncol, 2024. 42 (23)(23): p. 2741-2746., https://pubmed.ncbi.nlm.nih.gov/38810208/
303. Smith, AJB, Jones, TN, Miao, D, Fader, AN, Minimally Invasive Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-analysis., J Minim Invasive Gynecol, 2021. 28 (3)(3): p. 544-555.e7., https://pubmed.ncbi.nlm.nih.gov/33359291/
304. Hwang, JH, Kim, BW, Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer., J Minim Invasive Gynecol, 2021. 28 (5)(5): p. 971-981.e3., https://pubmed.ncbi.nlm.nih.gov/33321255/
305. Sun, S, Cai, J, Li, R, Wang, Y, Zhao, J, Huang, Y, et.al. A meta-analysis of survival after minimally invasive radical hysterectomy versus abdominal radical hysterectomy in cervical cancer: center-associated factors matter., Arch Gynecol Obstet, 2022. 306 (3)(3): p. 623-637., https://pubmed.ncbi.nlm.nih.gov/35061066/
306. Yu, Y, Deng, T, Gu, S, Minimally invasive surgery and abdominal radical hysterectomy in patients with early-stage cervical cancer: A meta-analysis., Int J Gynaecol Obstet, 2022. 157 (2)(2): p. 255-264., https://pubmed.ncbi.nlm.nih.gov/34165795/
307. Nasioudis, D, Albright, BB, Ko, EM, Haggerty, AF, Giuntoli Ii, RL, Kim, SH, et.al. Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size , Int J Gynecol Cancer, 2021. 31 (7)(7): p. 983-990., https://pubmed.ncbi.nlm.nih.gov/34016701/
308. Plante, M, Mahner, S, Sebastianelli, A, Bessette, P, Lambaudie, E, Guyon, F, et.al. Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial., Int J Gynecol Cancer, 2025. 35 (1)(1): p. 100001., https://pubmed.ncbi.nlm.nih.gov/39878257/
309. Ramirez, P. T., Robledo, K. P., Frumovitz, M., Pareja, R., Ribeiro, R., Lopez, A., et.al. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer, J Clin Oncol, 2024. 42(23): p. 2741-2746., https://ascopubs.org/doi/10.1200/JCO.23.02335?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
310. Nasioudis, D., Albright, B. B., Ko, E. M., Haggerty, A. F., Giuntoli Ii, R. L., Kim, S. H., et.al. Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size <2 cm: a systematic review and meta-analysis, Int J Gynecol Cancer, 2021. 31(7): p. 983-990., https://www.sciencedirect.com/science/article/pii/S1048891X24005437
311. Kampers, J, Gerhardt, E, Sibbertsen, P, Flock, T, Klapdor, R, Hertel, H, et.al. Protective operative techniques in radical hysterectomy in early cervical carcinoma and their influence on disease-free and overall survival: a systematic review and meta-analysis of risk groups., Arch Gynecol Obstet, 2021. 304 (3)(3): p. 577-587., https://pubmed.ncbi.nlm.nih.gov/34021804/
312. Marchand, G, Masoud, AT, Abdelsattar, A, King, A, Ulibarri, H, Parise, J, et.al. Meta-analysis of laparoscopic radical hysterectomy, excluding robotic assisted versus open radical hysterectomy for early stage cervical cancer., Sci Rep, 2023. 13 (1)(1): p. 273., https://pubmed.ncbi.nlm.nih.gov/36609438/
313. Song, Y. L., Li, R. Z., Feng, B. J., Lu, Y. H., Wang, L. F., Wang, Z. Y., et.al. Survival after minimally invasive radical hysterectomy with protective colpotomy for early-stage cervical cancer: A systematic review and meta-analysis, Eur J Surg Oncol, 2024. 50(4): p. 108240., https://www.sciencedirect.com/science/article/pii/S0748798324002920
314. Obermair, A, Asher, R, Pareja, R, Frumovitz, M, Lopez, A, Moretti-Marques, R, et.al. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial., Am J Obstet Gynecol, 2020. 222 (3)(3): p. 249.e1-249.e10., https://pubmed.ncbi.nlm.nih.gov/31586602/
315. Kampers, J., Gerhardt, E., Sibbertsen, P., Flock, T., Hertel, H., Klapdor, R., et.al. Perioperative morbidity of different operative approaches in early cervical carcinoma: a systematic review and meta-analysis comparing minimally invasive versus open radical hysterectomy, Arch Gynecol Obstet, 2022. 306(2): p. 295-314., https://pmc.ncbi.nlm.nih.gov/articles/PMC9349163/
316. Zeng, Z., Liu, J., Lv, T., Feng, Z., Zhang, L., Liao, Q., Evaluation of the efficacy of laparoscopic-assisted radical vaginal hysterectomy and abdominal radical hysterectomy for treating cervical cancer: a meta-analysis, Wideochir Inne Tech Maloinwazyjne, 2022. 17(1): p. 69-82., https://pubmed.ncbi.nlm.nih.gov/35251391/
317. Li, Y., Kong, Q., Wei, H., Wang, Y., Comparison of the complications between minimally invasive surgery and open surgical treatments for early-stage cervical cancer: A systematic review and meta-analysis, PLoS One, 2021. 16(7): p. e0253143., https://pmc.ncbi.nlm.nih.gov/articles/PMC8248723/
318. Obermair, A., Asher, R., Pareja, R., Frumovitz, M., Lopez, A., Moretti-Marques, R., et.al. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial, Am J Obstet Gynecol, 2020. 222(3): p. 249.e1-249.e10., https://www.ajog.org/article/S0002-9378(19)31165-2/fulltext
319. Zheng, S., Liu, X., Cheng, L., Wu, Q., Meng, F., Effect of minimally invasive surgery and laparotomy on wound infection and postoperative and intraoperative complications in the management of cervical cancer: A meta-analysis, Int Wound J, 2023. 20(4): p. 1061-1071., https://pubmed.ncbi.nlm.nih.gov/36111540/
320. Yun, Z., Li, X., Zhu, D., Li, L., Jiang, S., A meta-analysis examining the impact of open surgical therapy versus minimally invasive surgery on wound infection in females with cervical cancer, Int Wound J, 2024. 21(4): p. e14535., https://onlinelibrary.wiley.com/doi/full/10.1111/iwj.14535?msockid=332f510bf3de6e9403314678f2e76f30
321. Taliento, C, Scutiero, G, Arcieri, M, Pellecchia, G, Tius, V, Bogani, G, et.al. Simple hysterectomy versus radical hysterectomy in early-stage cervical cancer: A systematic review and meta-analysis., Eur J Surg Oncol, 2024. 50 (4)(4): p. 108252., https://pubmed.ncbi.nlm.nih.gov/38471373/
322. Wu, J, Logue, T, Kaplan, SJ, Melamed, A, Tergas, AI, Khoury-Collado, F, et.al. Less radical surgery for early-stage cervical cancer: a systematic review., Am J Obstet Gynecol, 2021. 224 (4)(4): p. 348-358.e5., https://pubmed.ncbi.nlm.nih.gov/33306971/
323. Zeng, S, Xiao, S, Xu, Y, Yang, P, Hu, C, Jin, X, et.al. Efficacy and safety analysis of non-radical surgery for early-stage cervical cancer (IA2 ~ IB1): a systematic review and meta-analysis., Front Med (Lausanne), 2024. 11 (): p. 1337752., https://pubmed.ncbi.nlm.nih.gov/38745744/
324. Plante, M, Kwon, JS, Ferguson, S, Samouëlian, V, Ferron, G, Maulard, A, et.al. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer., N Engl J Med, 2024. 390 (9)(9): p. 819-829., https://pubmed.ncbi.nlm.nih.gov/38416430/
325. Mahner, S, Trillsch, F, Kwon, JS, Ferguson, SE, Bessette, P, Sebastianelli, A, et.al. Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial., Int J Surg, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40694021/
326. Han, L, Chen, Y, Zheng, A, Chen, H, Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis., Gynecol Oncol, 2023. 174 (): p. 167-174., https://pubmed.ncbi.nlm.nih.gov/37207501/
327. Zhu, X, Ye, L, Fu, Y, You, B, Lu, W, Radical Hysterectomy With Preoperative Conization in Early-Stage Cervical Cancer: A Systematic Review and Pairwise and Network Meta-Analysis., J Minim Invasive Gynecol, 2024. 31 (3)(3): p. 193-199., https://pubmed.ncbi.nlm.nih.gov/38016630/
328. Wang, Y, Ma, B, Li, W, Li, P, The efficacy of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer: A meta-analysis., Eur J Surg Oncol, 2023. 49 (11)(11): p. 106995., https://pubmed.ncbi.nlm.nih.gov/37527959/
329. Ferguson, SE, Brotto, LA, Kwon, J, Samouelian, V, Ferron, G, Maulard, A, et.al. Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy., J Clin Oncol, 2025. 43 (2)(2): p. 167-179., https://pubmed.ncbi.nlm.nih.gov/39353164/
330. Sia, TY, Chen, L, Melamed, A, Tergas, AI, Khoury-Collado, F, Hou, JY, et.al. Trends in Use and Effect on Survival of Simple Hysterectomy for Early-Stage Cervical Cancer., Obstet Gynecol, 2019. 134 (6)(6): p. 1132-1143., https://pubmed.ncbi.nlm.nih.gov/31764721/
331. Zhang, Q., Li, W., Kanis, M. J., Qi, G., Li, M., Yang, X., et.al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis, Oncotarget, 2017. 8(28): p. 46580-46592., https://www.ncbi.nlm.nih.gov/pubmed/28418849
332. Plante, M., Renaud, M. C., Francois, H., Roy, M., Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature, Gynecol Oncol, 2004. 94(3): p. 614-23., https://www.ncbi.nlm.nih.gov/pubmed/15350349
333. Guo, J, Hu, Q, Deng, Z, Jin, X, Outcomes of Trachelectomy vs. Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-Analysis., Front Surg, 2021. 8 (): p. 735944., https://pubmed.ncbi.nlm.nih.gov/34859038/
334. Prodromidou, A, Iavazzo, C, Fotiou, A, Psomiadou, V, Douligeris, A, Vorgias, G, et.al. Short- and long term outcomes after abdominal radical trachelectomy versus radical hysterectomy for early stage cervical cancer: a systematic review of the literature and meta-analysis., Arch Gynecol Obstet, 2019. 300 (1)(1): p. 25-31., https://pubmed.ncbi.nlm.nih.gov/31062151/
335. Einstein, M. H., Park, K. J., Sonoda, Y., Carter, J., Chi, D. S., Barakat, R. R., et.al. Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes, Gynecol Oncol, 2009. 112(1): p. 73-7., https://www.ncbi.nlm.nih.gov/pubmed/18973933
336. Wright, JD, Grigsby, PW, Brooks, R, Powell, MA, Gibb, RK, Gao, F, et.al. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy., Cancer, 2007. 110 (6)(6): p. 1281-6., https://pubmed.ncbi.nlm.nih.gov/17654664/
337. Shim, S. H., Lim, M. C., Kim, H. J., Lee, M., Nam, E. J., Lee, J. Y., et.al. Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation, PLoS One, 2018. 13(1): p. e0189847., https://www.ncbi.nlm.nih.gov/pubmed/29385139
338. Ramirez, P. T., Pareja, R., Rendon, G. J., Millan, C., Frumovitz, M., Schmeler, K. M., Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?, Gynecol Oncol, 2014. 132(1): p. 254-9., https://www.ncbi.nlm.nih.gov/pubmed/24041877
339. Kohler, C, Plaikner, A, Siegler, K, Hertel, H, Hasenbein, K, Petzel, A, et.al. Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancer., Int J Gynecol Cancer, 2024. 34 (6)(6): p. 799-805., https://pubmed.ncbi.nlm.nih.gov/38599782/
340. Salvo, G, Ramirez, PT, Leitao, MM, Cibula, D, Wu, X, Falconer, H, et.al. Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study., Am J Obstet Gynecol, 2022. 226 (1)(1): p. 97.e1-97.e16., https://pubmed.ncbi.nlm.nih.gov/34461074/
341. Han, L, Chen, Y, Zheng, A, Tan, X, Chen, H, Minimally invasive versus abdominal radical trachelectomy for early-stage cervical cancer: a systematic review and meta-analysis., Am J Cancer Res, 2023. 13 (9)(9): p. 4466-4477., https://pubmed.ncbi.nlm.nih.gov/37818069/
342. Speiser, Dorothee, Köhler, Christhardt, Schneider, Achim, Mangler, Mandy, Radikale vaginale Trachelektomie, Dtsch Arztebl International, 2013. 110(17): p. 289-295., https://www.aerzteblatt.de/archiv/radikale-vaginale-trachelektomie-e98bfd60-33dc-4d67-a4f8-a0b1090410b2
343. Bentivegna, E., Maulard, A., Pautier, P., Chargari, C., Gouy, S., Morice, P., Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature, Fertil Steril, 2016. 106(5): p. 1195-1211 e5., https://www.ncbi.nlm.nih.gov/pubmed/27430207
344. Fricová, L, Kommoss, S, Scambia, G, Ferron, G, Kocián, R, Harter, P, et.al. Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study., Gynecol Oncol, 2024. 190 (): p. 179-185., https://pubmed.ncbi.nlm.nih.gov/39197417/
345. Slama, J, Runnebaum, IB, Scambia, G, Angeles, MA, Bahrehmand, K, Kommoss, S, et.al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study., Am J Obstet Gynecol, 2023. 228 (4)(4): p. 443.e1-443.e10., https://pubmed.ncbi.nlm.nih.gov/36427596/
346. Boss, E. A., van Golde, R. J., Beerendonk, C. C., Massuger, L. F., Pregnancy after radical trachelectomy: a real option?, Gynecol Oncol, 2005. 99(3 Suppl 1): p. S152-6., https://www.ncbi.nlm.nih.gov/pubmed/16140367
347. Selo-Ojeme, D. O., Ind, T., Shepherd, J. H., Isthmic stenosis following radical trachelectomy, J Obstet Gynaecol, 2002. 22(3): p. 327-8., https://www.ncbi.nlm.nih.gov/pubmed/12521522
348. Pareja, R., Rendon, G. J., Vasquez, M., Echeverri, L., Sanz-Lomana, C. M., Ramirez, P. T., Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2cm or larger: A literature review and analysis of oncological and obstetrical outcomes, Gynecol Oncol, 2015. 137(3): p. 574-80., https://www.ncbi.nlm.nih.gov/pubmed/25827293
349. van Kol, KGG, Vergeldt, TFM, Bekkers, RLM, Abdominal radical trachelectomy versus chemotherapy followed by vaginal radical trachelectomy in stage 1B2 (FIGO 2018) cervical cancer. A systematic review on fertility and recurrence rates., Gynecol Oncol, 2019. 155 (3)(3): p. 515-521., https://pubmed.ncbi.nlm.nih.gov/31606284/
350. Favre, G, Guani, B, Balaya, V, Magaud, L, Lecuru, F, Mathevet, P, Sentinel Lymph-Node Biopsy in Early-Stage Cervical Cancer: The 4-Year Follow-Up Results of the Senticol 2 Trial., Front Oncol, 2020. 10 (): p. 621518., https://pubmed.ncbi.nlm.nih.gov/33680944/
351. Mathevet, P, Lécuru, F, Uzan, C, Boutitie, F, Magaud, L, Guyon, F, et.al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)., Eur J Cancer, 2021. 148 (): p. 307-315., https://pubmed.ncbi.nlm.nih.gov/33773275/
352. Gianoni, M, Mathevet, P, Uzan, C, Bats, AS, Magaud, L, Boutitie, F, et.al. Does the Sentinel Lymph Node Sampling Alone Improve Quality of Life in Early Cervical Cancer Management?, Front Surg, 2020. 7 (): p. 31., https://pubmed.ncbi.nlm.nih.gov/32596252/
353. Ronsini, C, De Franciscis, P, Carotenuto, RM, Pasanisi, F, Cobellis, L, Colacurci, N, The Oncological Implication of Sentinel Lymph Node in Early Cervical Cancer: A Meta-Analysis of Oncological Outcomes and Type of Recurrences., Medicina (Kaunas), 2022. 58 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/36363496/
354. Chiyoda, T, Yoshihara, K, Kagabu, M, Nagase, S, Katabuchi, H, Mikami, M, et.al. Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis., Int J Clin Oncol, 2022. 27 (8)(8): p. 1247-1255., https://pubmed.ncbi.nlm.nih.gov/35612720/
355. Tu, H, Huang, H, Li, Y, Chen, X, Wang, C, Zheng, M, et.al. Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer., N Engl J Med, 2025. 393 (15)(15): p. 1463-1474., https://pubmed.ncbi.nlm.nih.gov/41092328/
356. Baeten, IGT, Hoogendam, JP, Jeremiasse, B, Braat, AJAT, Veldhuis, WB, Jonges, GN, et.al. Indocyanine green versus technetium-99m with blue dye for sentinel lymph node detection in early-stage cervical cancer: A systematic review and meta-analysis., Cancer Rep (Hoboken), 2022. 5 (1)(1): p. e1401., https://pubmed.ncbi.nlm.nih.gov/33973745/
357. Cheng-Yen Lai, J, Yang, MS, Lu, KW, Yu, L, Liou, WZ, Wang, KL, The role of sentinel lymph node biopsy in early-stage cervical cancer: A systematic review., Taiwan J Obstet Gynecol, 2018. 57 (5)(5): p. 627-635., https://pubmed.ncbi.nlm.nih.gov/30342641/
358. Altgassen, C., Hertel, H., Brandstadt, A., Kohler, C., Durst, M., Schneider, A., et.al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group, J Clin Oncol, 2008. 26(18): p. 2943-51., http://www.ncbi.nlm.nih.gov/pubmed/18565880, http://jco.ascopubs.org/content/26/18/2943.full.pdf
359. Zarganis, P, Kondi-Pafiti, A, Arapantoni-Dadioti, P, Trivizaki, E, Velentzas, K, Vorgias, G, et.al. The sentinel node in cervical cancer patients: role of tumor size and invasion of lymphatic vascular space., In Vivo, 2009. 23 (3)(3): p. 469-73., https://pubmed.ncbi.nlm.nih.gov/19454516/
360. Darlin, L, Persson, J, Bossmar, T, Lindahl, B, Kannisto, P, Måsbäck, A, et.al. The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm., Gynecol Oncol, 2010. 117 (2)(2): p. 266-9., https://pubmed.ncbi.nlm.nih.gov/20167355/
361. Balaya, V, Guani, B, Morice, P, Querleu, D, Fourchotte, V, Leblanc, E, et.al. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts., Gynecol Oncol, 2022. 164 (1)(1): p. 53-61., https://pubmed.ncbi.nlm.nih.gov/34696894/
362. Sponholtz, SE, Mogensen, O, Hildebrandt, MG, Schledermann, D, Parner, E, Markauskas, A, et.al. Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial)., Gynecol Oncol, 2021. 162 (3)(3): p. 546-554., https://pubmed.ncbi.nlm.nih.gov/34226018/
363. Delara, R, Yang, J, Buckner-Petty, S, Magtibay, P, Butler, K, Surgical or imaging lymph node assessment in locally advanced cervical cancer: a systematic review and meta-analysis., J Gynecol Oncol, 2020. 31 (6)(6): p. e79., https://pubmed.ncbi.nlm.nih.gov/33078589/
364. Marnitz, S, Tsunoda, AT, Martus, P, Vieira, M, Affonso Junior, RJ, Nunes, J, et.al. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study., Int J Gynecol Cancer, 2020. 30 (12)(12): p. 1855-1861., https://pubmed.ncbi.nlm.nih.gov/33293284/
365. Thelissen, AAB, Jürgenliemk-Schulz, IM, van der Leij, F, Peters, M, Gerestein, CG, Zweemer, RP, et.al. Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis., Gynecol Oncol, 2022. 164 (3)(3): p. 667-674., https://pubmed.ncbi.nlm.nih.gov/34969533/
366. Hacker, NF, Wain, GV, Nicklin, JL, Resection of bulky positive lymph nodes in patients with cervical carcinoma., Int J Gynecol Cancer, 1995. 5 (4)(4): p. 250-256., https://pubmed.ncbi.nlm.nih.gov/11578485/
367. Cheung, TH, Lo, KW, Yim, SF, Yau, SH, Yu, MM, Yeung, WK, Debulking metastatic pelvic nodes before radiotherapy in cervical cancer patients: a long-term follow-up result., Int J Clin Oncol, 2011. 16 (5)(5): p. 546-52., https://pubmed.ncbi.nlm.nih.gov/21437570/
368. Olthof, EP, Wenzel, H, van der Velden, J, Spijkerboer, AM, Bekkers, R, Beltman, JJ, et.al. Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking., Int J Gynecol Cancer, 2022. 32 (7)(7): p. 861-868., https://pubmed.ncbi.nlm.nih.gov/35483738/
369. Yun, BS, Lee, KB, Lee, KH, Chang, HK, Kim, JY, Lim, MC, et.al. Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)., J Gynecol Oncol, 2024. 35 (5)(5): p. e57., https://pubmed.ncbi.nlm.nih.gov/38330380/
370. Morice, P., Rouanet, P., Rey, A., Romestaing, P., Houvenaeghel, G., Boulanger, J. C., et.al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer, Oncologist, 2012. 17: p. 64-71., https://pubmed.ncbi.nlm.nih.gov/22234626/
371. Chereau, E., C, De La Hosseraye, Ballester, M., Monnier, L., Rouzier, R., Touboul, E., et.al. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer, Anticancer Res, 2013. 33: p. 1661-6., https://pubmed.ncbi.nlm.nih.gov/23564812/
372. Darus, C. J., Callahan, M. B., Nguyen, Q. N., Pastore, L. M., Schneider, B. F., Rice, L. W., et.al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma, Int J Gynecol Cancer, 2008. 18: p. 730-5., https://pubmed.ncbi.nlm.nih.gov/17949426/
373. Lu, W, Lu, C, Yu, Z, Gao, L, Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: A systematic review and updated meta-analysis., Oncol Lett, 2021. 21 (2)(2): p. 160., https://pubmed.ncbi.nlm.nih.gov/33552278/
374. Colombo, P. E., Bertrand, M. M., Gutowski, M., Mourregot, A., Fabbro, M., Saint-Aubert, B., et.al. Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results, Gynecol Oncol, 2009. 114: p. 404-9., https://pubmed.ncbi.nlm.nih.gov/19555996/
375. Keys, Henry M., Bundy, Brian N., Stehman, Frederick B., Okagaki, Takashi, Gallup, Donald G., Burnett, Alexander F., et.al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group, Gynecologic Oncology, 2003. 89: p. 343-353., https://pubmed.ncbi.nlm.nih.gov/12798694/
376. Touboul, C., Uzan, C., Mauguen, A., Gouy, S., Rey, A., Pautier, P., et.al. Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer, Oncologist, 2010. 15: p. 405-15., https://pubmed.ncbi.nlm.nih.gov/20332143/
377. Chargari, C, Tanderup, K, Planchamp, F, Chiva, L, Humphrey, P, Sturdza, A, et.al. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer., Radiother Oncol, 2023. 183 (): p. 109589., https://pubmed.ncbi.nlm.nih.gov/37268359/
378. Lin, Y., Chen, K., Lu, Z., Zhao, L., Tao, Y., Ouyang, Y., et.al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis, Radiat Oncol, 2018. 13(1): p. 177., https://www.ncbi.nlm.nih.gov/pubmed/30217165
379. Du, X. L., Tao, J., Sheng, X. G., Lu, C. H., Yu, H., Wang, C., et.al. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy, Gynecol Oncol, 2012. 125(1): p. 151-7., https://www.ncbi.nlm.nih.gov/pubmed/22198339
380. Gandhi, A. K., Sharma, D. N., Rath, G. K., Julka, P. K., Subramani, V., Sharma, S., et.al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study, Int J Radiat Oncol Biol Phys, 2013. 87(3): p. 542-8., https://www.ncbi.nlm.nih.gov/pubmed/24074927
381. Ghadjar, P., Budach, V., Kohler, C., Jantke, A., Marnitz, S., Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation, Radiat Oncol, 2015. 10: p. 50., https://www.ncbi.nlm.nih.gov/pubmed/25890342
382. Marnitz, S., Wlodarczyk, W., Neumann, O., Koehler, C., Weihrauch, M., Budach, V., et.al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation - an intraindividual comparison, Radiat Oncol, 2015. 10: p. 91., https://www.ncbi.nlm.nih.gov/pubmed/25896675
383. Marnitz, S., Lukarski, D., Kohler, C., Wlodarczyk, W., Ebert, A., Budach, V., et.al. Helical tomotherapy versus conventional intensity-modulated radiation therapy for primary chemoradiation in cervical cancer patients: an intraindividual comparison, Int J Radiat Oncol Biol Phys, 2011. 81: p. 424-30., https://www.ncbi.nlm.nih.gov/pubmed/20864270
384. Portelance, L., Chao, K. S. C., Grigsby, P. W., Bennet, H., Low, D., Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation, International Journal of Radiation Oncology Biology Physics, 2001. 51: p. 261-266., https://www.ncbi.nlm.nih.gov/pubmed/11516876
385. Roeske, J. C., Lujan, A., Rotmensch, J., Waggoner, S. E., Yamada, D., Mundt, A. J., Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies, Int J Radiat Oncol Biol Phys, 2000. 48: p. 1613-21., https://www.ncbi.nlm.nih.gov/pubmed/11121668
386. Song, S., Rudra, S., Hasselle, M. D., Dorn, P. L., Mell, L. K., Mundt, A. J., et.al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy, Cancer, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22806897
387. Marnitz, S., Martus, P., Kohler, C., Stromberger, C., Asse, E., Mallmann, P., et.al. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group, Int J Radiat Oncol Biol Phys, 2016. 94(2): p. 243-53., https://www.ncbi.nlm.nih.gov/pubmed/26853333
388. Manders, D. B., Sims, T. T., Bailey, A., Hwang, L., Richardson, D. L., Miller, D. S., et.al. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience, Am J Clin Oncol, 2018. 41(12): p. 1225-1230., https://www.ncbi.nlm.nih.gov/pubmed/29782361
389. Oh, J., Seol, K. H., Choi, Y. S., Lee, J. W., Bae, J. Y., Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy, Yeungnam Univ J Med, 2019. 36(2): p. 115-123., https://www.ncbi.nlm.nih.gov/pubmed/31620623
390. Judith, H. B., JRamon, A. H., Mario, B. T., Juan, G. G., Francisco, P., Randomized prospective trial of extended field radiation therapy versus pelvic radiation therapy alone and with chemotherapy for advanced cervical cancer, preliminary report., International Journal of Radiation Oncology Biology Physics, 1997. 39(2): p. 299-299., https://www.sciencedirect.com/science/article/pii/S036030169780884X
391. Rotman, M., Pajak, T. F., Choi, K., Clery, M., Marcial, V., Grigsby, P. W., et.al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20, JAMA, 1995. 274(5): p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/7616634, https://jamanetwork.com/journals/jama/article-abstract/389343
392. Chantalat, E., Vidal, F., Leguevaque, P., Lepage, B., Mathevet, P., Deslandres, M., et.al. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers, Eur J Obstet Gynecol Reprod Biol, 2015. 193: p. 118-22., https://www.ncbi.nlm.nih.gov/pubmed/26295788
393. Jensen, L. G., Hasselle, M. D., Rose, B. S., Nath, S. K., Hasan, Y., Scanderbeg, D. J., et.al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin, Int J Gynecol Cancer, 2013. 23(1): p. 119-25., https://www.ncbi.nlm.nih.gov/pubmed/23262521
394. Lee, K., Lee, S., Choi, J., Park, S., Shin, J., Lee, K., et.al. Promising results of extended-field radiation therapy and high dose rate brachytherapy with concurrent platinum-based chemotherapy for uterine cervical cancer with para-aortic lymph node involvement, Ejc Supplements, 2007. 5(4): p. 323-323., https://www.sciencedirect.com/science/article/pii/S1359634907712144?via%3Dihub
395. Marnitz, S., Schram, J., Budach, V., Sackerer, I., Vercellino, G. F., Sehouli, J., et.al. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy, Strahlenther Onkol, 2015. 191(5): p. 421-8., https://www.ncbi.nlm.nih.gov/pubmed/25413986
396. Vargo, J. A., Kim, H., Choi, S., Sukumvanich, P., Olawaiye, A. B., Kelley, J. L., et.al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era, Int J Radiat Oncol Biol Phys, 2014. 90(5): p. 1091-8., https://www.ncbi.nlm.nih.gov/pubmed/25303889
397. Hwang, L., Bailey, A., Lea, J., Albuquerque, K., Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management, Future Oncol, 2015. 11(2): p. 309-22., https://www.ncbi.nlm.nih.gov/pubmed/25591841
398. Lim, K., Small, W., Jr., Portelance, L., Creutzberg, C., Jurgenliemk-Schulz, I. M., Mundt, A., et.al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer, Int J Radiat Oncol Biol Phys, 2011. 79: p. 348-55., https://www.ncbi.nlm.nih.gov/pubmed/20472347
399. Shaverdian, N., Gondi, V., Sklenar, K. L., Dunn, E. F., Petereit, D. G., Straub, M. R., et.al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer, Int J Radiat Oncol Biol Phys, 2013. 86(3): p. 562-8., https://www.ncbi.nlm.nih.gov/pubmed/23561652
400. Tanderup, K., Fokdal, L. U., Sturdza, A., Haie-Meder, C., Mazeron, R., van Limbergen, E., et.al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer, Radiother Oncol, 2016. 120(3): p. 441-446., https://www.ncbi.nlm.nih.gov/pubmed/27350396
401. Pötter, R, Tanderup, K, Schmid, MP, Jürgenliemk-Schulz, I, Haie-Meder, C, Fokdal, LU, et.al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study., Lancet Oncol, 2021. 22 (4)(4): p. 538-547., https://pubmed.ncbi.nlm.nih.gov/33794207/
402. Han, K., Milosevic, M., Fyles, A., Pintilie, M., Viswanathan, A. N., Trends in the utilization of brachytherapy in cervical cancer in the United States, Int J Radiat Oncol Biol Phys, 2013. 87(1): p. 111-9., https://www.ncbi.nlm.nih.gov/pubmed/23849695
403. Haie-Meder, C., Potter, R., Van Limbergen, E., Briot, E., De Brabandere, M., Dimopoulos, J., et.al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV, Radiother Oncol, 2005. 74(3): p. 235-45., https://www.ncbi.nlm.nih.gov/pubmed/15763303
404. Schmid, MP, Lindegaard, JC, Mahantshetty, U, Tanderup, K, Jürgenliemk-Schulz, I, Haie-Meder, C, et.al. Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study., J Clin Oncol, 2023. 41 (10)(10): p. 1933-1942., https://pubmed.ncbi.nlm.nih.gov/36599120/
405. Potter, R., Haie-Meder, C., Van Limbergen, E., Barillot, I., De Brabandere, M., Dimopoulos, J., et.al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology, Radiother Oncol, 2006. 78(1): p. 67-77., https://pubmed.ncbi.nlm.nih.gov/16403584/
406. Report 89, J ICRU, 2013. 13(1-2): p. NP., https://www.ncbi.nlm.nih.gov/pubmed/27335498
407. Tanderup, K, Nesvacil, N, Kirchheiner, K, Serban, M, Spampinato, S, Jensen, NBK, et.al. Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer., Semin Radiat Oncol, 2020. 30 (4)(4): p. 311-327., https://pubmed.ncbi.nlm.nih.gov/32828387/
408. Knoth, J, Nout, RA, Pötter, R, Mahantshetty, U, Jürgenliemk-Schulz, I, Haie-Meder, C, et.al. Distant Metastasis After Chemoradiation and Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer., Int J Radiat Oncol Biol Phys, 2025. 123 (2)(2): p. 503-512., https://pubmed.ncbi.nlm.nih.gov/40354949/
409. Brotherton, J. M., Fridman, M., May, C. L., Chappell, G., Saville, A. M., Gertig, D. M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study, Lancet, 2011. 377(9783): p. 2085-92., https://pubmed.ncbi.nlm.nih.gov/21684381/
410. Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et.al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, Cochrane Database Syst Rev, 2005. p. CD002225., https://pubmed.ncbi.nlm.nih.gov/16034873/
411. Wang, N., Guan, Q. L., Wang, K., Zhou, X., Gao, C., Yang, H. T., et.al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis (Structured abstract), Archives of Gynecology and Obstetrics, 2011. 283: p. 103-108., https://pubmed.ncbi.nlm.nih.gov/20157716/
412. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., 3rd, et.al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 1999. 340: p. 1154-61., https://pubmed.ncbi.nlm.nih.gov/10202166/
413. Morris, M., Eifel, P. J., Lu, J. D., Grigsby, P. W., Levenback, C., Stevens, R. E., et.al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, New England Journal of Medicine, 1999. 340: p. 1137-1143., https://pubmed.ncbi.nlm.nih.gov/10202164/
414. Peters, W.A., Liu, P.Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a Phase III inter group study, Soc Gynecol Oncol, 1999., https://pubmed.ncbi.nlm.nih.gov/10764420/
415. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., et.al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 1999. 340: p. 1144-53., https://www.nejm.org/doi/full/10.1056/NEJM199904153401502
416. Whitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, W. C., Jr., et.al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, 1999. 17: p. 1339-48., https://pubmed.ncbi.nlm.nih.gov/10334517/
417. Group, Meta-Analysis, Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials, J Clin Oncol, 2008. 26: p. 5802-12., https://pubmed.ncbi.nlm.nih.gov/19001332/
418. Lukka, H., Hirte, H., Fyles, A., Thomas, G., Elit, L., Johnston, M., et.al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis, Clin Oncol (R Coll Radiol), 2002. 14: p. 203-12., https://pubmed.ncbi.nlm.nih.gov/12109823/
419. Landoni, F., Maneo, A., Colombo, A., Placa, F., Milani, R., Perego, P., et.al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer, Lancet, 1997. 350: p. 535-40., https://pubmed.ncbi.nlm.nih.gov/9284774/
420. Moore, K. N., Gold, M. A., McMeekin, D. S., Zorn, K. K., Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma, Gynecol Oncol, 2007. 106: p. 498-501., https://pubmed.ncbi.nlm.nih.gov/17561235/
421. Gupta, S., Maheshwari, A., Parab, P., Mahantshetty, U., Hawaldar, R., Sastri Chopra, S., et.al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial, J Clin Oncol, 2018. 36(16): p. 1548-1555., https://www.ncbi.nlm.nih.gov/pubmed/29432076
422. G, Kenter, S, Greggi, Vergote, Ignace, al., et., Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994., J Clin Oncol, 2019. 37:, https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5503
423. Zou, W., Han, Y., Zhang, Y., Hu, C., Feng, Y., Zhang, H., et.al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: A systematic review and meta-analysis, PLoS One, 2019. 14(11): p. e0225264., https://www.ncbi.nlm.nih.gov/pubmed/31725793
424. Marchetti, C., Fagotti, A., Tombolini, V., Scambia, G., De Felice, F., Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis, Cancer Treat Rev, 2020. 83: p. 101945., https://www.ncbi.nlm.nih.gov/pubmed/31838220
425. Tripathi, A., Rawat, S., Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix, J Obstet Gynaecol India, 2019. 69(6): p. 546-552., https://www.ncbi.nlm.nih.gov/pubmed/31844371
426. Chino, J, Erickson, B, Gaffney, D, Hsu, IC, Kamrava, M, Kim, Y, et.al. The American Brachytherapy Society (ABS) consensus guidance for hybrid intracavitary interstitial brachytherapy for locally advanced cervical cancer., Brachytherapy, 2025. 24 (4)(4): p. 463-478., https://pubmed.ncbi.nlm.nih.gov/40447530/
427. Sapienza, LG, Jhingran, A, Kollmeier, MA, Lin, LL, Calsavara, VF, Gomes, MJL, et.al. Decrease in uterine perforations with ultrasound image-guided applicator insertion in intracavitary brachytherapy for cervical cancer: A systematic review and meta-analysis., Gynecol Oncol, 2018. 151 (3)(3): p. 573-578., https://pubmed.ncbi.nlm.nih.gov/30333082/
428. Pareek, V, Barthwal, M, Giridhar, P, Patil, PA, Upadhyay, AD, Mallick, S, A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer., Gynecol Oncol, 2021. 160 (2)(2): p. 375-378., https://pubmed.ncbi.nlm.nih.gov/33293047/
429. Knoth, J, Nesvacil, N, Sturdza, A, Kronreif, G, Widder, J, Kirisits, C, et.al. Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer., Brachytherapy, 2022. 21 (2)(2): p. 186-192., https://pubmed.ncbi.nlm.nih.gov/34876361/
430. Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et.al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, Cochrane Database Syst Rev, 2005. p. CD002225., https://www.ncbi.nlm.nih.gov/pubmed/16034873
431. Wang, N., Guan, Q. L., Wang, K., Zhou, X., Gao, C., Yang, H. T., et.al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis (Structured abstract), Archives of Gynecology and Obstetrics, 2011. 283: p. 103-108., https://www.ncbi.nlm.nih.gov/pubmed/20157716
432. Lukka, H, Johnston, M, Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis., Clin Oncol (R Coll Radiol), 2004. 16 (2)(2): p. 160-1., https://pubmed.ncbi.nlm.nih.gov/15074747/
433. Rosa, DD, Medeiros, LR, Edelweiss, MI, Pohlmann, PR, Stein, AT, Adjuvant platinum-based chemotherapy for early stage cervical cancer., Cochrane Database Syst Rev, 2012. 6 (6)(6): p. CD005342., https://pubmed.ncbi.nlm.nih.gov/22696349/
434. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis., Cochrane Database Syst Rev, 2010. 2010 (1)(1): p. CD008285., https://pubmed.ncbi.nlm.nih.gov/20091664/
435. Rogers, Linda, Siu Shing Shun, N., Luesley, David, Bryant, Andrew, Dickinson Heather, O., Radiotherapy and chemoradiation after surgery for early cervical cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2012., https://pubmed.ncbi.nlm.nih.gov/22592722/
436. Wang, S. S., Bratti, M. C., Rodriguez, A. C., Herrero, R., Burk, R. D., Porras, C., et.al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer, J Infect Dis, 2009. 199: p. 20-30., https://pubmed.ncbi.nlm.nih.gov/19012493/
437. Sedlis, A., Bundy, B. N., Rotman, M. Z., Lentz, S. S., Muderspach, L. I., Zaino, R. J., A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study, Gynecol Oncol, 1999. 73: p. 177-83., https://www.ncbi.nlm.nih.gov/pubmed/10329031
438. Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., Liu, P. Y., et.al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial, Gynecologic Oncology, 2005. 96(3): p. 721-728., https://pubmed.ncbi.nlm.nih.gov/15721417/
439. Peters, W. A., 3rd, Liu, P. Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J Clin Oncol, 2000. 18: p. 1606-13., https://www.ncbi.nlm.nih.gov/pubmed/10764420
440. Cibula, D, Akilli, H, Jarkovsky, J, van Lonkhuijzen, L, Scambia, G, Meydanli, MM, et.al. Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study., Gynecol Oncol, 2023. 170 (): p. 195-202., https://pubmed.ncbi.nlm.nih.gov/36706646/
441. da Silva, PHCM, Molino, GOG, Dias, MMF, Pereira, AGA, Pimenta, NDS, Cavalcante, DVS, et.al. Adjuvant Radiotherapy for Intermediate-Risk Early-Stage Cervical Cancer Post Radical Hysterectomy: A Systematic Review and Meta-Analysis., J Clin Med, 2025. 14 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/40507766/
442. Ripepi, C, Cracco, F, Ricci, G, Nappi, L, Restaino, S, Vizzielli, G, et.al. Adjuvant Therapy in "Intermediate-Risk" Early-Stage Cervical Cancer: To Treat or Not to Treat? Systematic Review and Meta-Analysis., Cancers (Basel), 2025. 17 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/40282496/
443. Baiocchi, G, Zanvettor, PH, Lopes, A, Ribeiro, R, Pinto, GLS, Kanaguchi, G, et.al. Reconsidering adjuvant radiotherapy in intermediate-risk cervical cancer: findings from the CIRCOL study group., Int J Gynecol Cancer, 2025. 35 (12)(12): p. 102723., https://pubmed.ncbi.nlm.nih.gov/41175782/
444. Haesen, J, Salihi, R, Van Gorp, T, Van Nieuwenhuysen, E, Han, SN, Christiaens, M, et.al. Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria., Gynecol Oncol, 2021. 162 (3)(3): p. 539-545., https://pubmed.ncbi.nlm.nih.gov/34253389/
445. Petousis, S, Almperis, A, Margioula-Siarkou, C, Guyon, F, Pergialiotis, V, Thomakos, N, et.al. Adjuvant Treatment for Surgically-Treated Cervical Cancer Patients: A Comprehensive Review., Cancers (Basel), 2025. 17 (22)(22):, https://pubmed.ncbi.nlm.nih.gov/41301072/
446. Zhou, N, Beavis, AL, Lin, LL, Neibart, SS, Chino, J, Pierce, JY, et.al. Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S., Gynecol Oncol, 2025. 200 (): p. 193-202., https://pubmed.ncbi.nlm.nih.gov/40947175/
447. Pol, FJ, Zusterzeel, PL, van Ham, MA, Kuijpers, DA, Bulten, J, Massuger, LF, Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer., Gynecol Oncol, 2015. 138 (3)(3): p. 579-84., https://pubmed.ncbi.nlm.nih.gov/26126782/
448. Zhang, H, Yu, R, Zhang, L, Wang, R, Xiao, L, Chemotherapy versus chemoradiotherapy for FIGO stages IB1 and IIA1 cervical squamous cancer patients with lymphovascular space invasion: a retrospective study., BMC Cancer, 2022. 22 (1)(1): p. 202., https://pubmed.ncbi.nlm.nih.gov/35193525/
449. Agustí, N, Viveros-Carreño, D, Wu, CF, Wilke, RN, Kanbergs, A, Barajas, K, et.al. Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer., JAMA Oncol, 2025. 11 (5)(5): p. 511-518., https://pubmed.ncbi.nlm.nih.gov/40079948/
450. Ryu, SY, Deng, W, Albuquerque, K, Koh, WJ, Mayadev, J, Heugel, A, et.al. Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008., Ann Oncol, 2025. 36 (12)(12): p. 1514-1524., https://pubmed.ncbi.nlm.nih.gov/40947016/
451. Chase, DM, Huang, HQ, Deng, W, Koh, WJ, Rodgers, W, Small, W, et.al. Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)., Gynecol Oncol, 2025. 202 (): p. 102-109., https://pubmed.ncbi.nlm.nih.gov/41056581/
452. Cibula, D, Borčinová, M, Kocian, R, Feltl, D, Argalacsova, S, Dvorak, P, et.al. CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)., Int J Gynecol Cancer, 2022. 32 (10)(10): p. 1327-1331., https://pubmed.ncbi.nlm.nih.gov/36100282/
453. Matsuo, K, Matsuzaki, S, Nagase, Y, Keymeulen, S, Karunaratne, MS, Lee, AJ, et.al. Identifying the possible candidate population for adjuvant radiotherapy de-escalation for intermediate-risk cervical cancer., Int J Gynecol Cancer, 2025. 35 (11)(11): p. 102674., https://pubmed.ncbi.nlm.nih.gov/41075563/
454. Tempfer, C. B., Tischoff, I., Dogan, A., Hilal, Z., Schultheis, B., Kern, P., et.al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature, BMC Cancer, 2018. 18(1): p. 530., https://www.ncbi.nlm.nih.gov/pubmed/29728073
455. Salvo, G., Gonzalez Martin, A., Gonzales, N. R., Frumovitz, M., Updates and management algorithm for neuroendocrine tumors of the uterine cervix, Int J Gynecol Cancer, 2019. 29(6): p. 986-995., https://www.ncbi.nlm.nih.gov/pubmed/31263021
456. Landoni, F., Colombo, A., Milani, R., Placa, F., Zanagnolo, V., Mangioni, C., Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update, J Gynecol Oncol, 2017. 28(3): p. e34., https://www.ncbi.nlm.nih.gov/pubmed/28382797
457. Huang, H, Feng, YL, Wan, T, Zhang, YN, Cao, XP, Huang, YW, et.al. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial., JAMA Oncol, 2021. 7 (3)(3): p. 361-369., https://pubmed.ncbi.nlm.nih.gov/33443541/
458. Carcopino, X., Houvenaeghel, G., Buttarelli, M., Esterni, B., Tallet, A., Goncalves, A., et.al. Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy, Eur J Surg Oncol, 2008. 34(5): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/17531428
459. Haque, W., Verma, V., Butler, E. B., Teh, B. S., Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base, Anticancer Res, 2018. 38(5): p. 3175-3179., https://www.ncbi.nlm.nih.gov/pubmed/29715159
460. Shi, D., Liang, Z., Zhang, C., Zhang, H., Liu, X., The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis, BMC Cancer, 2018. 18(1): p. 308., https://www.ncbi.nlm.nih.gov/pubmed/29558900
461. Hass, P., Eggemann, H., Costa, S. D., Ignatov, A., Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer, Strahlenther Onkol, 2017. 193(12): p. 1048-1055., https://www.ncbi.nlm.nih.gov/pubmed/28660291
462. Huang, X. B., Zhang, W. W., Wu, S. G., Sun, J. Y., He, Z. Y., Zhou, J., Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix, J Surg Oncol, 2018. 118(3): p. 574-580., https://www.ncbi.nlm.nih.gov/pubmed/30114328
463. Platt, S. L., Patel, A., Humphrey, P. J., Al-Booz, H., Bailey, J., Completion surgery after chemoradiotherapy for cervical cancer - is there a role? UK Cancer Centre experience of hysterectomy post chemo-radiotherapy treatment for cervical cancer, J Obstet Gynaecol, 2019. 39(1): p. 68-73., https://www.ncbi.nlm.nih.gov/pubmed/30230397
464. Morice, P., Rouanet, P., Rey, A., Romestaing, P., Houvenaeghel, G., Boulanger, J. C., et.al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer, Oncologist, 2012. 17: p. 64-71., https://www.ncbi.nlm.nih.gov/pubmed/22234626
465. Shim, S. H., Kim, S. N., Chae, S. H., Kim, J. E., Lee, S. J., Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: a meta-analysis, J Gynecol Oncol, 2018. 29(2): p. e25., https://www.ncbi.nlm.nih.gov/pubmed/29400018
466. Gosset, M., Chargari, C., Bentivegna, E., Leary, A., Genestie, C., Maulard, A., et.al. Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?, Anticancer Res, 2019. 39(6): p. 2919-2926., https://www.ncbi.nlm.nih.gov/pubmed/31177130
467. Marnitz, S., Abt, E. C., Martus, P., Tsunoda, A., Kohler, C., Is Routine Curettage a Useful Tool to Evaluate Persistent Tumor in Patients Who Underwent Primary Chemoradiation for Locally Advanced and/or Lymph Node Positive Cervical Cancer?, Int J Gynecol Cancer, 2017. 27(6): p. 1216-1221., https://www.ncbi.nlm.nih.gov/pubmed/25950125
468. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010., https://pubmed.ncbi.nlm.nih.gov/20091664/
469. Duenas-Gonzalez, A., Zarba, J. J., Patel, F., Alcedo, J. C., Beslija, S., Casanova, L., et.al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix, J Clin Oncol, 2011. 29: p. 1678-85., https://pubmed.ncbi.nlm.nih.gov/21444871/
470. Mileshkin, LR, Moore, KN, Barnes, EH, Gebski, V, Narayan, K, King, MT, et.al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial., Lancet Oncol, 2023. 24 (5)(5): p. 468-482., https://pubmed.ncbi.nlm.nih.gov/37080223/
471. Peters, W. A., 3rd, Liu, P. Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J Clin Oncol, 2000. 18: p. 1606-13., https://pubmed.ncbi.nlm.nih.gov/10764420/
472. Lorvidhaya, V., Chitapanarux, I., Sangruchi, S., Lertsanguansinchai, P., Kongthanarat, Y., Tangkaratt, S., et.al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1226-32., https://pubmed.ncbi.nlm.nih.gov/12654431/
473. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010., https://www.ncbi.nlm.nih.gov/pubmed/19001332
474. Lorvidhaya, V., Chitapanarux, I., Sangruchi, S., Lertsanguansinchai, P., Kongthanarat, Y., Tangkaratt, S., et.al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1226-32., https://www.ncbi.nlm.nih.gov/pubmed/12654431
475. McCormack, M, Eminowicz, G, Gallardo, D, Diez, P, Farrelly, L, Kent, C, et.al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial., Lancet, 2024. 404 (10462)(10462): p. 1525-1535., https://pubmed.ncbi.nlm.nih.gov/39419054/
476. Lorusso, D, Xiang, Y, Hasegawa, K, Scambia, G, Leiva, M, Ramos-Elias, P, et.al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial., Lancet, 2024. 403 (10434)(10434): p. 1341-1350., https://pubmed.ncbi.nlm.nih.gov/38521086/
477. Monk, BJ, Toita, T, Wu, X, Vázquez Limón, JC, Tarnawski, R, Mandai, M, et.al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial., Lancet Oncol, 2023. 24 (12)(12): p. 1334-1348., https://pubmed.ncbi.nlm.nih.gov/38039991/
478. Ferrandina, G., Legge, F., Fagotti, A., Fanfani, F., Distefano, M., Morganti, A., et.al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures, Gynecol Oncol, 2007. 107: p. S127-32., https://pubmed.ncbi.nlm.nih.gov/17727936/
479. Mancuso, S., Smaniotto, D., Benedetti Panici, P., Favale, B., Greggi, S., Manfredi, R., et.al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma, Gynecol Oncol, 2000. 78: p. 324-8., https://pubmed.ncbi.nlm.nih.gov/10985888/
480. Mariagrazia, D., Anna, F., Gabriella, F., Francesco, F., Daniela, S., Giuseppe, D., et.al. Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications, Gynecol Oncol, 2005. 99: p. S166-70., https://pubmed.ncbi.nlm.nih.gov/16150482/
481. Shibata, K., Kikkawa, F., Suzuki, Y., Terauchi, M., Kajiyama, H., Ino, K., et.al. Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma, Gynecol Obstet Invest, 2004. 57: p. 93-9., https://pubmed.ncbi.nlm.nih.gov/14671418/
482. Wen, H., Wu, X., Li, Z., Wang, H., Zang, R., Sun, M., et.al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer, Int J Gynecol Cancer, 2012. 22: p. 296-302., https://pubmed.ncbi.nlm.nih.gov/22274319/
483. Kim, H. S., Sardi, J. E., Katsumata, N., Ryu, H. S., Nam, J. H., Chung, H. H., et.al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis, Eur J Surg Oncol, 2013. 39: p. 115-24., https://pubmed.ncbi.nlm.nih.gov/23084091/
484. Rydzewska, L., Tierney, J., Vale, C. L., Symonds, P. R., Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer, Cochrane Database Syst Rev, 2012. 12: p. CD007406., https://pubmed.ncbi.nlm.nih.gov/23235641/
485. Peralta, J, Caicedo, L, Rodríguez, J, Viveros-Carreño, D, Vieira-Serna, S, Lemus, MN, et.al. Oncological impact of pelvic vessels embolization in patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy., Int J Gynecol Cancer, 2026. 36 (1)(1): p. 102776., https://pubmed.ncbi.nlm.nih.gov/41270512/
486. Kapp, KS, Poschauko, J, Tauss, J, Berghold, A, Oechs, A, Lahousen, M, et.al. Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma., Int J Radiat Oncol Biol Phys, 2005. 62 (5)(5): p. 1399-404., https://pubmed.ncbi.nlm.nih.gov/16029799/
487. Tewari, KS, Cervical Cancer., N Engl J Med, 2025. 392 (1)(1): p. 56-71., https://pubmed.ncbi.nlm.nih.gov/39752299/
488. Gross, E., Champetier, C., Pointreau, Y., Zaccariotto, A., Duberge, T., Guerder, C., et.al. Normal tissue tolerance to external beam radiation therapy: ovaries, Cancer Radiother, 2010. 14: p. 373-5., https://www.ncbi.nlm.nih.gov/pubmed/20430663
489. Dittrich, R., Lotz, L., Hackl, J., Hildebrandt, T., Cupisti, S., Beckmann, M.W., Fertilitätserhalt bei Krebserkrankungen, Frauenarzt, 2014. 55(3): p. 240-246.
490. Hwang, J. H., Yoo, H. J., Park, S. H., Lim, M. C., Seo, S. S., Kang, S., et.al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy, Fertil Steril, 2012. 97: p. 1387-93 e1-2., https://www.ncbi.nlm.nih.gov/pubmed/22464082
491. Zhao, C., Wang, J. L., Wang, S. J., Zhao, L. J., Wei, L. H., Analysis of the risk factors for the recurrence of cervical cancer following ovarian transposition, Eur J Gynaecol Oncol, 2013. 34(2): p. 124-7., https://www.ncbi.nlm.nih.gov/pubmed/23781581
492. Nakanishi, T., Wakai, K., Ishikawa, H., Nawa, A., Suzuki, Y., Nakamura, S., et.al. A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix, Gynecol Oncol, 2001. 82(3): p. 504-9., http://www.ncbi.nlm.nih.gov/pubmed/11520147
493. Small, W., Jr., Beriwal, S., Demanes, D. J., Dusenbery, K. E., Eifel, P., Erickson, B., et.al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy, Brachytherapy, 2012. 11: p. 58-67., https://pubmed.ncbi.nlm.nih.gov/22265439/
494. Gemignani, M. L., Alektiar, K. M., Leitao, M., Mychalczak, B., Chi, D., Venkatraman, E., et.al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers, Int J Radiat Oncol Biol Phys, 2001. 50: p. 687-94., https://pubmed.ncbi.nlm.nih.gov/11395237/
495. Giorda, G., Boz, G., Gadducci, A., Lucia, E., De Piero, G., De Paoli, A., et.al. Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy. A phase II trial, Eur J Surg Oncol, 2011. 37: p. 442-7., https://pubmed.ncbi.nlm.nih.gov/21492777/
496. Jurado, M., Martinez-Monge, R., Garcia-Foncillas, J., Azinovic, I., Aristu, J., Lopez-Garcia, G., et.al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery, intraoperative electron beam radiotherapy in locally advanced cervical cancer, Gynecol Oncol, 1999. 74: p. 30-7., https://www.sciencedirect.com/science/article/pii/S0090825899954240
497. Mahe, M. A., Gerard, J. P., Dubois, J. B., Roussel, A., Bussieres, E., Delannes, M., et.al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients, Int J Radiat Oncol Biol Phys, 1996. 34: p. 21-6., https://pubmed.ncbi.nlm.nih.gov/12118553/
498. Tran, P. T., Su, Z., Hara, W., Husain, A., Teng, N., Kapp, D. S., Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies, Int J Radiat Oncol Biol Phys, 2007. 69: p. 504-11., https://pubmed.ncbi.nlm.nih.gov/17560736/
499. Winter, W. E., 3rd, Maxwell, G. L., Tian, C., Sobel, E., Rose, G. S., Thomas, G., et.al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study, Gynecol Oncol, 2004. 94: p. 495-501., https://www.ncbi.nlm.nih.gov/pubmed/15297194
500. Dunst, J., Kuhnt, T., Strauss, H. G., Krause, U., Pelz, T., Koelbl, H., et.al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis, Int J Radiat Oncol Biol Phys, 2003. 56: p. 778-87., https://www.ncbi.nlm.nih.gov/pubmed/12788185
501. Fyles, A. W., Milosevic, M., Pintilie, M., Syed, A., Hill, R. P., Anemia, hypoxia and transfusion in patients with cervix cancer: a review, Radiother Oncol, 2000. 57: p. 13-9., https://www.ncbi.nlm.nih.gov/pubmed/11033184
502. Bishop, A. J., Allen, P. K., Klopp, A. H., Meyer, L. A., Eifel, P. J., Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?, Int J Radiat Oncol Biol Phys, 2015. 91(1): p. 196-205., https://www.ncbi.nlm.nih.gov/pubmed/25446609
503. Thomas, G., Ali, S., Hoebers, F. J., Darcy, K. M., Rodgers, W. H., Patel, M., et.al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer, Gynecol Oncol, 2008. 108: p. 317-25., https://www.ncbi.nlm.nih.gov/pubmed/18037478
504. Strauss, H. G., Haensgen, G., Dunst, J., Hayward, C. R., Burger, H. U., Scherhag, A., et.al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer, Int J Gynecol Cancer, 2008. 18: p. 515-24., https://www.ncbi.nlm.nih.gov/pubmed/17645506
505. Gupta, S., Singh, P. K., Bisth, S. S., Bhatt, M. L., Pant, M., Gupta, R., et.al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy", Cancer Biol Ther, 2009. 8: p. 13-7., https://www.ncbi.nlm.nih.gov/pubmed/18981719
506. Blohmer, J. U., Paepke, S., Sehouli, J., Boehmer, D., Kolben, M., Wurschmidt, F., et.al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study, J Clin Oncol, 2011. 29: p. 3791-7., https://pubmed.ncbi.nlm.nih.gov/21860000/
507. Lutgens, L., van der Zee, J., Pijls-Johannesma, M., De Haas-Kock, D. F., Buijsen, J., Mastrigt, G. A., et.al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma, Cochrane Database Syst Rev, 2010. p. CD006377., https://www.ncbi.nlm.nih.gov/pubmed/20091593
508. Ohguri, T., Harima, Y., Imada, H., Sakurai, H., Ohno, T., Hiraki, Y., et.al. Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial, Int J Hyperthermia, 2018. 34(4): p. 461-468., https://www.ncbi.nlm.nih.gov/pubmed/28679349
509. Richel, O., Zum Vorde Sive Vording, P. J., Rietbroek, R., Van der Velden, J., Van Dijk, J. D., Schilthuis, M. S., et.al. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer, Gynecol Oncol, 2004. 95(3): p. 680-5., https://pubmed.ncbi.nlm.nih.gov/15581981/
510. De Lazzari, M, Carrapiço-Seabra, C, Marder, D, van Rhoon, GC, Curto, S, Dobšíček Trefná, H, Toward enhanced quality assurance guidelines for deep hyperthermia devices: a multi-institution study., Int J Hyperthermia, 2024. 41 (1)(1): p. 2436005., https://pubmed.ncbi.nlm.nih.gov/39658024/
511. Bruggmoser, G., Bauchowitz, S., Canters, R., Crezee, H., Ehmann, M., Gellermann, J., et.al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia, Strahlenther Onkol, 2012. 188 Suppl 2: p. 198-211., https://www.ncbi.nlm.nih.gov/pubmed/22926657
512. Harima, Y., Ohguri, T., Imada, H., Sakurai, H., Ohno, T., Hiraki, Y., et.al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer, Int J Hyperthermia, 2016. 32(7): p. 801-8., https://www.ncbi.nlm.nih.gov/pubmed/27418208
513. Wang, Y, Hong, W, Che, S, Zhang, Y, Meng, D, Shi, F, et.al. Outcomes for Hyperthermia Combined with Concurrent Radiochemotherapy for Patients with Cervical Cancer., Int J Radiat Oncol Biol Phys, 2020. 107 (3)(3): p. 499-511., https://pubmed.ncbi.nlm.nih.gov/32179132/
514. IJff, M, Crezee, J, Oei, AL, Stalpers, LJA, Westerveld, H, The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review., Int J Gynecol Cancer, 2022. 32 (3)(3): p. 288-296., https://pubmed.ncbi.nlm.nih.gov/35046082/
515. He, L., Wu, L., Su, G., Wei, W., Liang, L., Han, L., et.al. The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer, Gynecol Oncol, 2014. 134(2): p. 419-25., https://www.ncbi.nlm.nih.gov/pubmed/24918866
516. Laios, A., Kasius, J., Tranoulis, A., Gryparis, A., Ind, T., Obstetric Outcomes in Women With Early Bulky Cervical Cancer Downstaged by Neoadjuvant Chemotherapy to Allow for Fertility-Sparing Surgery: A Meta-analysis and Metaregression, Int J Gynecol Cancer, 2018. 28(4): p. 794-801., https://www.ncbi.nlm.nih.gov/pubmed/29538257
517. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, , AWMF), S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, AWMF-Registernummer: 032/054OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie
518. Wang, D, Fang, X, Meta-analysis of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer., Eur J Obstet Gynecol Reprod Biol, 2024. 297 (): p. 202-208., https://pubmed.ncbi.nlm.nih.gov/38678796/
519. Ronsini, C, Solazzo, MC, Braca, E, Andreoli, G, Vastarella, MG, Cianci, S, et.al. Locally Advanced Cervical Cancer: Neoadjuvant Treatment versus Standard Radio-Chemotherapy-An Updated Meta-Analysis., Cancers (Basel), 2024. 16 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/39061182/
520. Yang, SL, Chen, L, He, Y, Zhao, H, Wu, YM, Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I-II cervical cancer: a meta-analysis., J Int Med Res, 2020. 48 (8)(8): p. 300060520945507., https://pubmed.ncbi.nlm.nih.gov/32867558/
521. Ye, Q, Yang, Y, Tang, X, Li, J, Li, X, Zhang, Y, Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy (with or without Chemotherapy) in Patients with Stage IB2, IIA, or IIB Cervical Cancer: A Systematic Review and Meta-Analysis., Dis Markers, 2020. 2020 (): p. 7415056., https://pubmed.ncbi.nlm.nih.gov/32802215/
522. Zhao, H, He, Y, Yang, SL, Zhao, Q, Wu, YM, Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis., Onco Targets Ther, 2019. 12 (): p. 1881-1891., https://pubmed.ncbi.nlm.nih.gov/30881040/
523. Rydzewska, L., Tierney, J., Vale, C. L., Symonds, P. R., Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer, Cochrane Database Syst Rev, 2012. 12: p. CD007406., https://www.ncbi.nlm.nih.gov/pubmed/20091632
524. Peng, Y. H., Wang, X. X., Zhu, J. S., Gao, L., Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: Meta-analysis of randomized controlled trials, J Obstet Gynaecol Res, 2016. 42(2): p. 128-35., https://www.ncbi.nlm.nih.gov/pubmed/26807961
525. Yang, Z., Chen, D., Zhang, J., Yao, D., Gao, K., Wang, H., et.al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study, Gynecologic oncology, 2016. 141(2): p. 231-239., https://www.sciencedirect.com/science/article/pii/S0090825815300482?via%3Dihub
526. He, D., Duan, C., Chen, J., Lai, L., Chen, J., Chen, D., The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis, Int J Clin Exp Med, 2015. 8(9): p. 14693-700., https://www.ncbi.nlm.nih.gov/pubmed/26628951
527. Hu, Y, Han, Y, Shen, Y, Chen, J, Chen, Y, Chen, Y, et.al. Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial., BMC Cancer, 2022. 22 (1)(1): p. 1270., https://pubmed.ncbi.nlm.nih.gov/36471257/
528. Kenter, GG, Greggi, S, Vergote, I, Katsaros, D, Kobierski, J, van Doorn, H, et.al. Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994., J Clin Oncol, 2023. 41 (32)(32): p. 5035-5043., https://pubmed.ncbi.nlm.nih.gov/37656948/
529. Zhu, Y., Yang, J., Zhang, X., Chen, D., Zhang, S., Acquired treatment response from neoadjuvant chemotherapy predicts a favorable prognosis for local advanced cervical cancer: A meta-analysis, Medicine (Baltimore), 2018. 97(17): p. e0530., https://www.ncbi.nlm.nih.gov/pubmed/29703026
530. Ye, Q., Yuan, H. X., Chen, H. L., Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis, J Cancer Res Clin Oncol, 2013. 139(11): p. 1887-98., https://www.ncbi.nlm.nih.gov/pubmed/24022086
531. Chen, Z., Shi, Y., Wang, S., Lu, Q., Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients, Oncotarget, 2017. 8(35): p. 59609-59617., https://www.ncbi.nlm.nih.gov/pubmed/28938664
532. Hou, Q, Shen, J, Zhou, S, Wei, J, Wu, M, Chen, Q, et.al. Early response to neoadjuvant chemotherapy helps decrease recurrence rate of cervical cancer: a systematic review and meta-analysis., Ann Palliat Med, 2021. 10 (6)(6): p. 6092-6103., https://pubmed.ncbi.nlm.nih.gov/34118837/
533. Song, Y., Liu, Y., Lin, M., Sheng, B., Zhu, X., Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis, Drug Des Devel Ther, 2019. 13: p. 79-102., https://www.ncbi.nlm.nih.gov/pubmed/30587930
534. Gwacham, NI, McKenzie, ND, Fitzgerald, ER, Ahmad, S, Holloway, RW, Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives., Gynecol Oncol, 2021. 162 (3)(3): p. 809-815., https://pubmed.ncbi.nlm.nih.gov/34130862/
535. Kim, H. S., Sardi, J. E., Katsumata, N., Ryu, H. S., Nam, J. H., Chung, H. H., et.al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis, Eur J Surg Oncol, 2013. 39(2): p. 115-24., https://www.ncbi.nlm.nih.gov/pubmed/23084091
536. Chen, B, Wang, L, Ren, C, Shen, H, Ding, W, Zhu, D, et.al. The Effect of Neoadjuvant Chemotherapy on Lymph Node Metastasis of FIGO Stage IB1-IIB Cervical Cancer: A Systematic Review and Meta-Analysis., Front Oncol, 2020. 10 (): p. 570258., https://pubmed.ncbi.nlm.nih.gov/33251136/
537. Weng, D, Xiong, H, Zhu, C, Wan, X, Chen, Y, Wang, X, et.al. Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial., Front Med, 2023. 17 (1)(1): p. 93-104., https://pubmed.ncbi.nlm.nih.gov/36422763/
538. Tzioras, S., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P., Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis, Cancer Treat Rev, 2007. 33: p. 24-38., https://www.ncbi.nlm.nih.gov/pubmed/17112673
539. S2k Leitlinie Diagnostik und Therapie der Lymphödeme AWMF Reg.-Nr. 058-001 - Mai 2017, https://www.awmf.org/uploads/tx_szleitlinien/058-001l_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2019-07.pdf
540. Miles, T., Johnson, N., Vaginal dilator therapy for women receiving pelvic radiotherapy, Cochrane Database Syst Rev, 2014. p. CD007291., https://www.ncbi.nlm.nih.gov/pubmed/25198150
541. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50: p. 440-7., https://pubmed.ncbi.nlm.nih.gov/19855028/
542. Hodgkinson, K., Butow, P., Fuchs, A., Hunt, G. E., Stenlake, A., Hobbs, K. M., et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes, Gynecol Oncol, 2007. 104: p. 381-9., https://pubmed.ncbi.nlm.nih.gov/17027072/
543. Klee, M., Thranov, I., Machin Prof, D., The patients perspective on physical symptoms after radiotherapy for cervical cancer, Gynecol Oncol, 2000. 76: p. 14-23., https://pubmed.ncbi.nlm.nih.gov/10620435/
544. Li, C., Samsioe, G., Iosif, C., Quality of life in endometrial cancer survivors, Maturitas, 1999. 31: p. 227-36., https://pubmed.ncbi.nlm.nih.gov/10340282/
545. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16: p. 222-30., https://pubmed.ncbi.nlm.nih.gov/17508941/
546. Roth, A. J., Carter, J., Nelson, C. L., Sexuality after CancerOxford University Press, Psycho-Oncology, 2010., https://academic.oup.com/oxford-medicine-online?statusCode=404&404;http://oxfordmedicine.com:80/view/10.1093/med/9780195367430.001.0001/med-9780195367430-chapter-33
547. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31: p. 284-91., https://pubmed.ncbi.nlm.nih.gov/18600115/
548. Kaufmann, M., Ernst, B., Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen, Deutsches Ärzteblatt, 2000. 47: p. 191-196., https://api.aerzteblatt.de/pdf/97/47/a3191.pdf
549. Leitlinienprogramm_Onkologie, S3 Leitlinie "Psychoonkologische Diagnostik, Beratung und Behandlung von Krebspatienten“ (AWMF-Registernummer 032 - 051OL), 2014.
550. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22: p. 1369-81., https://pubmed.ncbi.nlm.nih.gov/8539178/
551. Herschbach, P., Weis, J., Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten, Deutsche Krebsgesellschaft Berlin, 2010. 2. Auflage:, https://www.wpo-ev.de/wp-content/uploads/2023/07/Screening_broschuere.pdf
552. Mehnert, A., Lehmann, C., Cao, P., Koch, U., Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments, Psychother Psychosom Med Psychol, 2006. 56: p. 462-79., https://pubmed.ncbi.nlm.nih.gov/17160791/
553. Chan, Y. M., Lee, P. W., Fong, D. Y., Fung, A. S., Wu, L. Y., Choi, A. Y., et.al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial, J Clin Oncol, 2005. 23: p. 4913-24., https://www.ncbi.nlm.nih.gov/pubmed/15939927
554. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2008. 17: p. 392-400., https://www.ncbi.nlm.nih.gov/pubmed/17680554
555. Radoschewski, M., Gesundheitsbezogene Lebensqualität - Konzepte und Maße: Entwicklungen und Stand im Überblick, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2000. 43: p. 165-189., https://link.springer.com/article/10.1007/s001030050033
556. Hack, C, Integrative Medizin in der Gynäkologischen Onkologie, Geburtsh Frauenheilk, 2013. 73: p. R65-R80., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0033-1350906
557. Horneber, M., Bueschel, G., Dennert, G., Less, D., Ritter, E., Zwahlen, M., How Many Cancer Patients Use Complementary and Alternative Medicine: A Systematic Review and Metaanalysis, Integr Cancer Ther, 2011., https://www.ncbi.nlm.nih.gov/pubmed/22019489
558. Consortion of Academic Health Centers for Integrative Medicine 2019:, https://imconsortium.org/about/introduction/
559. Hubner, J., Muenstedt, K., Muecke, R., Micke, O., Stoll, C., Kleeberg, U. R., et.al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities, Strahlenther Onkol, 2013. 189(8): p. 613-7., https://www.ncbi.nlm.nih.gov/pubmed/23824107
560. Han, E., Johnson, N., DelaMelena, T., Glissmeyer, M., Steinbock, K., Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes, Ann Surg Oncol, 2011. 18: p. 912-6., https://pubmed.ncbi.nlm.nih.gov/21225354/
561. Bagenal, F. S., Easton, D. F., Harris, E., Chilvers, C. E., McElwain, T. J., Survival of patients with breast cancer attending Bristol Cancer Help Centre, Lancet, 1990. 336: p. 606-10., https://pubmed.ncbi.nlm.nih.gov/1975387/
562. Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., Ames, M. M., High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison, N Engl J Med, 1985. 312: p. 137-41., https://pubmed.ncbi.nlm.nih.gov/3880867/
563. Chabot, J. A., Tsai, W. Y., Fine, R. L., Chen, C., Kumah, C. K., Antman, K. A., et.al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer, J Clin Oncol, 2010. 28: p. 2058-63., https://pubmed.ncbi.nlm.nih.gov/19687327/
564. Buiatti, E., Arniani, S., Verdecchia, A., Tomatis, L., Results from a historical survey of the survival of cancer patients given Di Bella multitherapy, Cancer, 1999. 86: p. 2143-9., https://pubmed.ncbi.nlm.nih.gov/10570444/
565. Milazzo, S., Lejeune, S., Ernst, E., Laetrile for cancer: a systematic review of the clinical evidence, Support Care Cancer, 2007. 15: p. 583-95., https://pubmed.ncbi.nlm.nih.gov/17106659/
566. Grossarth-Maticek, R., Ziegler, R., Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador), Forsch Komplementmed, 2007. 14: p. 140-7., https://pubmed.ncbi.nlm.nih.gov/17596694/
567. Melzer, J., Iten, F., Hostanska, K., Saller, R., Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review, Forsch Komplementmed, 2009. 16: p. 217-26., https://pubmed.ncbi.nlm.nih.gov/19729932/
568. Dale, P. S., Tamhankar, C. P., George, D., Daftary, G. V., Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects, Cancer Chemother Pharmacol, 2001. 47 Suppl: p. S29-34., https://pubmed.ncbi.nlm.nih.gov/11561869/
569. Chau, J. P., Liu, X., Lo, S. H., Chien, W. T., Hui, S. K., Choi, K. C., et.al. Perioperative enhanced recovery programmes for women with gynaecological cancers, Cochrane Database of Systematic Reviews, 2022., http://dx.doi.org/10.1002/14651858.CD008239.pub5
570. Chau, JPC, Liu, X, Lo, SHS, Chien, WT, Hui, SK, Choi, KC, et.al. Perioperative enhanced recovery programmes for women with gynaecological cancers., Cochrane Database Syst Rev, 2022. 3 (3)(3): p. CD008239., https://pubmed.ncbi.nlm.nih.gov/35289396/
571. Duijts, S. F., Faber, M. M., Oldenburg, H. S., van Beurden, M., Aaronson, N. K., Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis, Psychooncology, 2011. 20(2): p. 115-26., https://pubmed.ncbi.nlm.nih.gov/20336645/
572. Reuss-Borst, M. A., Wentrock, S., [Innovative individualized rehabilitation concepts in oncology], Dtsch Med Wochenschr, 2013. 138(17): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/23592347
573. Courneya, K. S., Exercise in cancer survivors: an overview of research, Med Sci Sports Exerc, 2003. 35(11): p. 1846-52., https://pubmed.ncbi.nlm.nih.gov/14600549/
574. Friendenreich, C. M., Courneya, K. S., Exercise as rehabilitation for cancer patients, Clin J Sport Med, 1996. 6(4): p. 237-44., https://pubmed.ncbi.nlm.nih.gov/8894336/
575. Oldervoll, L. M., Kaasa, S., Hjermstad, M. J., Lund, J. A., Loge, J. H., Physical exercise results in the improved subjective well-being of a few or is effective rehabilitation for all cancer patients?, Eur J Cancer, 2004. 40(7): p. 951-62., https://pubmed.ncbi.nlm.nih.gov/15093569/
576. Pinto, B. M., Maruyama, N. C., Exercise in the rehabilitation of breast cancer survivors, Psychooncology, 1999. 8(3): p. 191-206., https://pubmed.ncbi.nlm.nih.gov/10390732/
577. Stricker, C. T., Drake, D., Hoyer, K. A., Mock, V., Evidence-based practice for fatigue management in adults with cancer: exercise as an intervention, Oncol Nurs Forum, 2004. 31(5): p. 963-76., https://pubmed.ncbi.nlm.nih.gov/15378097/
578. Goodwin, J. S., Satish, S., Anderson, E. T., Nattinger, A. B., Freeman, J. L., Effect of nurse case management on the treatment of older women with breast cancer, J Am Geriatr Soc, 2003. 51(9): p. 1252-9., https://pubmed.ncbi.nlm.nih.gov/12919237/
579. Maunsell, E., Brisson, J., Deschenes, L., Frasure-Smith, N., Randomized trial of a psychologic distress screening program after breast cancer: effects on quality of life, J Clin Oncol, 1996. 14(10): p. 2747-55., https://pubmed.ncbi.nlm.nih.gov/8874336/
580. McArdle, J. M., George, W. D., McArdle, C. S., Smith, D. C., Moodie, A. R., Hughson, A. V., et.al. Psychological support for patients undergoing breast cancer surgery: a randomised study, Bmj, 1996. 312(7034): p. 813-6., https://pubmed.ncbi.nlm.nih.gov/8608288/
581. Rustoen, T., Begnum, S., Quality of life in women with breast cancer: a review of the literature and implications for nursing practice, Cancer Nurs, 2000. 23(6): p. 416-21., https://pubmed.ncbi.nlm.nih.gov/11128120/
582. Watson, Maggie, Denton, Sylvia, Baum, Michael, Greer, Steven, Counselling breast cancer patients: A specialist nurse service, Counselling Psychology Quarterly, 2007. 1(1): p. 25-34., https://www.tandfonline.com/doi/abs/10.1080/09515078808251418
583. Andersen, L., Hojris, I., Erlandsen, M., Andersen, J., Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage--a randomized study, Acta Oncol, 2000. 39(3): p. 399-405., https://pubmed.ncbi.nlm.nih.gov/10987238/
584. McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., Hanson, J., The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial, Breast Cancer Res Treat, 2004. 86(2): p. 95-106., https://pubmed.ncbi.nlm.nih.gov/15319562/
585. Box, R. C., Reul-Hirche, H. M., Bullock-Saxton, J. E., Furnival, C. M., Physiotherapy after breast cancer surgery: results of a randomised controlled study to minimise lymphoedema, Breast Cancer Res Treat, 2002. 75(1): p. 51-64., https://pubmed.ncbi.nlm.nih.gov/12500934/
586. Playdon, M., Thomas, G., Sanft, T., Harrigan, M., Ligibel, J., Irwin, M., Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review, Curr Breast Cancer Rep, 2013. 5(3): p. 222-246., https://www.ncbi.nlm.nih.gov/pubmed/26605003
587. Luebbert, K., Dahme, B., Hasenbring, M., The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review, Psychooncology, 2001. 10(6): p. 490-502., https://pubmed.ncbi.nlm.nih.gov/11747061/
588. Devine, E. C., Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer, Oncol Nurs Forum, 2003. 30(1): p. 75-89., https://pubmed.ncbi.nlm.nih.gov/12515986/
589. Van Kuiken, D., A meta-analysis of the effect of guided imagery practice on outcomes, J Holist Nurs, 2004. 22(2): p. 164-79., https://pubmed.ncbi.nlm.nih.gov/15154991/
590. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22(9): p. 1369-81., https://www.ncbi.nlm.nih.gov/books/NBK66396/
591. Edwards, Adrian, Hailey, S., Maxwell, M., Psychological interventions for women with metastatic breast cancer (Cochrane Review), Cochrane database of systematic reviews (Online), 2004. 2: p. CD004253., https://pubmed.ncbi.nlm.nih.gov/15106244/
592. Spiegel, D., Bloom, J. R., Kraemer, H. C., Gottheil, E., Effect of psychosocial treatment on survival of patients with metastatic breast cancer, Lancet, 1989. 2(8668): p. 888-91., https://pubmed.ncbi.nlm.nih.gov/2571815/
593. S, Burke, DW, Kissane, Psychosocial impact of breast cancer: a review of interventions by specialist providers: a summary of the literature 1976-1996, 1998., http://www.nbcc.org.au/pages/info/resource/nbccpubs/psych/interv/contents.htm
594. Chow, E., Tsao, M. N., Harth, T., Does psychosocial intervention improve survival in cancer? A meta-analysis, Palliat Med, 2004. 18(1): p. 25-31., https://pubmed.ncbi.nlm.nih.gov/14982204/
595. Meyer, T. J., Mark, M. M., Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments, Health Psychol, 1995. 14(2): p. 101-8., https://pubmed.ncbi.nlm.nih.gov/7789344/
596. Bourbonniere, M., Kagan, S. H., Nursing intervention and older adults who have cancer: specific science and evidence based practice, Nurs Clin North Am, 2004. 39(3): p. 529-43., https://pubmed.ncbi.nlm.nih.gov/15331300/
597. Edgar, L., Rosberger, Z., Nowlis, D., Coping with cancer during the first year after diagnosis. Assessment and intervention, Cancer, 1992. 69(3): p. 817-28., https://pubmed.ncbi.nlm.nih.gov/1730131/
598. Zibecchi, L., Greendale, G. A., Ganz, P. A., Continuing education: Comprehensive menopausal assessment: an approach to managing vasomotor and urogenital symptoms in breast cancer survivors, Oncol Nurs Forum, 2003. 30(3): p. 393-407., https://pubmed.ncbi.nlm.nih.gov/12719740/
599. Allen, S. M., Shah, A. C., Nezu, A. M., Nezu, C. M., Ciambrone, D., Hogan, J., et.al. A problem-solving approach to stress reduction among younger women with breast carcinoma: a randomized controlled trial, Cancer, 2002. 94(12): p. 3089-100., https://pubmed.ncbi.nlm.nih.gov/12115339/
600. Badger, T. A., Braden, C. J., Mishel, M. H., Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer, Oncol Nurs Forum, 2001. 28(3): p. 567-74., https://pubmed.ncbi.nlm.nih.gov/11338763/
601. Fawzy, F. I., Fawzy, N. W., Arndt, L. A., Pasnau, R. O., Critical review of psychosocial interventions in cancer care, Arch Gen Psychiatry, 1995. 52(2): p. 100-13., https://pubmed.ncbi.nlm.nih.gov/7848046/
602. Sellick, S. M., Crooks, D. L., Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions, Psychooncology, 1999. 8(4): p. 315-33., https://pubmed.ncbi.nlm.nih.gov/10474850/
603. Arathuzik, D., Effects of cognitive-behavioral strategies on pain in cancer patients, Cancer Nurs, 1994. 17(3): p. 207-14., https://www.ovid.com/jnls/cancernursingonline/fulltext/00002820-199406000-00005~effects-of-cognitive-behavioral-strategies-on-pain-in-cancer
604. D, Kissane, S, Burke, Psychosocial support for breast cancer patients provided by members of the treatment team: A summary of the literature, 1976-1996. NHMRC National Breast Cancer Centre, 1998., http://www.nbcc.org.au/pages/info/resource/nbccpubs/psych/interv/contents.htm
605. Berghmans, B., van Waalwijk van Doorn, E., Nieman, F., de Bie, R., van den Brandt, P., Van Kerrebroeck, P., Efficacy of physical therapeutic modalities in women with proven bladder overactivity, Eur Urol, 2002. 41: p. 581-7., https://pubmed.ncbi.nlm.nih.gov/12074773/
606. Choi, H., Palmer, M. H., Park, J., Meta-analysis of pelvic floor muscle training: randomized controlled trials in incontinent women, Nurs Res, 2007. 56: p. 226-34., https://pubmed.ncbi.nlm.nih.gov/17625461/
607. Dumoulin, C., Hay-Smith, J., Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women, Cochrane Database Syst Rev, 2010. p. CD005654., https://pubmed.ncbi.nlm.nih.gov/30288727/
608. Hartmann, K. E., McPheeters, M. L., Biller, D. H., Ward, R. M., McKoy, J. N., Jerome, R. N., et.al. Treatment of overactive bladder in women, Evid Rep Technol Assess (Full Rep), 2009. p. 1-120, v., https://pubmed.ncbi.nlm.nih.gov/19947666/
609. Hay-Smith, E. J., Herderschee, R., Dumoulin, C., Herbison, G. P., Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women, Cochrane Database Syst Rev, 2011. p. CD009508., https://pubmed.ncbi.nlm.nih.gov/22161451/
610. Hosker, G., Cody, J. D., Norton, C. C., Electrical stimulation for faecal incontinence in adults, Cochrane Database Syst Rev, 2007. p. CD001310., https://pubmed.ncbi.nlm.nih.gov/17636665/
611. Imamura, M., Abrams, P., Bain, C., Buckley, B., Cardozo, L., Cody, J., et.al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence, Health Technol Assess, 2010. 14: p. 1-188, iii-iv., https://pubmed.ncbi.nlm.nih.gov/20738930/
612. Lo, SK, Naidu, J, Cao, Y, Additive effect of interferential therapy over pelvic poor exercise alone in the treatment of femele urinary stress and urge incontinence: a randomized controlled trial., Hong Kong Physiotherapy Journal, 2003. 21: p. 37-42., https://www.scirp.org/reference/referencespapers?referenceid=3356879
613. Norton, C., Cody, J. D., Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults, Cochrane Database Syst Rev, 2012. 7: p. CD002111., https://pubmed.ncbi.nlm.nih.gov/22786479/
614. Patil SP, Nagrale AV, SD, Ganvir, Additive effect of interferential therapy over pelvic floor exercises, International Journal of Therapy & Rehabilitation, 2010. 17: p. 596-602., https://www.researchgate.net/publication/272529742_Additive_effect_of_interferential_therapy_over_pelvic_floor_exercises
615. Wang, A. C., Wang, Y. Y., Chen, M. C., Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder, Urology, 2004. 63: p. 61-6., https://pubmed.ncbi.nlm.nih.gov/14751349/
616. Brown, J. C., Huedo-Medina, T. B., Pescatello, L. S., Pescatello, S. M., Ferrer, R. A., Johnson, B. T., Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2011. 20: p. 123-33., https://pubmed.ncbi.nlm.nih.gov/21051654/
617. Cramp, F., Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2008. p. CD006145., https://pubmed.ncbi.nlm.nih.gov/23152233/
618. Velthuis, M. J., Agasi-Idenburg, S. C., Aufdemkampe, G., Wittink, H. M., The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials, Clin Oncol (R Coll Radiol), 2010. 22: p. 208-21., https://pubmed.ncbi.nlm.nih.gov/20110159/
619. Adamsen, L., Quist, M., Andersen, C., Moller, T., Herrstedt, J., Kronborg, D., et.al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial, BMJ, 2009. 339: p. b3410., https://pubmed.ncbi.nlm.nih.gov/19826172/
620. Bourke, L., Thompson, G., Gibson, D. J., Daley, A., Crank, H., Adam, I., et.al. Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study, Arch Phys Med Rehabil, 2011. 92: p. 749-55., https://pubmed.ncbi.nlm.nih.gov/21530722/
621. Cantarero-Villanueva, I., Fernandez-Lao, C., Del Moral-Avila, R., Fernandez-de-Las-Penas, C., Feriche-Fernandez-Castanys, M. B., Arroyo-Morales, M., Effectiveness of core stability exercises and recovery myofascial release massage on fatigue in breast cancer survivors: a randomized controlled clinical trial, Evid Based Complement Alternat Med, 2012. 2012: p. 620619., https://pubmed.ncbi.nlm.nih.gov/21792370/
622. Courneya, K. S., Segal, R. J., Reid, R. D., Jones, L. W., Malone, S. C., Venner, P. M., et.al. Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors, J Clin Epidemiol, 2004. 57: p. 571-9., https://pubmed.ncbi.nlm.nih.gov/15246125/
623. Danhauer, S. C., Mihalko, S. L., Russell, G. B., Campbell, C. R., Felder, L., Daley, K., et.al. Restorative yoga for women with breast cancer: findings from a randomized pilot study, Psychooncology, 2009. 18: p. 360-8., https://pubmed.ncbi.nlm.nih.gov/19242916/
624. Fillion, L., Gagnon, P., Leblond, F., Gelinas, C., Savard, J., Dupuis, R., et.al. A brief intervention for fatigue management in breast cancer survivors, Cancer Nurs, 2008. 31: p. 145-59., https://pubmed.ncbi.nlm.nih.gov/18490891/
625. Heim, M. E., v d Malsburg, M. L., Niklas, A., Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue, Onkologie, 2007. 30: p. 429-34., https://pubmed.ncbi.nlm.nih.gov/17848814/
626. Littman, A. J., Bertram, L. C., Ceballos, R., Ulrich, C. M., Ramaprasad, J., McGregor, B., et.al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures, Support Care Cancer, 2012. 20: p. 267-77., https://pmc.ncbi.nlm.nih.gov/articles/PMC3188686/
627. Moadel, A. B., Shah, C., Wylie-Rosett, J., Harris, M. S., Patel, S. R., Hall, C. B., et.al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life, J Clin Oncol, 2007. 25: p. 4387-95., https://pubmed.ncbi.nlm.nih.gov/17785709/
628. Pinto, B. M., Rabin, C., Papandonatos, G. D., Frierson, G. M., Trunzo, J. J., Marcus, B. H., Maintenance of effects of a home-based physical activity program among breast cancer survivors, Support Care Cancer, 2008. 16: p. 1279-89., https://pmc.ncbi.nlm.nih.gov/articles/PMC2747581/
629. Rogers, L. Q., Hopkins-Price, P., Vicari, S., Markwell, S., Pamenter, R., Courneya, K. S., et.al. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects, Cancer Epidemiol Biomarkers Prev, 2009. 18: p. 1410-8., https://pubmed.ncbi.nlm.nih.gov/19383889/
630. van Weert, E., May, A. M., Korstjens, I., Post, W. J., van der Schans, C. P., van den Borne, B., et.al. Cancer-related fatigue and rehabilitation: a randomized controlled multicenter trial comparing physical training combined with cognitive-behavioral therapy with physical training only and with no intervention, Phys Ther, 2010. 90: p. 1413-25., https://pubmed.ncbi.nlm.nih.gov/20651011/
631. Chandwani, K. D., Thornton, B., Perkins, G. H., Arun, B., Raghuram, N. V., Nagendra, H. R., et.al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer, J Soc Integr Oncol, 2010. 8: p. 43-55., https://pubmed.ncbi.nlm.nih.gov/20388445/
632. Mustian, K. M., Peppone, L., Darling, T. V., Palesh, O., Heckler, C. E., Morrow, G. R., A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial, J Support Oncol, 2009. 7: p. 158-67., https://pubmed.ncbi.nlm.nih.gov/19831159/
633. Donnelly, C. M., Blaney, J. M., Lowe-Strong, A., Rankin, J. P., Campbell, A., McCrum-Gardner, E., et.al. A randomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors, Gynecol Oncol, 2011. 122: p. 618-24., https://pubmed.ncbi.nlm.nih.gov/21689848/
634. Ebede, C. C., Jang, Y., Escalante, C. P., Cancer-Related Fatigue in Cancer Survivorship, Med Clin North Am, 2017. 101(6): p. 1085-1097., https://www.ncbi.nlm.nih.gov/pubmed/28992856
635. Mohandas, H., Jaganathan, S. K., Mani, M. P., Ayyar, M., Rohini Thevi, G. V., Cancer-related fatigue treatment: An overview, J Cancer Res Ther, 2017. 13(6): p. 916-929., https://www.ncbi.nlm.nih.gov/pubmed/29237952
636. Bower, J. E., Cancer-related fatigue--mechanisms, risk factors, and treatments, Nat Rev Clin Oncol, 2014. 11(10): p. 597-609., https://www.ncbi.nlm.nih.gov/pubmed/25113839
637. Frumovitz, M., Sun, C. C., Schover, L. R., Munsell, M. F., Jhingran, A., Wharton, J. T., et.al. Quality of life and sexual functioning in cervical cancer survivors, J Clin Oncol, 2005. 23: p. 7428-36., https://pubmed.ncbi.nlm.nih.gov/16234510/
638. Wilmoth, M. C., Botchway, P., Psychosexual implications of breast and gynecologic cancer, Cancer Invest, 1999. 17: p. 631-6., https://pubmed.ncbi.nlm.nih.gov/10592769/
639. Juraskova, I., Butow, P., Robertson, R., Sharpe, L., McLeod, C., Hacker, N., Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight, Psychooncology, 2003. 12: p. 267-79., https://pubmed.ncbi.nlm.nih.gov/12673810/
640. Andersen, B. L., Woods, X. A., Copeland, L. J., Sexual self-schema and sexual morbidity among gynecologic cancer survivors, J Consult Clin Psychol, 1997. 65: p. 221-9., https://pubmed.ncbi.nlm.nih.gov/9086685/
641. Flynn, Paul, Kew, Fiona, Kisely Steve, R., Interventions for psychosexual dysfunction in women treated for gynaecological malignancyJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2009., https://pubmed.ncbi.nlm.nih.gov/19370605/
642. Brotto, L. A., Heiman, J. R., Goff, B., Greer, B., Lentz, G. M., Swisher, E., et.al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer, Arch Sex Behav, 2008. 37: p. 317-29., https://pubmed.ncbi.nlm.nih.gov/17680353/
643. Amsterdam, A., Krychman, M. L., Sexual dysfunction in patients with gynecologic neoplasms: a retrospective pilot study, J Sex Med, 2006. 3: p. 646-9., https://pubmed.ncbi.nlm.nih.gov/16776780/
644. Miles, Tracie, Johnson, Nick, Vaginal dilator therapy for women receiving pelvic radiotherapyJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010., https://pubmed.ncbi.nlm.nih.gov/20824858/
645. Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., et.al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, J Clin Oncol, 2006. 24: p. 5091-7., https://pubmed.ncbi.nlm.nih.gov/17033037/
646. Grunfeld, E., Dhesy-Thind, S., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update), CMAJ, 2005. 172: p. 1319-20., https://pmc.ncbi.nlm.nih.gov/articles/PMC557103/
647. Pestalozzi, B. C., Luporsi-Gely, E., Jost, L. M., Bergh, J., ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer, Ann Oncol, 2005. 16 Suppl 1: p. i7-9., https://pubmed.ncbi.nlm.nih.gov/15888763/
648. Hurria, A., Hudis, C., Follow-up care of breast cancer survivors, Crit Rev Oncol Hematol, 2003. 48: p. 89-99., https://www.sciencedirect.com/science/article/pii/S1040842803000970
649. Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., et.al. Follow-up strategies for women treated for early breast cancer, Cochrane Database Syst Rev, 2005. p. CD001768., https://pubmed.ncbi.nlm.nih.gov/11034727/
650. Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del Turco, M., Distante, V., et.al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up, JAMA, 1999. 281: p. 1586., https://pubmed.ncbi.nlm.nih.gov/10235147/
651. Gulliford, T., Opomu, M., Wilson, E., Hanham, I., Epstein, R., Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study, BMJ, 1997. 314: p. 174-7., https://pubmed.ncbi.nlm.nih.gov/9022429/
652. Elit, L., Fyles, A. W., Devries, M. C., Oliver, T. K., Fung-Kee-Fung, M., Gynecology Cancer Disease Site, Group, Follow-up for women after treatment for cervical cancer: a systematic review, Gynecol Oncol, 2009. 114: p. 528-35., https://pubmed.ncbi.nlm.nih.gov/20567627/
653. Hillesheim, I., Limone, G. A., Klimann, L., Monego, H., Appel, M., de Souza, A., et.al. Cervical Cancer Posttreatment Follow-up: Critical Analysis, Int J Gynecol Cancer, 2017. 27(8): p. 1747-1752., https://www.ncbi.nlm.nih.gov/pubmed/28937445
654. Taarnhøj, GA, Christensen, IJ, Lajer, H, Fuglsang, K, Jeppesen, MM, Kahr, HS, et.al. Risk of recurrence, prognosis, and follow-up for Danish women with cervical cancer in 2005-2013: A national cohort study., Cancer, 2018. 124 (5)(5): p. 943-951., https://pubmed.ncbi.nlm.nih.gov/29211304/
655. Nelson, HD, Cantor, AG, Pappas, M, Blackie, K, Yu, Y, Fu, R, Patient Navigation Services for Breast and Cervical Cancer Screening and Follow-Up: A Meta-Analysis., JAMA Intern Med, 2025. 185 (8)(8): p. 976-985., https://pubmed.ncbi.nlm.nih.gov/40489104/
656. Selby, P., Gillis, C., Haward, R., Benefits from specialised cancer care, Lancet, 1996. 348: p. 313-8., https://pubmed.ncbi.nlm.nih.gov/8709693/
657. Lanceley, A., Fiander, A., McCormack, M., Bryant, A., Follow-up protocols for women with cervical cancer after primary treatment, Cochrane Database Syst Rev, 2013. 11: p. Cd008767., https://pubmed.ncbi.nlm.nih.gov/24277645/
658. Rimel, B. J., Ferda, A., Erwin, J., Dewdney, S. B., Seamon, L., Gao, F., et.al. Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment, Obstet Gynecol, 2011. 118: p. 548-53., https://pubmed.ncbi.nlm.nih.gov/21860282/
659. Nezhat, C., Roman, R. A., Rambhatla, A., Nezhat, F., Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review, Fertil Steril, 2020. 113(4): p. 685-703., https://www.sciencedirect.com/science/article/pii/S001502822030090X
660. Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J., Poljak, M., Ogilvie, G., et.al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, 2012. 30 Suppl 5: p. F88-99., https://pubmed.ncbi.nlm.nih.gov/23199969/
661. Edey, K., Denton, K., Murdoch, J., The role of cytological follow-up after radical vaginal trachelectomy for early-stage cervical cancer, Cytopathology, 2013., https://pubmed.ncbi.nlm.nih.gov/23802711/
662. SIGN, Management of cervical cancer - A national clinical guideline, 2008., https://pmc.ncbi.nlm.nih.gov/articles/PMC2174776/
663. Sturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaarenstroom, K., et.al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers, Clin Chem, 2010. 56: p. e1-48., https://pubmed.ncbi.nlm.nih.gov/20207771/
664. Wong, T. Z., Jones, E. L., Coleman, R. E., Positron emission tomography with 2-deoxy-2-((18)F)fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer, Mol Imaging Biol, 2004. 6: p. 55-62., https://www.ncbi.nlm.nih.gov/pubmed/15018829
665. Zhou, Z., Liu, X., Hu, K., Zhang, F., The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence, Nucl Med Commun, 2018. 39(2): p. 97-102., https://www.ncbi.nlm.nih.gov/pubmed/29189444
666. Brito, A. E. T., Matushita, C., Esteves, F., Gomes, G., Bernardo, W. M., Amorim, B. J., Cervical cancer - staging and restaging with 18F-FDG PET/CT, Rev Assoc Med Bras (1992), 2019. 65(4): p. 568-575., https://www.ncbi.nlm.nih.gov/pubmed/31066810
667. Viswanathan, C., Faria, S., Devine, C., Patnana, M., Sagebiel, T., Iyer, R. B., et.al. [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer, PET Clin, 2018. 13(2): p. 165-177., https://www.ncbi.nlm.nih.gov/pubmed/29482748
668. Mirpour, S., Mhlanga, J. C., Logeswaran, P., Russo, G., Mercier, G., Subramaniam, R. M., The role of PET/CT in the management of cervical cancer, AJR Am J Roentgenol, 2013. 201: p. W192-205., https://pubmed.ncbi.nlm.nih.gov/23883234/
669. Fyles, A., Walker-Dilks, C., PET Imaging in Cervical Cancer, Cancer Care Ontario, 2009., https://www.cancercareontario.ca/en/file/17821/download?token=vBFOpaRB
670. Beier, D, HPV-Impfung - Mitteilung der Sächsischen Impfkommissiom, Ärzteblatt Sachsen, 2011. 1:, https://www.slaek.de/media/dokumente/ueber-uns/presse/aerzteblatt/archiv/2011-2020/2011/01/0111_006.pdf
671. Hampl, M., Value of general human papillomavirus vaccination in sexually active women, Dtsch Med Wochenschr, 2009. 134 Suppl 2: p. S95-9., https://pubmed.ncbi.nlm.nih.gov/19353480/
672. Munoz, N., Manalastas, R., Jr., Pitisuttithum, P., Tresukosol, D., Monsonego, J., Ault, K., et.al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial, Lancet, 2009. 373: p. 1949-57., https://pubmed.ncbi.nlm.nih.gov/19493565/
673. Olsson, S. E., Kjaer, S. K., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Wheeler, C. M., et.al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Hum Vaccin, 2009. 5: p. 696-704., https://pubmed.ncbi.nlm.nih.gov/19855170/
674. Schwarz, T. F., Spaczynski, M., Schneider, A., Wysocki, J., Galaj, A., Perona, P., et.al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years, Vaccine, 2009. 27: p. 581-7., https://pubmed.ncbi.nlm.nih.gov/19022320/
675. Castellsague, X., Schneider, A., Kaufmann, A. M., Bosch, F. X., HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives, Gynecol Oncol, 2009. 115: p. S15-23., https://pubmed.ncbi.nlm.nih.gov/19819540/
676. Mundt, A. J., Mell, L. K., Roeske, J. C., Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy, Int J Radiat Oncol Biol Phys, 2003. 56: p. 1354-60., https://pubmed.ncbi.nlm.nih.gov/12873680/
677. Joura, E. A., Garland, S. M., Paavonen, J., Ferris, D. G., Perez, G., Ault, K. A., et.al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data, BMJ, 2012. 344: p. e1401., https://pubmed.ncbi.nlm.nih.gov/22454089/
678. Kang, W. D., Choi, H. S., Kim, S. M., Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?, Gynecol Oncol, 2013. 130: p. 264-8., https://pubmed.ncbi.nlm.nih.gov/23623831/
679. Petráš, M, Lomozová, D, Dvořák, V, Dvořák, V, Malinová, J, Trnková, M, et.al. Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: a retrospective cohort study in the Czech Republic., Lancet Reg Health Eur, 2025. 55 (): p. 101337., https://pubmed.ncbi.nlm.nih.gov/40525201/
680. Monsonego, J., Cortes, J., Greppe, C., Hampl, M., Joura, E., Singer, A., Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine, Vaccine, 2010. 28: p. 8065-72., https://pubmed.ncbi.nlm.nih.gov/20971114/
681. STIKO, STIKO-Impfkalender 2011, 2011., https://edoc.rki.de/bitstream/handle/176904/4591/28CKjOWgLiRzg.pdf?isAllowed=y&sequence=1&utm
682. Koch-Institut, Robert, Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2011, Epid Bulletin, 2011. 30: p. 275–94., https://edoc.rki.de/bitstream/handle/176904/338/28Wp9wmykrt3Q2.pdf?isAllowed=y&sequence=1&utm
683. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds)., SEER Cancer Statistics Review 1975-2016, 2019., https://seer.cancer.gov/archive/csr/1975_2016/index.html
684. van Nagell, J. R., Jr., Rayburn, W., Donaldson, E. S., Hanson, M., Gay, E. C., Yoneda, J., et.al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix, Cancer, 1979. 44: p. 2354-61., https://www.ncbi.nlm.nih.gov/pubmed/116764
685. Guskova, Ekaterina, Kit, Oleg Ivanovich, Nerodo, Galina Andreevna, Guskova, Nailya, Chernikova, Natalia V., Poryvaev, Yuriy A., et.al. Prognostic factors of cervical cancer recurrence, Journal of Clinical Oncology, 2016. 34(15_suppl): p. e17025-e17025., https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e17025
686. Hong, J. H., Tsai, C. S., Lai, C. H., Chang, T. C., Wang, C. C., Chou, H. H., et.al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 60: p. 249-57., https://www.ncbi.nlm.nih.gov/pubmed/15337563
687. Kamura, T., Tsukamoto, N., Tsuruchi, N., Saito, T., Matsuyama, T., Akazawa, K., et.al. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy, Cancer, 1992. 69(1): p. 181-6., https://www.ncbi.nlm.nih.gov/pubmed/1727662
688. Noh, J. M., Park, W., Kim, Y. S., Kim, J. Y., Kim, H. J., Kim, J., et.al. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10), Gynecol Oncol, 2014. 132(3): p. 618-23., https://www.ncbi.nlm.nih.gov/pubmed/24486605
689. Perez, C. A., Fox, S., Lockett, M. A., Grigsby, P. W., Camel, H. M., Galakatos, A., et.al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods, Int J Radiat Oncol Biol Phys, 1991. 21: p. 885-98., https://www.ncbi.nlm.nih.gov/pubmed/1917616
690. Song, Y. J., Kim, J. Y., Lee, S. K., Lim, H. S., Lim, M. C., Seo, S. S., et.al. Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer, Int J Cancer, 2011. 129: p. 896-902., https://www.ncbi.nlm.nih.gov/pubmed/21064095
691. Paunier, J. P., Delclos, L., Fletcher, G. H., Causes, time of death, and sites of failure in squamous-cell carcinoma of the uterine cervix on intact uterus, Radiology, 1967. 88: p. 555-62., https://www.ncbi.nlm.nih.gov/pubmed/6019520
692. van Kol, K, Ebisch, R, Beugeling, M, Cnossen, J, Nederend, J, van Hamont, D, et.al. Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer., Cancers (Basel), 2023. 16 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/38201625/
693. James, R. M., Cruickshank, M. E., Siddiqui, N., Guideline Development, Group, Management of cervical cancer: summary of SIGN guidelines, BMJ, 2008. 336(7634): p. 41-3., https://www.ncbi.nlm.nih.gov/pubmed/18174599
694. Olthof, EP, Bergink-Voorthuis, BJ, Wenzel, HHB, Mongula, J, van der Velden, J, Spijkerboer, AM, et.al. Diagnostic accuracy of MRI, CT, and [, Insights Imaging, 2024. 15 (1)(1): p. 36., https://pubmed.ncbi.nlm.nih.gov/38332397/
695. Sawicki, LM, Kirchner, J, Grueneisen, J, Ruhlmann, V, Aktas, B, Schaarschmidt, BM, et.al. Comparison of , Eur J Nucl Med Mol Imaging, 2018. 45 (4)(4): p. 622-629., https://pubmed.ncbi.nlm.nih.gov/29164299/
696. Stojiljkovic, M, Sobic Saranovic, D, Odalovic, S, Popovic, M, Petrovic, J, Rankovic, N, et.al. FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI., Radiol Oncol, 2022. 56 (4)(4): p. 453-460., https://pubmed.ncbi.nlm.nih.gov/36317553/
697. Chu, Y, Zheng, A, Wang, F, Lin, W, Yang, X, Han, L, et.al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis., Nucl Med Commun, 2014. 35 (2)(2): p. 144-50., https://pubmed.ncbi.nlm.nih.gov/24177043/
698. Peiretti, M., Zapardiel, I., Zanagnolo, V., Landoni, F., Morrow, C. P., Maggioni, A., Management of recurrent cervical cancer: a review of the literature, Surg Oncol, 2012. 21: p. e59-66., https://www.ncbi.nlm.nih.gov/pubmed/22244884
699. Cibula, D., Potter, R., Planchamp, F., Avall-Lundqvist, E., Fischerova, D., Haie Meder, C., et.al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer, Int J Gynecol Cancer, 2018. 28(4): p. 641-655., https://www.ncbi.nlm.nih.gov/pubmed/29688967
700. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., 3rd, et.al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 1999. 340: p. 1154-61., https://www.ncbi.nlm.nih.gov/pubmed/10202166
701. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., et.al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 1999. 340: p. 1144-53., https://www.ncbi.nlm.nih.gov/pubmed/10202165
702. Whitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, W. C., Jr., et.al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, 1999. 17: p. 1339-48., https://www.ncbi.nlm.nih.gov/pubmed/10334517
703. Morris, M., Eifel, P. J., Lu, J. D., Grigsby, P. W., Levenback, C., Stevens, R. E., et.al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, New England Journal of Medicine, 1999. 340: p. 1137-1143., https://www.ncbi.nlm.nih.gov/pubmed/10202164
704. Maneo, A., Landoni, F., Cormio, G., Colombo, A., Placa, F., Pellegrino, A., et.al. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma, Ann Oncol, 1999. 10(7): p. 803-7., https://www.ncbi.nlm.nih.gov/pubmed/10470427
705. Ito, H., Shigematsu, N., Kawada, T., Kubo, A., Isobe, K., Hara, R., et.al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy, Gynecol Oncol, 1997. 67: p. 154-61., https://www.ncbi.nlm.nih.gov/pubmed/9367699
706. Jain, P., Hunter, R. D., Livsey, J. E., Coyle, C., Swindell, R., Davidson, S. E., Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer, Clin Oncol (R Coll Radiol), 2007. 19: p. 763-8., https://www.ncbi.nlm.nih.gov/pubmed/17931845
707. Ijaz, T., Eifel, P. J., Burke, T., Oswald, M. J., Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma, Gynecol Oncol, 1998. 70: p. 241-6., https://www.ncbi.nlm.nih.gov/pubmed/9740698
708. Berek, J. S., Howe, C., Lagasse, L. D., Hacker, N. F., Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA, Gynecol Oncol, 2005. 99: p. 153-9., https://pubmed.ncbi.nlm.nih.gov/16054678/
709. Magrina, J. F., Stanhope, C. R., Weaver, A. L., Pelvic exenterations: supralevator, infralevator, and with vulvectomy, Gynecol Oncol, 1997. 64: p. 130-5., https://pubmed.ncbi.nlm.nih.gov/8995561/
710. Possover, M., Drahonowski, J., Plaul, K., Schneider, A., Laparoscopic-assisted formation of a colon neovagina, Surg Endosc, 2001. 15: p. 623., https://www.ncbi.nlm.nih.gov/pubmed/11591954
711. Lopez-Graniel, C., Dolores, R., Cetina, L., Gonzalez, A., Cantu, D., Chanona, J., et.al. Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer, BMC Cancer, 2005. 5: p. 118., https://pmc.ncbi.nlm.nih.gov/articles/PMC1260014/
712. Hockel, M., Laterally extended endopelvic resection (LEER)-principles and practice, Gynecol Oncol, 2008. 111: p. S13-7., https://pubmed.ncbi.nlm.nih.gov/18723213/
713. Hong, J. H., Tsai, C. S., Lai, C. H., Chang, T. C., Wang, C. C., Chou, H. H., et.al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 60: p. 249-57., https://pubmed.ncbi.nlm.nih.gov/15337563/
714. Berek, J. S., Howe, C., Lagasse, L. D., Hacker, N. F., Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA, Gynecol Oncol, 2005. 99: p. 153-9., https://www.ncbi.nlm.nih.gov/pubmed/16054678
715. Yoo, H. J., Lim, M. C., Seo, S. S., Kang, S., Yoo, C. W., Kim, J. Y., et.al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea, J Gynecol Oncol, 2012. 23: p. 242-50., https://www.ncbi.nlm.nih.gov/pubmed/23094127
716. Marnitz, S., Kohler, C., Muller, M., Behrens, K., Hasenbein, K., Schneider, A., Indications for primary and secondary exenterations in patients with cervical cancer, Gynecol Oncol, 2006. 103: p. 1023-30., https://www.ncbi.nlm.nih.gov/pubmed/16890276
717. Forner, D. M., Lampe, B., Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors, Am J Obstet Gynecol, 2011. 205: p. 148 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/21640963
718. Schmidt, A. M., Imesch, P., Fink, D., Egger, H., Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer, Gynecol Oncol, 2012. 125: p. 604-9., https://www.ncbi.nlm.nih.gov/pubmed/22406639
719. Estape, R., Angioli, R., Surgical management of advanced and recurrent cervical cancer, Semin Surg Oncol, 1999. 16: p. 236-41., https://www.ncbi.nlm.nih.gov/pubmed/10225302
720. Hockel, M., Laterally extended endopelvic resection (LEER)-principles and practice, Gynecol Oncol, 2008. 111: p. S13-7., https://www.ncbi.nlm.nih.gov/pubmed/18723213
721. Coleman, R. L., Keeney, E. D., Freedman, R. S., Burke, T. W., Eifel, P. J., Rutledge, F. N., Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy, Gynecol Oncol, 1994. 55: p. 29-35., https://www.ncbi.nlm.nih.gov/pubmed/7959262
722. Haasbeek, C. J., Uitterhoeve, A. L., van der Velden, J., Gonzalez, D. G., Stalpers, L. J., Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery, Radiother Oncol, 2008. 89: p. 197-204., https://www.ncbi.nlm.nih.gov/pubmed/18237803
723. Mundt, A. J., Roeske, J. C., Lujan, A. E., Yamada, S. D., Waggoner, S. E., Fleming, G., et.al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies, Gynecol Oncol, 2001. 82(3): p. 456-63., https://www.ncbi.nlm.nih.gov/pubmed/11520140
724. Liu, S. P., Huang, X., Ke, G. H., Huang, X. W., 3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience, PLoS One, 2012. 7(6): p. e40299., https://www.ncbi.nlm.nih.gov/pubmed/22768273
725. Fokdal, L., Sturdza, A., Mazeron, R., Haie-Meder, C., Tan, L. T., Gillham, C., et.al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study, Radiother Oncol, 2016. 120(3): p. 434-440., https://www.ncbi.nlm.nih.gov/pubmed/27113795
726. Seo, Y., Kim, M. S., Yoo, H. J., Jang, W. I., Rhu, S. Y., Choi, S. C., et.al. Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication, Asia Pac J Clin Oncol, 2016. 12(2): p. e280-8., https://www.ncbi.nlm.nih.gov/pubmed/24889550
727. Grigsby, P. W., Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy, Int J Gynecol Cancer, 2004. 14: p. 860-4., https://www.ncbi.nlm.nih.gov/pubmed/15361195
728. Westermann, A., Mella, O., Van Der Zee, J., Jones, E. L., Van Der Steen-Banasik, E., Koper, P., et.al. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update, Int J Hyperthermia, 2012. 28: p. 549-53., https://www.ncbi.nlm.nih.gov/pubmed/22788973
729. Windschall, A., Ott, O. J., Sauer, R., Strnad, V., Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma, Strahlenther Onkol, 2005. 181: p. 545-50., https://www.ncbi.nlm.nih.gov/pubmed/16044224
730. Mahe, M. A., Gerard, J. P., Dubois, J. B., Roussel, A., Bussieres, E., Delannes, M., et.al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients, Int J Radiat Oncol Biol Phys, 1996. 34: p. 21-6., https://www.ncbi.nlm.nih.gov/pubmed/12118553
731. Lopez-Graniel, C., Dolores, R., Cetina, L., Gonzalez, A., Cantu, D., Chanona, J., et.al. Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer, BMC Cancer, 2005. 5: p. 118., https://www.ncbi.nlm.nih.gov/pubmed/16171526
732. Krengli, M., Pisani, C., Deantonio, L., Surico, D., Volpe, A., Surico, N., et.al. Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers, Radiat Oncol, 2017. 12(1): p. 18., https://www.ncbi.nlm.nih.gov/pubmed/28100242
733. Stelzer, K. J., Koh, W. J., Greer, B. E., Cain, J. M., Tamimi, H. K., Figge, D. C., et.al. The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity, Am J Obstet Gynecol, 1995. 172(6): p. 1881-6; discussion 1886-8., https://www.ncbi.nlm.nih.gov/pubmed/7778648
734. Jurado, M., Alcazar, J. L., Martinez-Monge, R., Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience, Gynecol Oncol, 2010. 116: p. 38-43., https://www.ncbi.nlm.nih.gov/pubmed/19878978
735. Hockel, M., Horn, L. C., Einenkel, J., (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy, Gynecol Oncol, 2012. 127: p. 297-302., https://www.ncbi.nlm.nih.gov/pubmed/22864112
736. Fagundes, H., Perez, C. A., Grigsby, P. W., Lockett, M. A., Distant metastases after irradiation alone in carcinoma of the uterine cervix, Int J Radiat Oncol Biol Phys, 1992. 24: p. 197-204., https://www.ncbi.nlm.nih.gov/pubmed/1526855
737. Chou, H. H., Wang, C. C., Lai, C. H., Hong, J. H., Ng, K. K., Chang, T. C., et.al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma, Int J Radiat Oncol Biol Phys, 2001. 51: p. 442-8., https://www.ncbi.nlm.nih.gov/pubmed/11567819
738. Singh, A. K., Grigsby, P. W., Rader, J. S., Mutch, D. G., Powell, M. A., Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence, Int J Radiat Oncol Biol Phys, 2005. 61: p. 450-5., https://www.ncbi.nlm.nih.gov/pubmed/15667966
739. Kubota, H., Tsujino, K., Sulaiman, N. S., Sekii, S., Matsumoto, Y., Ota, Y., et.al. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment, Radiat Oncol, 2019. 14(1): p. 236., https://www.ncbi.nlm.nih.gov/pubmed/31878944
740. Lim, M. C., Lee, H. S., Seo, S. S., Kim, M. S., Kim, J. Y., Zo, J. I., et.al. Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery, Gynecol Oncol, 2010. 116: p. 478-82., https://www.ncbi.nlm.nih.gov/pubmed/19889448
741. Lambrou, N. C., Pearson, J. M., Averette, H. E., Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations, Surg Oncol Clin N Am, 2005. 14: p. 289-300., https://www.ncbi.nlm.nih.gov/pubmed/15817240
742. Mishra, S. K., Laskar, S., Muckaden, M. A., Mohindra, P., Shrivastava, S. K., Dinshaw, K. A., Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix, J Cancer Res Ther, 2005. 1: p. 208-12., https://www.ncbi.nlm.nih.gov/pubmed/17998655
743. Lievens, Y, Guckenberger, M, Gomez, D, Hoyer, M, Iyengar, P, Kindts, I, et.al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document., Radiother Oncol, 2020. 148 (): p. 157-166., https://pubmed.ncbi.nlm.nih.gov/32388150/
744. Macchia, G, Pezzulla, D, Campitelli, M, Laliscia, C, Fodor, A, Bonome, P, et.al. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups., Int J Radiat Oncol Biol Phys, 2023. 117 (2)(2): p. 321-332., https://pubmed.ncbi.nlm.nih.gov/37150261/
745. Chopra, S, Mangaj, A, Sharma, A, Tan, LT, Sturdza, A, Jürgenliemk-Schulz, I, et.al. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network., Radiother Oncol, 2021. 155 (): p. 151-159., https://pubmed.ncbi.nlm.nih.gov/33144247/
746. Macchia, G, Nardangeli, A, Laliscia, C, Fodor, A, Draghini, L, Gentile, PC, et.al. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups., Int J Gynecol Cancer, 2022. 32 (6)(6): p. 732-739., https://pubmed.ncbi.nlm.nih.gov/35193941/
747. Bizzarri, N, Di Berardino, S, Benkortbi, K, Balaya, V, Gambacorta, MA, Macchia, G, et.al. External beam radiotherapy boost versus surgical debulking followed by radiotherapy for the treatment of metastatic lymph nodes in cervical cancer: A systematic review and meta-analysis., Eur J Surg Oncol, 2024. 50 (4)(4): p. 108013., https://pubmed.ncbi.nlm.nih.gov/38401353/
748. Gao, H, Wu, H, Zhang, Y, Chen, Z, Qi, Z, Wang, M, et.al. Locoregional therapy for oligometastatic cervical cancer: a single-center retrospective study., Int J Gynecol Cancer, 2023. 33 (2)(2): p. 198-207., https://pubmed.ncbi.nlm.nih.gov/36229079/
749. Fleisch, M. C., Pantke, P., Beckmann, M. W., Schnuerch, H. G., Ackermann, R., Grimm, M. O., et.al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers, J Surg Oncol, 2007. 95: p. 476-84., https://www.ncbi.nlm.nih.gov/pubmed/17192947
750. Bartl, T, Dorittke, T, Ciocsirescu, C, Knoth, J, Schmid, M, Grimm, C, et.al. Oncologic outcome of metachronous oligometastatic recurrence in advanced cervical cancer patients after primary radio-chemotherapy., J Gynecol Oncol, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40350705/
751. Patil, CG, Pricola, K, Garg, SK, Bryant, A, Black, KL, Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases., Cochrane Database Syst Rev, 2010. (6)(6): p. CD006121., https://pubmed.ncbi.nlm.nih.gov/20556764/
752. Li, S, Lee, JH, Makineni, P, Zadeh, A, Choi, S, Harris, E, et.al. Stereotactic radiosurgery for brain metastasis from gynecological cancers: A systematic review., Neurooncol Adv, 2025. 7 (1)(1): p. vdaf106., https://pubmed.ncbi.nlm.nih.gov/40842641/
753. El Shafie, RA, Bernhardt, D, Welzel, T, Schiele, A, Schmitt, D, Thalmann, P, et.al. Hypofractionated Stereotactic Radiotherapy versus Whole-Brain Radiotherapy following Brain Metastasis Resection - Results of the ESTRON Randomized Phase 2 Trial., Neuro Oncol, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40747537/
754. Hirte, H. W., Strychowsky, J. E., Oliver, T., Fung-Kee-Fung, M., Elit, L., Oza, A. M., Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review (Structured abstract), International Journal of Gynecological Cancer, 2007. 17: p. 1194-1204., https://pubmed.ncbi.nlm.nih.gov/17540006/
755. Scatchard, K., Forrest, J. L., Flubacher, M., Cornes, P., Williams, C., Chemotherapy for metastatic and recurrent cervical cancer, Cochrane Database Syst Rev, 2012. 10: p. CD006469., https://pubmed.ncbi.nlm.nih.gov/23076924/
756. Tzioras, S., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P., Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis (Structured abstract), Cancer Treatment Reviews, 2007. 33: p. 24-38., https://pubmed.ncbi.nlm.nih.gov/17112673/
757. Scatchard, K., Forrest, J. L., Flubacher, M., Cornes, P., Williams, C., Chemotherapy for metastatic and recurrent cervical cancer, Cochrane Database Syst Rev, 2012. 10: p. CD006469., https://www.ncbi.nlm.nih.gov/pubmed/23076924
758. Hirte, H. W., Strychowsky, J. E., Oliver, T., Fung-Kee-Fung, M., Elit, L., Oza, A. M., Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review (Structured abstract), International Journal of Gynecological Cancer, 2007. 17: p. 1194-1204., https://www.ncbi.nlm.nih.gov/pubmed/17540006
759. Tewari, K. S., Monk, B. J., Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group, Semin Oncol, 2009. 36: p. 170-80., https://www.ncbi.nlm.nih.gov/pubmed/19332251
760. Leath, C. A., 3rd, Straughn, J. M., Jr., Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials, Gynecol Oncol, 2013. 129: p. 251-7., https://www.ncbi.nlm.nih.gov/pubmed/23280089
761. Tewari, KS, Sill, MW, Birrer, MJ, Penson, RT, Huang, H, Moore, DH, et.al. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study., Gynecol Oncol, 2023. 171 (): p. 141-150., https://pubmed.ncbi.nlm.nih.gov/36898292/
762. Gass, P, Thiel, FC, Häberle, L, Ackermann, S, Theuser, AK, Hummel, N, et.al. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer., Gynecol Oncol, 2024. 183 (): p. 25-32., https://pubmed.ncbi.nlm.nih.gov/38490057/
763. Kim, J. S., Kim, S. Y., Kim, Ki, Cho, M. J., Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1247-53., https://www.ncbi.nlm.nih.gov/pubmed/12654434
764. Kitagawa, R., Katsumata, N., Shibata, T., Kamura, T., Kasamatsu, T., Nakanishi, T., et.al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. 33(19): p. 2129-35., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/694/CN-01085694/frame.html
765. Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F., Barni, S., A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer, Gynecol Oncol, 2014. 133(1): p. 117-23., https://www.ncbi.nlm.nih.gov/pubmed/24486604
766. Kitagawa, R., Katsumata, N., Ando, M., Shimizu, C., Fujiwara, Y., Yoshikawa, H., et.al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer, Gynecol Oncol, 2012. 125: p. 307-11., https://www.ncbi.nlm.nih.gov/pubmed/22333993
767. Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., et.al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240), Lancet, 2017. (no pagination):, https://www.sciencedirect.com/science/article/pii/S0140673617316070
768. Rosen, V. M., Guerra, I., McCormack, M., Nogueira-Rodrigues, A., Sasse, A., Munk, V. C., et.al. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer, Int J Gynecol Cancer, 2017. 27(6): p. 1237-1246., https://www.ncbi.nlm.nih.gov/pubmed/28448304
769. Yang, ST, Liu, HH, Liu, CH, Wang, LW, Wang, PH, Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy., Int J Gynaecol Obstet, 2024. 167 (1)(1): p. 80-87., https://pubmed.ncbi.nlm.nih.gov/38746971/
770. Tewari, K. S., Sill, M. W., Long, H. J., 3rd, Penson, R. T., Huang, H., Ramondetta, L. M., et.al. Improved survival with bevacizumab in advanced cervical cancer, N Engl J Med, 2014. 370: p. 734-43., https://www.ncbi.nlm.nih.gov/pubmed/24552320
771. Colombo, N, Dubot, C, Lorusso, D, Caceres, MV, Hasegawa, K, Shapira-Frommer, R, et.al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer., N Engl J Med, 2021. 385 (20)(20): p. 1856-1867., https://pubmed.ncbi.nlm.nih.gov/34534429/
772. Monk, BJ, Colombo, N, Tewari, KS, Dubot, C, Caceres, MV, Hasegawa, K, et.al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826., J Clin Oncol, 2023. 41 (36)(36): p. 5505-5511., https://pubmed.ncbi.nlm.nih.gov/37910822/
773. Lorusso, D, Colombo, N, Dubot, C, Cáceres, MV, Hasegawa, K, Shapira-Frommer, R, et.al. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study., Ann Oncol, 2025. 36 (1)(1): p. 65-75., https://pubmed.ncbi.nlm.nih.gov/39393777/
774. Monk, BJ, Tewari, KS, Dubot, C, Caceres, MV, Hasegawa, K, Shapira-Frommer, R, et.al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2023. 24 (4)(4): p. 392-402., https://pubmed.ncbi.nlm.nih.gov/36878237/
775. Wang, YZ, Wang, JS, Du, J, Tang, XL, Xiao, JP, Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review., Front Immunol, 2024. 15 (): p. 1305810., https://pubmed.ncbi.nlm.nih.gov/38327524/
776. Huang, RSP, Haberberger, J, Murugesan, K, Danziger, N, Hiemenz, M, Severson, E, et.al. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma., Mod Pathol, 2021. 34 (7)(7): p. 1425-1433., https://pubmed.ncbi.nlm.nih.gov/33637877/
777. Gemeinsamer Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Pembrolizumab (Neues Anwendungsgebiet: Zervixkarzinom, PD-L1-Expression ≥ 1 (CPS), Kombination mit oder ohne Bevacizumab) - Gemeinsamer BundesausschussG-BA, AMNOG – Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V - Gemeinsamer Bundesausschuss, 2023., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/857/
778. Gemeinsamer Bundesauschuss, AMNOG – Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V, Arzneimittel-Richtlinie, 2011., https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/nutzenbewertung-35a/
779. Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, et.al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial., Lancet, 2024. 403 (10421)(10421): p. 31-43., https://pubmed.ncbi.nlm.nih.gov/38048793/
780. Lou, H, Cai, H, Huang, X, Li, G, Wang, L, Liu, F, et.al. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study., Clin Cancer Res, 2024. 30 (8)(8): p. 1501-1508., https://pubmed.ncbi.nlm.nih.gov/38372727/
781. Wu, X, Sun, Y, Yang, H, Wang, J, Lou, H, Li, D, et.al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China., Lancet, 2024. 404 (10463)(10463): p. 1668-1676., https://pubmed.ncbi.nlm.nih.gov/39426385/
782. Vergote, I, González-Martín, A, Fujiwara, K, Kalbacher, E, Bagaméri, A, Ghamande, S, et.al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer., N Engl J Med, 2024. 391 (1)(1): p. 44-55., https://pubmed.ncbi.nlm.nih.gov/38959480/
783. Tewari, KS, Monk, BJ, Vergote, I, Miller, A, de Melo, AC, Kim, HS, et.al. Survival with Cemiplimab in Recurrent Cervical Cancer., N Engl J Med, 2022. 386 (6)(6): p. 544-555., https://pubmed.ncbi.nlm.nih.gov/35139273/
784. Oaknin, A, Monk, BJ, Vergote, I, Cristina de Melo, A, Kim, YM, Lisyanskaya, AS, et.al. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer., Eur J Cancer, 2022. 174 (): p. 299-309., https://pubmed.ncbi.nlm.nih.gov/35922251/
785. Gemeinsamer Bundesausschuss, Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Cemiplimab (neues Anwendungsgebiet: Zervixkarzinom, vorbehandelt), AMNOG – Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V - Gemeinsamer Bundesausschuss, 2023., https://www.g-ba.de/downloads/39-261-6234/2023-10-19_AM-RL-XII_Cemiplimab_D-931_BAnz.pdf
786. Gemeinsamer Bundesausschuss, Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Cemiplimab (neues Anwendungsgebiet: Zervixkarzinom, vorbehandelt), AMNOG – Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V - Gemeinsamer Bundesausschuss, 2023., https://www.g-ba.de/downloads/40-268-9887/2023-10-19_AM-RL-XII_Cemiplimab_D-931_TrG.pdf
787. Chung, H. C., Ros, W., Delord, J. P., Perets, R., Italiano, A., Shapira-Frommer, R., et.al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol, 2019. 37(17): p. 1470-1478., https://www.ncbi.nlm.nih.gov/pubmed/30943124
788. Oaknin, A, Moore, K, Meyer, T, López-Picazo González, J, Devriese, LA, Amin, A, et.al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial., Lancet Oncol, 2024. 25 (5)(5): p. 588-602., https://pubmed.ncbi.nlm.nih.gov/38608691/
789. Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., et.al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study, Gynecol Oncol, 2012. 127(3): p. 451-5., https://www.ncbi.nlm.nih.gov/pubmed/22986144
790. Muggia, F. M., Blessing, J. A., Method, M., Miller, D. S., Johnson, G. A., Lee, R. B., et.al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, Gynecol Oncol, 2004. 92(2): p. 639-43., https://www.ncbi.nlm.nih.gov/pubmed/14766259
791. Sutton, G. P., Blessing, J. A., DeMars, L. R., Moore, D., Burke, T. W., Grendys, E. C., A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium, Gynecol Oncol, 1996. 63(1): p. 25-7., https://www.ncbi.nlm.nih.gov/pubmed/8898163
792. Bookman, M. A., Blessing, J. A., Hanjani, P., Herzog, T. J., Andersen, W. A., Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group, Gynecol Oncol, 2000. 77(3): p. 446-9., https://www.ncbi.nlm.nih.gov/pubmed/10831357
793. Lorusso, D., Ferrandina, G., Pignata, S., Ludovisi, M., Vigano, R., Scalone, S., et.al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group, Ann Oncol, 2010. 21(1): p. 61-6., https://www.ncbi.nlm.nih.gov/pubmed/19605508
794. Verschraegen, C. F., Levy, T., Kudelka, A. P., Llerena, E., Ende, K., Freedman, R. S., et.al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix, J Clin Oncol, 1997. 15(2): p. 625-31., https://www.ncbi.nlm.nih.gov/pubmed/9053486
795. Schilder, RJ, Blessing, JA, Morgan, M, Mangan, CE, Rader, JS, Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group., Gynecol Oncol, 2000. 76 (2)(2): p. 204-7., https://pubmed.ncbi.nlm.nih.gov/10637071/
796. Mutch, DG, Bloss, JD, Gemcitabine in cervical cancer., Gynecol Oncol, 2003. 90 (2 Pt 2)(2 Pt 2): p. S8-15., https://pubmed.ncbi.nlm.nih.gov/12928000/
797. Rose, PG, Blessing, JA, Lele, S, Abulafia, O, Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group., Gynecol Oncol, 2006. 102 (2)(2): p. 210-3., https://pubmed.ncbi.nlm.nih.gov/16478630/
798. Patrono, MG, Calvo, MF, Franco, JVA, Garrote, V, Vietto, V, A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer., Ecancermedicalscience, 2021. 15 (): p. 1200., https://pubmed.ncbi.nlm.nih.gov/33889209/
799. Friedman, CF, D'Souza, A, Bello Roufai, D, Tinker, AV, de Miguel, M, Gambardella, V, et.al. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial., Gynecol Oncol, 2024. 181 (): p. 162-169., https://pubmed.ncbi.nlm.nih.gov/38211393/
800. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6: p. CD011129., https://www.ncbi.nlm.nih.gov/pubmed/28603881
801. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. [Integration of palliative care into intensive care : Systematic review], Anaesthesist, 2017. 66(9): p. 660-666., https://www.ncbi.nlm.nih.gov/pubmed/28589374
802. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., https://www.ncbi.nlm.nih.gov/pubmed/24621947
803. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., https://www.ncbi.nlm.nih.gov/pubmed/26231807
804. Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925., https://www.ncbi.nlm.nih.gov/pubmed/28676557
805. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826
806. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://www.ncbi.nlm.nih.gov/pubmed/26464077
807. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/27185614
808. Radbruch, L., Payne, S., White Paper on standards and norms for hospice and palliative care in Europe: part 2, European Journal of Palliative Care, 2010. 17: p. 22-33., https://research.lancaster-university.uk/en/publications/white-paper-on-standards-and-norms-for-hospice-and-palliative-car/
809. WHO, Palliative care, Geneva, 2007. p. 62., https://iris.who.int/handle/10665/44024
810. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30: p. 880-7., https://pubmed.ncbi.nlm.nih.gov/22312101/
811. European Association for Palliative Care (EAPC), Lukas Radbruch, Sheila Payne, Board of Directors of the EAPC outline, White Paper on standards and norms for hospice and palliative care in Europe: part 1, European Journal of Palliative Care, 2009., https://uu.diva-portal.org/smash/get/diva2:1439369/FULLTEXT01.pdf
812. network, National comprehensive cancer, Palliative Care 2.2012, Clinical practical guidelines in oncology, 2012., https://jnccn.org/view/journals/jnccn/10/10/article-p1284.xml?ArticleBodyColorStyles=pdf-5483&print
813. Project, National Consensus, National Consensus Project for Quality Palliative Care, Clinical Practice Guidelines for Quality Palliative Care Second Edition., 2009., https://www.hopkinsmedicine.org/-/media/som/documents/appointments/clinical-practice-guidelines-for-quality-palliative-care.pdf
814. Improvement, Institute for Clinical Systems, Health care guidelines: palliative care- 3d edition, 2009., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/GGPO_Palliative_Care_ShortVersion_2.2.pdf
815. Douglas, C., Murtagh, F. E., Chambers, E. J., Howse, M., Ellershaw, J., Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group, Palliat Med, 2009. 23: p. 103-10., https://pubmed.ncbi.nlm.nih.gov/19273566/
816. Committee, Ontario Guidelines Advisory, Palliative Care: Recognizing Eligible Patients and Starting the Discussion, 2008., https://hpco.ca/qhpcco/Creating_an_Integrated_HPC_System_in%20Ontario_-_29_Nov_2010.pdf
817. John P. Griffin, MD, FCCP; Kathryn A. Koch, MD, FCCP; Judith E. Nelson, MD, JD, FCCP; and Mary E. Cooley, RN, PhD, Palliative Care Consultation, Quality-of-Life Measurements, and Bereavement for End-of-Life Care in Patients With Lung Cancer ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)American College of Chest Physicians, 2007., https://pubmed.ncbi.nlm.nih.gov/17873182/
818. Organization, World Health, Palliative Care; Cancer control : knowledge into action : WHO guide for effective programmes ; module 5, 2007., https://pubmed.ncbi.nlm.nih.gov/24716262/
819. Committee, Ontario Guidelines Advisory, Palliative Care: Improving Palliative Care Planning for Identified Patients, 2007., https://hpco.ca/qhpcco/Creating_an_Integrated_HPC_System_in%20Ontario_-_29_Nov_2010.pdf
820. (NICE), National Institutie for Clinical Excellence, Improving Supportive and Palliative Care for Adults with Cancer, 2004., https://www.nice.org.uk/guidance/retired/csg4/CSG4-20251218.pdf
821. NIH State-of-the-Science Conference Statement on improving end-of-life care, NIH Consens State Sci Statements, 2004. 21: p. 1-26., https://www.federalregister.gov/documents/2004/11/03/04-24479/state-of-the-science-conference-on-improving-end-of-life-care
822. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29: p. 755-60., https://pubmed.ncbi.nlm.nih.gov/21263086/
823. Excellence, National Institute for Clinical, Guidance on Cancer Services; Improving Supportive and Palliative Care for Adults with Cancer; The manual, 2004., https://pubmed.ncbi.nlm.nih.gov/14562664/
824. Dudgeon, D., King, S., Howell, D., Green, E., Gilbert, J., Hughes, E., et.al. Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening, Psychooncology, 2012. 21: p. 357-64., https://www.ncbi.nlm.nih.gov/pubmed/21308858
825. Carlson, L. E., Waller, A., Groff, S. L., Zhong, L., Bultz, B. D., Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage, Br J Cancer, 2012. 107: p. 617-25., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419958/
826. Lindenfeld, J., Albert, N. M., Boehmer, J. P., Collins, S. P., Ezekowitz, J. A., Givertz, M. M., et.al. HFSA 2010 Comprehensive Heart Failure Practice Guideline, J Card Fail, 2010. 16: p. e1-194., https://pubmed.ncbi.nlm.nih.gov/20610207/
827. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30: p. 880-7., https://www.ncbi.nlm.nih.gov/pubmed/22312101
828. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29: p. 755-60., https://www.ncbi.nlm.nih.gov/pubmed/21263086
829. Gaertner, J., Frechen, S., Sladek, M., Ostgathe, C., Voltz, R., Palliative care consultation service and palliative care unit: why do we need both?, Oncologist, 2012. 17: p. 428-35., https://www.ncbi.nlm.nih.gov/pubmed/22357732
830. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363: p. 733-42., https://www.ncbi.nlm.nih.gov/pubmed/20818875
831. Project, National Consensus, National Consensus Project for Quality Palliative Care, Clinical Practice Guidelines for Quality Palliative Care Second Edition., 2009., http://www.nationalconsensusproject.org/
832. Bruera, E., Hui, D., Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care, J Clin Oncol, 2010. 28: p. 4013-7., https://www.ncbi.nlm.nih.gov/pubmed/20660825
833. Bruera, E., Yennurajalingam, S., Palliative Care in Advanced Cancer Patients: How and When?, Oncologist, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22252934
834. Levy, M. H., Back, A., Benedetti, C., Billings, J. A., Block, S., Boston, B., et.al. NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr Canc Netw, 2009. 7: p. 436-73., https://www.ncbi.nlm.nih.gov/pubmed/19406043
835. Gaertner, J., Wuerstlein, R., Klein, U., Scheicht, D., Frechen, S., Wolf, J., et.al. Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project, Breast Care (Basel), 2011. 6: p. 215-220., https://www.ncbi.nlm.nih.gov/pubmed/21779227
836. Ridner, S. H., Dietrich, M. S., Development and validation of the Lymphedema Symptom and Intensity Survey-Arm, Support Care Cancer, 2015. 23(10): p. 3103-12., https://www.ncbi.nlm.nih.gov/pubmed/25752884
837. Pottharst, A., Steckkönig, A., Aulitzky, W., Subkutane Drainage zur Behandlung des malignen Lymphödems in der palliativen Situation nach Versagen der komplexen physikalischen Entstauungstherapie, Zeitschrift für Palliativmedizin, 2009. 10(01): p. 51-54., https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0028-1090170
838. Landers, A, Holyoake, J, Lymphoedema in advanced cancer: does subcutaneous needle drainage improve quality of life?, BMJ Support Palliat Care, 2022. 12 (e6)(e6): p. e821-e825., https://pubmed.ncbi.nlm.nih.gov/31471494/
839. S2k_Fertilitätserhalt bei onkologischen Erkrankungen (AWMF-Registernummer 015/082; Version 1.0; September 2017), https://www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12.pdf
840. Wallace, W. H., Thomson, A. B., Kelsey, T. W., The radiosensitivity of the human oocyte, Hum Reprod, 2003. 18(1): p. 117-21., https://www.ncbi.nlm.nih.gov/pubmed/12525451
841. Irtan, S., Orbach, D., Helfre, S., Sarnacki, S., Ovarian transposition in prepubescent and adolescent girls with cancer, Lancet Oncol, 2013. 14(13): p. e601-8., https://www.ncbi.nlm.nih.gov/pubmed/24275133
842. Lapuz, C., Kondalsamy-Chennakesavan, S., Bernshaw, D., Khaw, P., Narayan, K., Stage IB cervix cancer with nodal involvement treated with primary surgery or primary radiotherapy: Patterns of failure and outcomes in a contemporary population, J Med Imaging Radiat Oncol, 2016. 60(2): p. 274-82., https://www.ncbi.nlm.nih.gov/pubmed/26549207
843. Dasari, S., Wudayagiri, R., Valluru, L., Cervical cancer: Biomarkers for diagnosis and treatment, Clin Chim Acta, 2015. 445: p. 7-11., https://www.ncbi.nlm.nih.gov/pubmed/25773118
844. Mossa, B., Schimberni, M., Di Benedetto, L., Mossa, S., Ovarian transposition in young women and fertility sparing, Eur Rev Med Pharmacol Sci, 2015. 19(18): p. 3418-25., https://www.ncbi.nlm.nih.gov/pubmed/26439037
845. Laios, A., Otify, M., Papadopoulou, A., Gallos, I. D., Ind, T., Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis, BMC Womens Health, 2022. 22(1): p. 305., https://link.springer.com/article/10.1186/s12905-022-01887-8
846. Kim, J., Turan, V., Oktay, K., Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer, J Clin Endocrinol Metab, 2016. 101(4): p. 1364-71., https://www.ncbi.nlm.nih.gov/pubmed/26751194
847. Kurt, M., Uncu, G., Cetintas, S. K., Kucuk, N., Guler, S., Ozkan, L., Successful spontaneous pregnancy in a patient with rectal carcinoma treated with pelvic radiotherapy and concurrent chemotherapy: the unique role of laparoscopic lateral ovary transposition, Eur J Gynaecol Oncol, 2007. 28(5): p. 408-10., https://www.ncbi.nlm.nih.gov/pubmed/17966224
848. Salih, S. M., Albayrak, S., Seo, S., Stewart, S. L., Bradley, K., Kushner, D. M., Diminished Utilization of in Vitro Fertilization Following Ovarian Transposition in Cervical Cancer Patients, J Reprod Med, 2015. 60(7-8): p. 345-53., https://www.ncbi.nlm.nih.gov/pubmed/26380495
849. Teh, W. T., Stern, C., Chander, S., Hickey, M., The impact of uterine radiation on subsequent fertility and pregnancy outcomes, Biomed Res Int, 2014. 2014: p. 482968., https://www.ncbi.nlm.nih.gov/pubmed/25165706
850. Somigliana, E, Mangili, G, Martinelli, F, Noli, S, Filippi, F, Bergamini, A, et.al. Fertility preservation in women with cervical cancer., Crit Rev Oncol Hematol, 2020. 154 (): p. 103092., https://pubmed.ncbi.nlm.nih.gov/32896752/
851. Salman, L, Covens, A, Fertility Preservation in Cervical Cancer-Treatment Strategies and Indications., Curr Oncol, 2024. 31 (1)(1): p. 296-306., https://pubmed.ncbi.nlm.nih.gov/38248104/
852. Brannstrom, M., Johannesson, L., Dahm-Kahler, P., Enskog, A., Molne, J., Kvarnstrom, N., et.al. First clinical uterus transplantation trial: a six-month report, Fertil Steril, 2014. 101(5): p. 1228-36., https://www.ncbi.nlm.nih.gov/pubmed/24582522
853. Piselli, P., Verdirosi, D., Cimaglia, C., Busnach, G., Fratino, L., Ettorre, G. M., et.al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors, Best Pract Res Clin Obstet Gynaecol, 2014. 28(8): p. 1251-65., https://www.ncbi.nlm.nih.gov/pubmed/25209964
854. Goldman, RH, Racowsky, C, Farland, LV, Munné, S, Ribustello, L, Fox, JH, Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients., Hum Reprod, 2017. 32 (4)(4): p. 853-859., https://pubmed.ncbi.nlm.nih.gov/28166330/
855. Khattak, H, Malhas, R, Craciunas, L, Afifi, Y, Amorim, CA, Fishel, S, et.al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis., Hum Reprod Update, 2022. 28 (3)(3): p. 400-416., https://pubmed.ncbi.nlm.nih.gov/35199164/
856. Cordeiro, C. N., Gemignani, M. L., Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety, Obstet Gynecol Surv, 2017. 72(3): p. 184-193., https://www.ncbi.nlm.nih.gov/pubmed/28304416
857. De Vincenzo, R., Tortorella, L., Ricci, C., Cavaliere, A. F., Zannoni, G. F., Cefalo, M. G., et.al. Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome, Gynecol Oncol, 2018. 150(3): p. 398-405., https://www.ncbi.nlm.nih.gov/pubmed/30126588
858. Goncalves, C. V., Duarte, G., Costa, J. S., Marcolin, A. C., Bianchi, M. S., Dias, D., et.al. Diagnosis and treatment of cervical cancer during pregnancy, Sao Paulo Med J, 2009. 127: p. 359-65., https://www.ncbi.nlm.nih.gov/pubmed/20512291
859. Fader, A. N., Alward, E. K., Niederhauser, A., Chirico, C., Lesnock, J. L., Zwiesler, D. J., et.al. Cervical dysplasia in pregnancy: a multi-institutional evaluation, Am J Obstet Gynecol, 2010. 203: p. 113 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20522409
860. Wright, T. C., Jr., Massad, L. S., Dunton, C. J., Spitzer, M., Wilkinson, E. J., Solomon, D., et.al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ, Am J Obstet Gynecol, 2007. 197: p. 340-5., https://www.ncbi.nlm.nih.gov/pubmed/17904956
861. Han, S. N., Mhallem Gziri, M., Van Calsteren, K., Amant, F., Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies, Ther Adv Med Oncol, 2013. 5(4): p. 211-9., https://www.ncbi.nlm.nih.gov/pubmed/23858330
862. Balleyguier, C., Fournet, C., Ben Hassen, W., Zareski, E., Morice, P., Haie-Meder, C., et.al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging, Clin Imaging, 2013. 37(1): p. 70-6., https://www.ncbi.nlm.nih.gov/pubmed/23206610
863. Morice, P., Uzan, C., Gouy, S., Verschraegen, C., Haie-Meder, C., Gynaecological cancers in pregnancy, Lancet, 2012. 379(9815): p. 558-69., https://www.ncbi.nlm.nih.gov/pubmed/22325661
864. Maggen, C, Wolters, VERA, Cardonick, E, Fumagalli, M, Halaska, MJ, Lok, CAR, et.al. Pregnancy and Cancer: the INCIP Project., Curr Oncol Rep, 2020. 22 (2)(2): p. 17., https://pubmed.ncbi.nlm.nih.gov/32025953/
865. Boyd SC, Look KY., Prognostic factors for carcinoma of the cervical stump and cervical carcinoma associated with pregnancy., Cme J Gynecol Oncol, 2001. 6: p. 347-56.
866. Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Van Calster, B., et.al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy, Int J Gynecol Cancer, 2019., https://www.ncbi.nlm.nih.gov/pubmed/30898935
867. Fukushima, K., Ogawa, S., Tsukimori, K., Kobayashi, H., Wake, N., Can we diagnose invasive cervical cancer during pregnancy as precise as in nonpregnant women?: maternal and perinatal outcome in pregnancies complicated with cervical cancers, Int J Gynecol Cancer, 2009. 19: p. 1439-45., https://www.ncbi.nlm.nih.gov/pubmed/20009904
868. Germann, N., Haie-Meder, C., Morice, P., Lhomme, C., Duvillard, P., Hacene, K., et.al. Management and clinical outcomes of pregnant patients with invasive cervical cancer, Ann Oncol, 2005. 16(3): p. 397-402., https://www.ncbi.nlm.nih.gov/pubmed/15668263
869. Sorosky, J. I., Squatrito, R., Ndubisi, B. U., Anderson, B., Podczaski, E. S., Mayr, N., et.al. Stage I squamous cell cervical carcinoma in pregnancy: planned delay in therapy awaiting fetal maturity, Gynecol Oncol, 1995. 59(2): p. 207-10., https://www.ncbi.nlm.nih.gov/pubmed/7590474
870. Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., et.al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting, Int J Gynecol Cancer, 2014. 24(3): p. 394-403., https://www.ncbi.nlm.nih.gov/pubmed/24445819
871. Vercellino, G. F., Koehler, C., Erdemoglu, E., Mangler, M., Lanowska, M., Malak, A. H., et.al. Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome, Int J Gynecol Cancer, 2014. 24(2): p. 364-71., https://www.ncbi.nlm.nih.gov/pubmed/24424374
872. Morice, P., Narducci, F., Mathevet, P., Marret, H., Darai, E., Querleu, D., French recommendations on the management of invasive cervical cancer during pregnancy, Int J Gynecol Cancer, 2009. 19: p. 1638-41., https://www.ncbi.nlm.nih.gov/pubmed/19955951
873. Marnitz, S., Kohler, C., Oppelt, P., Schmittel, A., Favero, G., Hasenbein, K., et.al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients, Oncology, 2010. 79(1-2): p. 72-7., https://www.ncbi.nlm.nih.gov/pubmed/21071993
874. Esposito, S., Tenconi, R., Preti, V., Groppali, E., Principi, N., Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes, Medicine (Baltimore), 2016. 95(38): p. e4899., https://www.ncbi.nlm.nih.gov/pubmed/27661036
875. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Bartsch, R., Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis, Obstet Gynecol, 2013. 121(2 Pt 1): p. 337-343., https://www.ncbi.nlm.nih.gov/pubmed/23344284
876. Zagouri, F, Korakiti, AM, Zakopoulou, R, Kyriazoglou, A, Zografos, E, Haidopoulos, D, et.al. Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis., Cancer Treat Rev, 2019. 79 (): p. 101885., https://pubmed.ncbi.nlm.nih.gov/31442939/
877. Kohler, C., Oppelt, P., Favero, G., Morgenstern, B., Runnebaum, I., Tsunoda, A., et.al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy, Am J Obstet Gynecol, 2015. 213(2): p. 206 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/25731691
878. Cardonick, E., Usmani, A., Ghaffar, S., Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry, Am J Clin Oncol, 2010. 33(3): p. 221-8., https://www.ncbi.nlm.nih.gov/pubmed/19745695
879. Cardonick, E. H., Gringlas, M. B., Hunter, K., Greenspan, J., Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls, Am J Obstet Gynecol, 2015. 212(5): p. 658 e1-8., https://www.ncbi.nlm.nih.gov/pubmed/25434835
880. Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., et.al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy, N Engl J Med, 2015. 373(19): p. 1824-34., https://www.ncbi.nlm.nih.gov/pubmed/26415085
881. Vandenbroucke, T., Verheecke, M., Fumagalli, M., Lok, C., Amant, F., Effects of cancer treatment during pregnancy on fetal and child development, Lancet Child Adolesc Health, 2017. 1(4): p. 302-310., https://www.ncbi.nlm.nih.gov/pubmed/30169185
882. Capriglione, S., Manzano, A., Gulino, F. A., Lopez, S., Management of gynecological cancer in pregnant patients, Minerva Ginecol, 2019. 71(2): p. 133-145., https://www.ncbi.nlm.nih.gov/pubmed/30318875
883. de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., et.al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients, Lancet Oncol, 2018. 19(3): p. 337-346., https://www.ncbi.nlm.nih.gov/pubmed/29395867
884. Hopkins, M. P., Morley, G. W., The prognosis and management of cervical cancer associated with pregnancy, Obstet Gynecol, 1992. 80(1): p. 9-13., https://www.ncbi.nlm.nih.gov/pubmed/1318532
885. Smith, A. L., Frumovitz, M., Schmeler, K. M., dos Reis, R., Nick, A. M., Coleman, R. L., et.al. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?, Gynecol Oncol, 2010. 119: p. 183-6., https://www.ncbi.nlm.nih.gov/pubmed/20708227
886. Hsu, W. L., Shueng, P. W., Jen, Y. M., Wu, C. J., Hwang, J. M., Chang, L. P., et.al. Long-term treatment results of invasive cervical cancer patients undergoing inadvertent hysterectomy followed by salvage radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 59: p. 521-7., https://www.ncbi.nlm.nih.gov/pubmed/15145172
887. Park, J. Y., Kim, D. Y., Kim, J. H., Kim, Y. M., Kim, Y. T., Nam, J. H., Management of occult invasive cervical cancer found after simple hysterectomy, Ann Oncol, 2010. 21: p. 994-1000., https://www.ncbi.nlm.nih.gov/pubmed/19858083
888. Munstedt, K., Johnson, P., von Georgi, R., Vahrson, H., Tinneberg, H. R., Consequences of inadvertent, suboptimal primary surgery in carcinoma of the uterine cervix, Gynecol Oncol, 2004. 94: p. 515-20., https://www.ncbi.nlm.nih.gov/pubmed/15297197
889. Wang, Y, Ouyang, Y, Su, J, Xiao, L, Bai, Z, Cai, Q, et.al. Is salvage radiotherapy optimal to patients with occult cervical cancer undergoing inadvertent simple hysterectomy? A propensity score-matched analysis of a nationwide clinical oncology database., Jpn J Clin Oncol, 2021. 51 (4)(4): p. 630-638., https://pubmed.ncbi.nlm.nih.gov/33395486/
890. Tran, A. Q., Sullivan, S. A., Gehrig, P. A., Soper, J. T., Boggess, J. F., Kim, K. H., Robotic Radical Parametrectomy With Upper Vaginectomy and Pelvic Lymphadenectomy in Patients With Occult Cervical Carcinoma After Extrafascial Hysterectomy, J Minim Invasive Gynecol, 2017. 24(5): p. 757-763., https://www.ncbi.nlm.nih.gov/pubmed/28254677
891. Gadducci, A., Carinelli, S., Aletti, G., Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists, Gynecol Oncol, 2017. 144(3): p. 637-646., https://www.ncbi.nlm.nih.gov/pubmed/28057354
892. Burzawa, J., Gonzales, N., Frumovitz, M., Challenges in the diagnosis and management of cervical neuroendocrine carcinoma, Expert Rev Anticancer Ther, 2015. 15(7): p. 805-10., https://www.ncbi.nlm.nih.gov/pubmed/25980782
893. Viswanathan, A. N., Deavers, M. T., Jhingran, A., Ramirez, P. T., Levenback, C., Eifel, P. J., Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence, Gynecol Oncol, 2004. 93(1): p. 27-33., https://www.ncbi.nlm.nih.gov/pubmed/15047210
894. Cohen, J. G., Kapp, D. S., Shin, J. Y., Urban, R., Sherman, A. E., Chen, L. M., et.al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients, Am J Obstet Gynecol, 2010. 203: p. 347 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20579961
895. Miyoshi, AI, Ueda, Y, Kurita, T, Kimura, T, Yoshino, K, Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix., Anticancer Res, 2023. 43 (4)(4): p. 1397-1405., https://pubmed.ncbi.nlm.nih.gov/36974776/
896. Castle, P. E., Pierz, A., Stoler, M. H., A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix, Gynecol Oncol, 2018. 148(2): p. 422-429., https://www.ncbi.nlm.nih.gov/pubmed/29248196
897. Schmidt, D., Horn, L. C., Kommoss, F., Neuroendocrine carcinomas of the cervix, Pathologe, 2005. 26: p. 262-5., https://www.ncbi.nlm.nih.gov/pubmed/15915327
898. Kurman, R.J., M.L. Carcangiu, and C.S. Herrington, eds., WHO Classification of Tumours of the Female Genital Tract. ed. R.H. Young., IARC Press: Lyon., 2014. p. 169-206.., https://www.researchgate.net/publication/313617888_WHO_classification_of_tumours_of_female_reproductive_organs
899. Lee, S. W., Nam, J. H., Kim, D. Y., Kim, J. H., Kim, K. R., Kim, Y. M., et.al. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study, Int J Gynecol Cancer, 2010. 20: p. 411-6., https://www.ncbi.nlm.nih.gov/pubmed/20375806
900. Tian, W. J., Zhang, M. Q., Shui, R. H., Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix, Oncol Lett, 2012. 3: p. 125-130., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362381/
901. Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., et.al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study, J Clin Oncol, 2004. 22: p. 3113-9., https://www.ncbi.nlm.nih.gov/pubmed/15284262
902. McCusker, M. E., Cote, T. R., Clegg, L. X., Tavassoli, F. J., Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma, Gynecol Oncol, 2003. 88(3): p. 333-9., https://www.ncbi.nlm.nih.gov/pubmed/12648583
903. Chen, J., Macdonald, O. K., Gaffney, D. K., Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix, Obstet Gynecol, 2008. 111(6): p. 1394-402., https://www.ncbi.nlm.nih.gov/pubmed/18515524
904. Prodromidou, A, Phelps, DL, Pergialiotis, V, Cunnea, P, Thomakos, N, Rodolakis, A, et.al. Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis., Eur J Obstet Gynecol Reprod Biol, 2022. 270 (): p. 212-220., https://pubmed.ncbi.nlm.nih.gov/35093830/
905. Wang, K. L., Chang, T. C., Jung, S. M., Chen, C. H., Cheng, Y. M., Wu, H. H., et.al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study, Eur J Cancer, 2012. 48: p. 1484-94., https://www.ncbi.nlm.nih.gov/pubmed/22244826
906. Chan, J. K., Loizzi, V., Burger, R. A., Rutgers, J., Monk, B. J., Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis, Cancer, 2003. 97: p. 568-74., https://www.ncbi.nlm.nih.gov/pubmed/12548598
907. Xu, F., Ma, J., Yi, H., Hu, H., Fan, L., Wu, P., et.al. Clinicopathological Aspects of Small Cell Neuroendocrine Carcinoma of the Uterine Cervix: a Multicenter Retrospective Study and Meta-Analysis, Cell Physiol Biochem, 2018. 50(3): p. 1113-1122., https://www.ncbi.nlm.nih.gov/pubmed/30355937
908. Gardner, GJ, Reidy-Lagunes, D, Gehrig, PA, Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document., Gynecol Oncol, 2011. 122 (1)(1): p. 190-8., https://pubmed.ncbi.nlm.nih.gov/21621706/
909. Salvo, G., Gonzalez Martin, A., Gonzales, N. R., Frumovitz, M., Updates and management algorithm for neuroendocrine tumors of the uterine cervix, Int J Gynecol Cancer, 2019. 29(6): p. 986-995., https://www.ncbi.nlm.nih.gov/pubmed/31263021
910. Li, H, Li, X, Yang, M, Su, H, Zhang, J, Hu, C, et.al. PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma., J Clin Transl Res, 2023. 9 (4)(4): p. 272-281., https://pubmed.ncbi.nlm.nih.gov/37593242/
911. Qiu, H, Wang, M, Wang, D, Wang, Y, Su, N, Yan, S, et.al. Efficacy of PD-1/PD-L1 blockade immunotherapy in recurrent/metastatic high-grade neuroendocrine carcinoma of the cervix: A retrospective study., Heliyon, 2024. 10 (18)(18): p. e37503., https://pubmed.ncbi.nlm.nih.gov/39309812/
912. Schmitt, J, Klinkhammer-Schalke, M, Bierbaum, V, Gerken, M, Bobeth, C, Rößler, M, et.al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals., Dtsch Arztebl Int, 2023. 120 (39)(39): p. 647-654., https://pubmed.ncbi.nlm.nih.gov/37583089/
913. Beckmann, Matthias W., Jud, S.M., Gynäkologische Krebszentren- Kompetenzbündelung zur Qualitätsbesserung, Frauenheilkunde up2date, 2009. 3: p. 71-74., https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0028-1098885
914. Wesselmann, S., Beckmann, M. W., Winter, A., The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care, Arch Gynecol Obstet, 2014. 289(1): p. 7-12., https://www.ncbi.nlm.nih.gov/pubmed/24220845
915. Kowalski, C., Wesselmann, S., Ansmann, L., Kreienberg, R., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonen-Befragung, Geburtsh Frauenheilk, 2012. 72: p. 235-242., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0031-1298249
916. Huthmann, D., T., Seufferlein, Post, S., Benz, S., Stinner, B., Wesselmann, S., Zertifizierte Darmkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonenbefragung, Z Gastroenterol, 2012. 50: p. 753–759., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0032-1313004
917. Kowalski, C., Wesselmann, S., Kreienberg, R., Schulte, H., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Patientinnen: Stärken und Verbesserungspotenziale, Geburtsh Frauenheilk, 2012. 71:, https://pubmed.ncbi.nlm.nih.gov/25284830/
918. Wesselmann, S., Winter, A., Ferencz, J., Seufferlein, T., Post, S., Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013, Int J Colorectal Dis, 2014. 29(4): p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/24584335
919. Beckmann, Matthias W., Adler, Guido, Albers, Peter, Bruns, Johannes, Ehninger, Gerhard, Hauschild, Axel, et.al. Dreistufenmodell optimiert Behandlung unter Kostendeckung, Dtsch Arztebl, 2007. 104: p. 3004-3009., https://api.aerzteblatt.de/pdf/104/44/a3004.pdf
920. Hansinger, J, Völkel, V, Gerken, M, Schoffer, O, Wimberger, P, Bierbaum, V, et.al. Endometrial Cancer - Long-Term Survival in Certified Cancer Centers and Non-Certified Hospitals: Comparative Analysis Based on a Large German Retrospective Cohort Study (WiZen)., Geburtshilfe Frauenheilkd, 2024. 84 (10)(10): p. 979-988., https://pubmed.ncbi.nlm.nih.gov/39359541/
921. Hansinger, J, Schoffer, O, Völkel, V, Gerken, M, Wimberger, P, Bierbaum, V, et.al. Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen)., J Ovarian Res, 2025. 18 (1)(1): p. 238., https://pubmed.ncbi.nlm.nih.gov/41188998/
922. Schoffer, O, Wimberger, P, Gerken, M, Bierbaum, V, Bobeth, C, Rößler, M, et.al. Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer: Evidence Based on Health Care Data from the WiZen Study., Geburtshilfe Frauenheilkd, 2024. 84 (2)(2): p. 153-163., https://pubmed.ncbi.nlm.nih.gov/38344046/
923. Bierbaum, V, Bobeth, C, Roessler, M, Gerken, M, Tol, KK, Reissfelder, C, et.al. Treatment in certified cancer centers is related to better survival in patients with colon and rectal cancer: evidence from a large German cohort study., World J Surg Oncol, 2024. 22 (1)(1): p. 11., https://pubmed.ncbi.nlm.nih.gov/38183134/
924. Völkel, V, Gerken, M, Kleihues-van Tol, K, Schoffer, O, Bierbaum, V, Bobeth, C, et.al. Treatment of Colorectal Cancer in Certified Centers: Results of a Large German Registry Study Focusing on Long-Term Survival., Cancers (Basel), 2023. 15 (18)(18):, https://pubmed.ncbi.nlm.nih.gov/37760537/
925. Roessler, M, Schmitt, J, Bobeth, C, Gerken, M, Kleihues-van Tol, K, Reissfelder, C, et.al. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study., BMC Cancer, 2022. 22 (1)(1): p. 621., https://pubmed.ncbi.nlm.nih.gov/35672675/
926. Jacob, A, Albert, W, Jackisch, T, Jakob, C, Sims, A, Witzigmann, H, et.al. Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit., Int J Colorectal Dis, 2021. 36 (3)(3): p. 517-533., https://pubmed.ncbi.nlm.nih.gov/33165684/
927. Völkel, V, Gerken, M, Kleihues-van Tol, K, Schoffer, O, Bierbaum, V, Bobeth, C, et.al. Long-term survival after treatment in certified lung cancer centers and not certified hospitals: Results of a large German cohort study using clinical routine data., Gesundheitswesen, 2025. 87 (S 03)(S 03): p. S373-S382., https://pubmed.ncbi.nlm.nih.gov/40628376/
928. Butea-Bocu, M. C., Muller, G., Pucheril, D., Kroger, E., Otto, U., Is there a clinical benefit from prostate cancer center certification? An evaluation of functional and oncologic outcomes from 22,649 radical prostatectomy patients, World J Urol, 2021. 39(1): p. 5-10., https://www.ncbi.nlm.nih.gov/pubmed/32851440
929. Kreienberg, R., Wockel, A., Wischnewsky, M., Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: An evaluation of 8323 patients, Breast, 2018. 40: p. 54-59., https://www.ncbi.nlm.nih.gov/pubmed/29698925
930. Trautmann, F., Reissfelder, C., Pecqueux, M., Weitz, J., Schmitt, J., Evidence-based quality standards improve prognosis in colon cancer care, Eur J Surg Oncol, 2018. 44(9): p. 1324-1330., https://www.ncbi.nlm.nih.gov/pubmed/29885983
931. Weinhold, I., Keck, T., Merseburger, A., Rody, A., Wollenberg, B., Wende, D., et.al. [Utility Analysis of Oncological Centre Building in the Field of Colorectal Cancer], Zentralbl Chir, 2018. 143(2): p. 181-192., https://www.ncbi.nlm.nih.gov/pubmed/28472845
932. Busch, J., Magheli, A., Erber, B., Friedersdorff, F., Hoffmann, I., Kempkensteffen, C., et.al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis, BMC Urol, 2012. 12: p. 15., https://www.ncbi.nlm.nih.gov/pubmed/22651395
933. Haj, A., Doenitz, C., Schebesch, K. M., Ehrensberger, D., Hau, P., Putnik, K., et.al. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center, Brain Sci, 2017. 8(1):, https://www.ncbi.nlm.nih.gov/pubmed/29295569
934. Beckmann, M. W., Brucker, C., Hanf, V., Rauh, C., Bani, M. R., Knob, S., et.al. Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients, Onkologie, 2011. 34(7): p. 362-7., https://www.ncbi.nlm.nih.gov/pubmed/21734422
935. Beckmann, M. W., Quaas, J., Bischofberger, A., Kammerle, A., Lux, M. P., Wesselmann, S., Establishment of the Certification System "Gynaecological Dysplasia" in Germany, Geburtshilfe Frauenheilkd, 2014. 74(9): p. 860-867., https://www.ncbi.nlm.nih.gov/pubmed/25278628
936. Stuebs, FA, Beckmann, MW, Fehm, T, Dannecker, C, Follmann, M, Langer, T, et.al. Implementation and update of guideline-derived quality indicators for cervical cancer in gynecological cancer centers certified by the German Cancer Society (DKG)., J Cancer Res Clin Oncol, 2023. 149 (14)(14): p. 12755-12764., https://pubmed.ncbi.nlm.nih.gov/37452203/
937. Beckmann, M. W., Gitsch, G., Emons, G., Berg, D., Ortmann, O., Jonat, W., et.al. Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?, Geburtsh Frauenheilk, 2006. 66: p. 123-127., https://www.semanticscholar.org/paper/Der-neue-Schwerpunkt-Gyn%C3%A4kologische-Onkologie%3A-und-Beckmann-Gitsch/e984d238b96cba4a4fa00b836180fc9f31a8c170
938. Beckmann, M. W., Frauenarzt/-ärztin der Zukunft: müssen die Kliniken neu strukturiert werden?, Der Gynäkologe, 2010. 43: p. 748-756., https://link.springer.com/article/10.1007/s00129-010-2563-z?
939. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG), Methodische Grundlagen. Version 2.1, 2024., https://iqtig.org/veroeffentlichungen/methodische-grundlagen/
940. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 4.1, 2025., http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/
941. Wittekind, C, TNM Klassifikation maligner Tumoren - Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019Wiley-VCH, Weinheim, 2020., https://katalog.dnb.de/DE/resource.html?id=1204006059